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Abstract 
The human genome encodes information that instructs human development, physiology, 
medicine, and evolution. Massive amount of genomic data has generated an ever-growing 
pool of hypothesis. Genome editing, broadly defined as targeted changes to the genome, 
posits to deliver the promise of genomic revolution to transform basic science and 
personalized medicine. This thesis aims to contribute to this scientific endeavor with a 
particular focus on the development of effective human genome engineering tools.  
Chapter 1 introduces the key topics on genome editing, with an emphasis on its 
implications, current status, and potential applications.   
Chapter 2 describes the generation of reTALEs, a simplified form of TALENs, and the 
assembly of a pipeline to scarlessly edit human stem cells. We demonstrate the utility of 
this pipeline by generating hiPSCs with mutations in HIV resistance genes within 3 
weeks.  
Chapter 3 describes the generation of a novel RNA-guided human genome editing tool. 
We reprogrammed a type II bacterial CRISPR system to function in a human context, and 
demonstrated an efficient & multiplexable version of this approach in multiple cell types 
including human iPSCs.  We compared the efficiency and specificity of CRISPR with 
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TALE and designed a new strategy to mitigate the off-target issues associated with 
CRISPR.  
To expand our genome editing toolbox, Chapter 4 describes the assembly of novel 
chimeric deaminases that perform sequence-specific genome editing without generating 
DSBs and the need to simultaneously provide replacement (i.e., donor) DNA. Targeted 
deaminases are both efficient and specific in Escherichia coli and human cells, presenting 
an alternative platform that can eventually be used in multiplex genome editing.  
Chapter 5 describes our effort in combining genetically engineered iPSCs with organ-
on-chip models to investigate the cellular etiology of disease and to identify potential 
therapeutic targets. We generated isogenic iPSCs carrying a mutation identified in 
cardiomyopathy patients. Cardiomyocytes derived from engineered hiPSC recapitulated 
disease abnormalities and engineered “heart on chip” tissues contracted poorly. 
Replacement of the defective gene product corrected these abnormalities.  
We finally conclude with remarks on the future prospects for genome editing to expand 
our understanding of fundamental biology and to enhance the wellness of human beings.  
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 “What I cannot create, I do not understand.” 
                                  – Richard P. Feynman 
 
Genome editing  
Overview 
A genome encodes instructions for executable actions that most organisms require to 
develop and respond to the environment. In 1928, a bacteriologist Frederic Griffith discovered 
that traits can be transferred between different strains of Pneumococcus by mixing dead bacteria 
with living recipients (1). The material that carries this information was suggested as DNA; one 
decade later Dr. Oswald Avery and his colleagues identified DNA as a “transforming principle” 
(2). Subsequently, DNA’s role in the flow of genetic information was confirmed and stated in the 
central dogma of molecular biology (3) - “DNA makes RNA makes protein”.  Further 
technology advancements have enabled one to “read” the genome. More specifically, the 
development of Sanger sequencing in the 1970’s (4) first allowed reliable analysis of DNA 
fragment sequences in the lab. Thereafter, the invention of DNA microarray and next-generation 
sequencing technology have continuously revolutionized the way genomic data is collected and 
perceived.  Currently, the genomes of over 1000 organisms, including all three main domains of 
life (bacteria, archaea, and eukaryote) as well as many viruses, phages, plasmids and organelles 
have been sequenced (5). In addition, the number of annotations deposited in the Genebank 
database is growing at a breathtaking pace. 
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With the resulting wealth of information, scientists are poised to deliver upon the 
promises of the genomic revolution to translate basic science to personalized medicine. Central 
to this task, massive amounts of data must be converted into a functional and clinically relevant 
form.  Genome editing, the effort to introduce targeted and defined chromosomal changes, can 
greatly facilitate our progress towards this direction.  
First, biology questions can be answered directly and more simply using genome editing 
tools. For example, the large scale genome wide association studies (GWAS) and whole genome 
sequencing  have identified thousands of genetic variations associated with diseases (6). While 
the function of each variant can be explored with reporter constructs in human or non-human 
cells, a direct path would be to edit a variant directly and precisely in the genomes of human 
cells to examine if this results in detectable phenotypes relative to unedited cells.  This may be 
especially powerful for human induced pluripotent stem cells (hiPSCs), which can be 
differentiated into defined cell types to check for phenotypes specific to certain types (7). 
Second, genome editing can be used to produce useful organisms and cure human 
diseases.  Since DNA encodes the instructions used in the development and functionality of 
almost organisms, the implications of genome editing are far reaching. We can use such a tool to 
modify industrial and agricultural relevant organisms and confer them with desired traits.  In 
addition, genome editing enables the treatment of genetic disorders by enabling permanent 
correction of specific mutations in DNA that cause an associated human disease. 
 
Tools for genome editing 
Overview 
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Considerable progress has been made to develop effective genome editing tools. Two 
categories of these tools are discussed, homologous recombination (HR)-mediated genome 
editing and non-HR-mediated genome editing, with emphasis on the former, which is also the 
approach most commonly used.    
 
HR-mediated genome engineering  
HR is a DNA repair mechanism highly conserved across all three domains of life to 
accurately repair harmful breaks that occur in the genome. In this naturally occurring genetic 
recombination event, nucleotide sequences are exchanged between two similar or identical 
molecules of DNA. HR is also used to produce new combinations of DNA sequence during 
meiosis.  
Using the endogenous HR machinery, DNA information carried by exogenously 
introduced cloned DNA can be effectively introduced into the chromosome. This type of genetic 
manipulation was first demonstrated in yeast (8)and later exploited in other biological systems.  
Specific genome editing techniques applied in creation of the mouse models was first 
reported in the late 1980’s to generate knock-out and knock-in mice (9). In 1985, the first study 
of gene targeting in human cells was reported (10). Introduction of exogenous DNA carrying 
homology arms against the native β-globin locus successfully inserted non-human elements into 
the defined region with 10
-3
 frequency (10).  These specific one-copy insertions were not 
accompanied by insertions of exogenous sequences at other off-target genomic sites. However, 
the broad utility of this HR approach was greatly limited by its low efficiency.  
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The effect of double-strand break (DSB) on homologous recombination emerged from 
the study of yeast model system in 1980s (11). DSBs stimulate the cellular DNA repair 
mechanisms, including the error-prone nonhomologous end joining (NHEJ) and HR. It was 
found that introduction of a DSB within or near the targeting site enhances the rate of HR 10-100 
folds in the yeast (11).  In the following decades, a number of labs demonstrated that a specific 
DSB in the genomic target created by the I-SceI homing endonuclease stimulated HR between 
the genomic target and transfected plasmid (‘‘gene targeting’’) by 1,000-fold (12). With 
optimization, gene targeting rates of 3%–5% can be obtained.  
Inspired by the discovery of the effect of DSB, scientists proceeded to devise methods to 
introduce DSBs at a gene of interest in a targeted fashion. One solution is to engineer nucleases 
that enable sequence specific cuttings at the target site. To this end, engineered nucleases must 
have a combination of qualities:  first, an engineered nuclease should be sufficiently adaptable; 
second, it needs to recognize sufficiently long target sequence that is unique in complicated 
eukaryotic genome.  Chimeric nucleases, composed of programmable DNA-binding domains, 
such as engineered zinc fingers (ZF) and transcription activator-like effectors (TALE), fused to a 
nonspecific DNA cleavage module, possess these critical features.  
The zinc finger domain is the most abundant DNA-binding motif in the human genome 
and was the first DNA binding domain used in chimeric nucleases (13). It consists of a ββα 
protein configuration, in which the α-helix binds to the major groove of DNA and recognizes 3 
bp contiguous nucleotides. A tandem array of zinc finger domain can bind to longer DNA 
sequence, such that a 3 zinc finger array has 9bp DNA recognition specificity. Zinc finger 
nucleases, fusing of a zinc finger array with the nuclease domain derived from the type IIS 
restriction enzyme FokI, were first developed by Chandrasegaran and his colleagues (14).  Fok1 
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must dimerize to cleave DNA, thus cleavage by Fok1 as part of a ZFN-based system requires 
two adjacent and independent binding events, enabling specific targeting of long and potentially 
unique recognition sites (2X9=18).  The DNA-binding specificity of zinc finger domain has been 
extensively engineered. Methods such as “modular assembly” (15), combinatorial selection, and 
“OPEN (Oligomerized Pool Engineering)” (16) have collectively, yielded unique zinc finger 
domains with specificity for almost all the possible nucleotide triplets.  Commercialized zinc 
fingers are also available through Sangoma.  Engineered ZFNs have been used to conduct 
genome editing in C. elegance, drosophalia, zebrafish, mouse, rat, catfish, sea urchin, rabbit, pig 
and corn (17). In 2003, Porteus and Baltimore demonstrated that ZFNs could enhance gene 
targeting by several-thousand–fold in human stem cells (18). Subsequently, it has been 
demonstrated in human primary T cells that ZFNs can mediate genome targeting on IL2RG gene 
with efficiency up to 5% (19). These results opened up the possibility of using ZFNs to product 
human genome editing. However, the prohibitive price and long selection process made ZFNs 
not accessible to the broad scientific communities.  
Discovery of the elegant correlations between protein sequences of transcription 
activator-like effectors (TALEs) with their DNA binding sequence expanded the option of 
engineering  a programmable DNA-binding protein (20). TALE is a naturally occurring protein 
originally from Xanthomonas bacteria. It mimics the transcriptional regulatory factors to hijack 
the host expression system. TALE carries a central DNA-binding domain, consisting of a 
repeating chain of nearly identical 34-amino acid monomers. Each monomer recognizes a single 
DNA target base with four common monomer variants optimally binding one of the four DNA 
base pairs. Like zinc finger domains, these TALE repeat can be linked together to recognize a 
specific contiguous DNA sequence (21). Several protocols have been developed to assemble 
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customized TALE, including golden gate cloning (22), hierarchical ligation (21) and solid phase 
synthesis (23, 24). Customized TALEs have become commercially available through Cellectis 
Bioresearch (Paris, France) and Life Technologies (Grand Island, NY). Engineered TALE, when 
fused to other user-specified domains, can address a vast range of proteins and other molecules 
to particular genomic locations both in vivo and in vitro.  TALEN, with TALE fusing with the 
catalytic domain of Fok I, have been engineered to generate novel DNA nucleases (25). Similar 
to ZFN, dimerization of TALENs with designated orientation and spacer is required to function 
at defined region. As of writing this thesis, TALENs have been widely applied to many 
organisms and cell lines (24, 26).   
Apart from the engineered chimeric nucleases described above, the recently developed 
Clustered, regularly interspaced, short palindromic repeat (CRISPR)/ CRISPR associated system 
(Cas) present an alternative approach for introducing sequence specific cutting in the genome. 
CRSPR/Cas, the adaptive immune system found in bacteria and archaea, uses short RNA to 
direct degradation of foreign DNA. In type II CRISPR/Cas sytem, short CRISPR RNA (crRNA) 
anneals with trans-activating crRNAs (tracrRNAs) and direct DNA cleavage at crRNA matching 
site by Cas9 protein (27, 28). A recent in vitro reconstitution of the Streptococcus pyogenes type 
II CRISPR system demonstrated that crRNA fused with tracrRNA by a linker is sufficient to 
direct Cas9 protein to sequence-specifically cleave target DNA sequences matching the crRNA 
(29). The fully defined nature of this two-component system suggested that this system can be 
grafted into mammalian cell setting and used for genome editing.  
 
Non-HR-mediated genome editing tools  
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    An alternate approach of HR for achieving targeted genomic editing is the use of site 
specific recombinases (SSRs). SSRs can be categorized into two distinct two families, tyrosine 
recombinases, including most commonly used Cre and FLP, and serine recombinases (30). 
Despite different origins, SSRs rearrange DNA sequence using similar mechanism: the SSR 
catalyzes cutting at the recognition sites and rejoining of DNA strands to which it binds. This 
reaction promotes defined deletion, integration, inversion and cassette exchange. Given the 
coupling of chromosomal cutting with genetic material exchange, SSR has advantage over 
nucleases used to promote HR due to its elimination of NHEJ product (31).  
  Progresses have been made to reengineer SSR to act on novel sequence, but further 
work is needed to fully program SSR specificity. One approach to reprogram SSR exploits the 
modular nature of some serine recombinases. The catalytic domain and DNA binding domain are 
separated in some serine recombinase, in which the catalytic domain interacts with the central 
14bp residues and the DNA binding domains recognizing the remaining 14bp. Thus, substitution 
of the DNA binding domain with customized DNA binding protein would confer the chimeric 
enzyme new sequence specificity, as demonstrated by zinc finger recombinases (32) and TALE 
recombinases (33). Nevertheless, the 14 bp fixed sequence specificity carried by catalytic 
domain still limits the broad targeting capacity of engineered recombinases. Selection among 
SSR mutants has also been conducted to obtain SSR variants acting on different central 
sequences, but success was only obtained on sequences that closely resemble the enzyme’s 
nature sites (30).  
Single-stranded oligodeoxyribonucleotides (ssODNs) (34) are another alternative method 
for mammalian genome editing. The simple requirements of ssODNs for genome editing make 
ssODNs convenient to use and potentially highly multiplexible. ssODNs mediated genome 
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editing has proven very efficient to incorporate the information in E.coli genome via mimicking 
the okazaki fragment during DNA replication (35). The mechanism for ssODN-mediated gene 
targeting in mammalian cell is unclear. In addition, although mammalian cell system, site-
specific sequence alterations have successfully been introduced into mouse embryonic stem cells 
(mESCs)  and several transformed human cells using ssODNs (36), the targeting efficiency is 
still low, ranging from 10
-3
~10
-6
 in a variety of human cells (37). The suppression of mismatch 
repair (MMR) activity can enable effective ssODN-mediated genome targeting in many cell 
types (37), but the level of undesired mutations accumulated in the modified cells during the 
brief period of MMR suppression is unknown. Future studies addressing the mechanism and 
enhancing the efficiency of ssODNs-mediated genome editing is ssODNs approach practical to 
use on the mammalian genomes.    
 
Applications of genome editing 
Overview 
In addition to functional studies of the genome, the efficient alteration of genomic 
sequences in a wide range of organisms and cell types has inspired endeavors to use these tools 
in various academic, pharmaceutical and industrial settings. We will discuss the applications and 
prospects in 1) building model organisms, 2) agriculture and industrial productions and 3) 
therapeutic and pharmaceutical applications.  
 
Applications in building animal/cellular models system 
10 
 
The ability to efficiently edit the genome has led to the development of new animal 
models and cellular systems for biological research and clinical applications. Genome 
manipulation has been conducted in commonly used model organisms (38) such as 
Caenorhabditis elegans,  zebrafish, drosophila, rats and mice, in addition to more exotic species 
including frogs, sea urchins, cricket, rabbits and butterflies. Moreover,  genome editing 
approaches have been extended to human pluripotent cell lines to model a broad range of genetic 
conditions (39).  These model systems can help us study human diseases. For example, 
inactivation of the gene encoding low-density lipoprotein (LDL) receptor in pig models familial 
hypercholesterolemia (40). In addition, modified human stem cells carrying specific diseases 
mutations can be used in the in vitro drug screening and toxicological tests that otherwise not 
directly feasible in human subject (7).  
 
Applications in agriculture 
Genome editing tools can be used to generate new agriculturally- relevant plants and 
animal species.  It has been demonstrated that introduction of specific mutations and transgenic 
insertions can confer herbicide resistants (38, 41) in corn, tobacco and Arabidopsis thaliana. In 
addition, genetically modified live stocks have also been produced (42). For example, 
‘enviropigs’, produced by the addition of the Phytase gene of E.coli origin in pigs, is capable of 
digesting phytic acid in the cereal grains, thus reducing feed costs and phosphorus pollution.  
 
Applications in gene therapy 
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The ability to edit the human genome presents opportunities for treatment of genetic 
disorders. In general, there are two different approaches, 1) stem cell based ex-vivo gene 
therapies and 2) direct in vivo gene therapies.  
The idea of human stem cell-based gene therapy is centered around the prospect of 
restoring normal gene function under the control of endogenous regulatory elements and 
generating a ready supply of genome corrected cells for autologous transplantation (43, 44). 
Although the concept of stem cell based gene therapy seems futuristic, scientists have made 
considerable progress on various fronts.  First, following the exciting study conducted by 
Yamanaka’s group (45), several non-transgenic approaches have been developed to reprogram 
human somatic cells into human induced pluripotent stem cells (hiPSCs) (46).  Second, genomic 
defects within hiPSCs can be corrected by the deployment of site-specific nucleases and DNA 
donors. It has been demonstrated that monogenicdisorders, such as sickle cell anemia (47), cystic 
fibrosis (48), Huntington’s diseases(49), Parknison’s (50), X- linked severe combined immune 
deficiency (SCID) (51) and hemophilia B (52) can be genetically corrected.  Third, hiPSCs 
demonstrate the ability to differentiate into many defined somatic cell types of the body (43), 
including hepatic, pancreatic, intestinal, pulmonary, neural progenitor cells, haematopoietic cells 
and cardiomyocyte for autologous transplantation. In addition, the therapeutic value of gene 
editing for stem cell-based therapy has been demonstrated in mouse models. For example,  
Jaenisch and colleagues used homologous recombination to repair the genetic defect in iPS cells 
derived from a humanized mouse model of sickle-differentiation (53); subsequently, it was 
demonstrated that transplantation of the corrected haematopoietic progenitors into the affected 
mice rescued the disease phenotype.   
12 
 
In vivo genome editing is another promising approach for the treatment of genetic 
disorders. It has been demonstrated in a mouse model of haemophilia that ZFNs are able to 
induce DSBs efficiently when delivered directly to mouse liver (52). The level of gene targeting 
achieved was sufficient to correct the prolonged clotting times in mice, and remained persistent 
after induced liver regeneration.  
Despite heady progress, to realize the potential of using gene therapy tools in clinical 
practice, several technique hurdles must be addressed. First, it is important to demonstrate that 
no oncogenic mutations have been made in the corrected cells or transfected tissues. Non-
specific DSBs introduced by customized nucleases are known to be mutagenic and can lead to 
unspecific regional mutations and chromosomal translocations. Genome wide sequencing has 
been performed to investigate the off-target mutations generated by ZFNs and only a few 
mutations were identified in the colonized cells (47). However, this aspect is not clear for 
TALEN edited cells, or CRISPR targeted systems. It is critical, therefore, to systematically 
assess the specificity of the nucleases and engineer better system that minimizes these off-target 
effects. Second, for in vivo gene therapy, efficient and specific gene delivery methods as well as 
strategies to address potential adverse immune responses need to be investigated.  
Aside from restoring the function of disease genes, genome editing tools can be used for 
other types of clinical applications. For example, genome targeting practices have been 
performed to disrupt C-C chemokine receptor type 5 (CCR5) (54–56), the HIV co-receptor, in 
hematopoietic stem cells, which confers differentiated T cells and transplanted mouse HIV 
resistance.  This approach is currently in clinical trials (NCT01252641, NCT00842634 and 
NCT01044654).  Besides that, the concept of epigenetic chromosome therapy has been 
successfully demonstrated. In this exciting study, insertion of a copy of XIST (the X-inactivation 
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gene) on the extra copy of chromosome 21 silent the host chromosome, thus correcting gene 
imbalance of pluripotent stem cells derived from Down’s syndrome patients (57). 
 
Development of new genome editing tools  
Throughout this thesis, we described the development of novel genome editing tools: 
first, reTALEs (Chapter 2), which simplify tool synthesis and enable the elusive construction of 
lentivirus particles encoding TALE; CIRSPR (Chapter 3), a highly multiplexible and robust 
genome editing venue; and targeted demainases (Chapter 4), a genome editing tool that does not 
introduce DSBs and does not require DNA donors. Additionally, we investigated the genome 
editing specificity of TALE and CRISPR (Chapter 3) and devised strategies to mitigate off-target 
effects. Finally, we enhanced accessibility to these new methods by constructing a robust 
pipeline for scarless human stem cell genome engineering and demonstrated the utility of these 
tools by applying the engineered cell lines to study cellular etiology of human diseases. 
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Summary 
Precise genome editing in human induced pluripotent cells (hiPSCs) with targeted 
nucleases promises to advance biomedical research and personalized therapies. However, despite 
much progress, technical barriers in nuclease synthesis, accurate assessments of editing, and 
isolation of correctly edited cells continue to impede progress. To address these problems, we 
developed a robust pipeline for scarless genome modification of hiPSCs within three weeks that 
integrates: (1) TALEs that were recoded (re-TALEs) to eliminate DNA repeats, (2) rapid one-pot 
assembly of re-TALE nucleases (re-TALENs), (3) sensitive genome editing assessment, and (4) 
isolation of scarlessly edited hiPSCs without selection. Using our pipeline, we synthesized and 
tested 15 re- TALEN pairs targeting the CCR5 locus and achieved targeted homology directed 
repair (HDR) rates in hiPSCs of 0.3~1.8% with single stranded DNA oligonucleotides 
(ssODNs). DNA repeat elimination enabled generation of functional re-TALE coding 
lentiviruses. We also documented effects on genome editing efficiency of target site chromatin 
state and quantified impacts of ssODN design parameters. 
 
Introduction 
Understanding the mechanisms by which genetic variation contributes to phenotype and 
disease is a central goal of human genetics and will be critical to the development of 
personalized medicine. Despite the rapidly-growing knowledge-base on human genetic variants 
associated with human disease (1–3), the functional significance of most of these variants is 
unknown. While the function of each variant can be explored with reporter constructs in human 
or non-human cells, a clearer path would be to edit a variant directly and precisely in the 
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genomes of human cells to examine if this results in detectable phenotypes relative to unedited 
cells.  This may be especially powerful for human induced pluripotent cells (hiPSCs), which can 
be differentiated into defined cell types to check for phenotypes specific to certain types (4). 
Such an approach, ensuring permanent correction of specific mutations, also presents an 
opportunity in the treatment of genetic disorders (5), such as sickle cell anaemia (6), α1-
antitrypsin deﬁciency (7), X-linked SCID (8) and p53-related cancers (9). In addition, precise 
genome editing in concert with the pluripotency of hiPSCs provides new venues for infectious 
disease treatment. For example, disruption of the CCR5 locus, the gene encoding the HIV co-
receptor, in human stem cells has made differentiated T cells resistant to HIV virus infection (10, 
11). Clinical trials are underway with this approach and current data have demonstrated 
improvement in several clinical parameters while being well tolerated.   
Currently, nuclease-mediated genome editing provides the most efficient way to precisely 
edit cells, including human cells (12–14).  By generating a double-stranded DNA (dsDNA) cut 
near the sequence to be edited, while providing homologous donor DNA containing the intended 
changes, cells can be induced to repair the cut with the donor and incorporate the desired 
sequence change with efficiencies as high as ~50% (Urnov et al., 2005; Cade et al., 2012), 
although generally less for hiPSCs (18–20).  The most common approach in recent years to 
targeting dsDNA cuts has been to generate Zinc Finger Nucleases (ZFNs), with ZF domains 
programmed to bind to a target site being fused to FokI nuclease domains (15, 21) to cut that site.  
Recently, however, Transcription Activator-Like Effectors (TALE) are being increasingly 
adopted in place of ZFs, since TALES not only have the advantage of a much simpler design 
(22), but when fused to FokI to produce TALE-Nucleases (TALENs), are proven to be more 
specific and less toxic than ZFNs (23, 24), A number of methods have been published for 
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synthesizing TALENs increasingly rapidly and efficiently (24–27). However, TALENs target 
particular DNA sequences by means of an array of many (~12-20+) Repeat Variable Diresidue 
(RVD) domains (one RVD per target bp) that are extremely similar (22). This repeat structure 
complicates TALEN synthesis.  Current methods circumvent this problem by iterative assembly 
that require building up the arrays from smaller pieces (24, 25).  It might be desirable therefore 
to eliminate the repeats at the DNA sequence level, which could eliminate the need for iterative 
methods and enable a faster, simpler, and less expensive one-pot synthesis of extended RVD 
arrays.  Eliminating the RVD repeats left behind by current iterative methods could also address 
important post-synthesis problems that arise because the DNA repeats remain, such as the 
generation of high titers of lentivirus containing RVD arrays, which is critical for delivering the 
gene targeting tools into many cell types and animals (28).  
Finally, it remains difficult to isolate scarlessly genome-edited hiPSCs.  Owing to our 
limited knowledge of genome editing efficiencies in hiPSCs, most current methods introduce 
selectable or screenable markers along with the edit to enable isolation of correctly altered cells 
(18, 19), leaving the host genome with contaminating non-human elements, or requiring 
additional steps with complex constructs and secondary selections (7) to remove the undesired 
elements. Recent genome-editing works using ssODNs in combination with ZFNs (29) obtained 
isogenic hiPSCs with precise genome editing without selection (30), raising the prospects of 
simplified scarless genome engineering. Nevertheless, the precise efficiency, scope, and 
biological mechanisms of ssODN mediated HDR (31, 32) remain elusive. In addition, while 
correctly edited cells can be isolated by cloning out single cells and sequencing for the targeted 
changes if correct alteration frequencies are on the order of ~1%, this is challenging for hiPSCs 
which grow poorly as isolated cells deprived of cell-cell contacts (20). Thus, special methods 
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that assist clonal isolation of hiPSCs will improve both the therapeutic and experimental 
potential of hiPSCs.  
Here we address all of these problems by presenting an integrated and extensible pipeline 
for conducting precise genome editing, including four novel components:  
(1) A platform to design customized recoded TALEs (re-TALEs) that minimizes 
DNA repeats 
(2) A robust protocol to assemble re-TALE transcription factors and re-TALE 
nucleases (re-TALENs) in a one-hour, one-pot reaction  
(3) A high-throughput sequencing-based system to accurately and comprehensively 
assess both NHEJ and HDR genome editing efficiency, where HDR is assessed using ssODN 
donor DNA  
(4) An efficient and rapid platform to conduct genotype screening of monoclonal 
hiPSCs 
We demonstrate our pipeline by designing, generating, and testing 30 re-TALENs 
targeted to 15 distinct loci upstream of the CCR5 gene, a therapeutic gene target of HIV 
treatment, in both K562 cells and hiPSCs, and then isolating monoclonal correctly edited hiPSCs. 
With the accuracy and sensitivity provided by our assessment system, we found more than half 
of the re-TALENs/ssODN achieving 0.3%-1.8% HDR and 0.3%-1.3% NHEJ efficiency in 
hiPSCs, and 3%-37% HDR and 3%-79% NHEJ in K562 cells, suggesting that re-TALENs in 
conjunction with ssODNs constitute a facile and broadly applicable genome editing tool.  We 
show that eliminating the repeats in our recoded TALENs does not reduce the efficiency of 
genome editing compared with non-recoded TALENs, and that generating high titers of 
functional re-TALE lentiviruses is possible. Additionally, we found that there is no correlation 
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between genome editing efficiency and target site DNase I hypersensitivity (HS) but that there is 
an inverse correlation of HDR and nucleosome occupancy. We demonstrate that our pipeline can 
aid the improvement of genome editing by identifying optimal ssODN DNA donor design 
parameters.  Lastly, by integrating our tools, we demonstrated a robust pipeline for obtaining 
scarless genome edited hiPSCs without selection within 3 weeks.  
Our work presents an efficient and integrated toolkit for the design, synthesis and 
assessment of re-TALEs for genome editing in general and a robust pipeline for genome 
engineering of hiPSCs. The pipeline is also extensible in that tools generated in our system can 
be used with other targeted genome manipulations and vice versa. Our genome editing pipeline 
will provide researchers, clinicians and technologists alike with a flexible and powerful method 
for conducting genome editing in biomedical studies and, ultimately, clinical practice.  
 
Results 
Design of re-TALEs for genome editing 
TALEs recognize target DNA sequences by means of arrays of tandem repeats of a 33-34 
amino acid RVD domain with two variable positions, which consecutively recognize and bind 
individual base pairs of their target DNA sequence (22).  However, this system leads to extensive 
repeats within TALE DNA coding sequence, which complicates the synthesis of DNA constructs 
expressing them. To overcome this problem, we devised an algorithm to radically redesign the 
sequence of TALE RVD arrays. The algorithm uses the redundancy of the genetic code to design 
a set of recoded TALE DNA sequences (re-TALE) which generates identical RVD amino acid 
sequences without the repetition of DNA sequences individually and as a group. (Figure 2_1 A)  
We also incorporated additional constraints to ensure that the re-TALEs present low potential for  
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5’ mRNA secondary structure, and an adequate codon adaptation index for human expression. 
Re-TALEs encoding 16 tandem DNA recognition monomers, plus the final half RVD repeat 
(16.5), are devoid of any 12bp repeats (Figure 2_1 A). Notably, this level of recoding is 
sufficient to allow PCR amplification of any specific monomer or sub-section from a full-length 
re-TALE construct (Figure 2_1 B).  Our re-TALE design algorithm and code is made available 
to the public. This code can be used to eliminate DNA repeats in other arrayed repeated protein 
domains, including alternative TALE monomers or novel TALE frameworks such as the Goldy 
framework (33).  
 
Robust re-TALE-N/TALE-TF Assembly 
The improved design of re-TALEs makes it possible to order them from gene synthesis 
companies using standard technology (34), without incurring the added costs or extra procedures 
that come with sequences containing many repeats.  For investigators wishing to synthesize re-
TALEs in-house, however, we developed a library of RVD dimer blocks and backbone 
constructs (Figure 2_2 A) for a robust and cost-effective  
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Figure 2_1. Design of reTALE   
(A) Sequence alignment of the original TALE RVD monomer with monomers in re-TALE-16.5 (re-TALE-M1re-
TALE-M17). Nucleotide alterations from the original sequence are highlighted in gray.  
(B) Test of repetitiveness of re-TALE by PCR. Top panel illustrates the structure of re-TALE/TALE and positions 
of the primers in the PCR reaction. Bottom panel illustrates PCR bands with condition indicated below. Note the 
PCR laddering presents with the original TALE template (right lane).  
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assembly protocol we call TASA (re-TALE Single-incubation Assembly). To enable specific 
assembly of re-TALEs, we designed the blocks such that each one shares unique 32 bp overlaps 
with adjacent blocks or the vector backbones, similar to the design of other assembly methods 
such as SLIC/ Gibson and CPEC (35–37).  Unlike other TALE assembly methods, our re-TALE 
dimer blocks allow the full length re-TALEs to be efficiently assembled and amplified by PCR. 
Additionally, to simplify the procedure, we modified the destination vectors by incorporating 
ccdB, a bacterial negative selection cassette, flanked with paired endonuclease cutting sites at 
designated re-TALE cloning positions. With the concerted action of endonucleases, exonucleases, 
polymerases and ligases in the TASA reaction, re-TALE-TF/N plasmids can be directly 
assembled from re-TALE blocks and destination vectors. (Figure 2_2B)  To reduce the 
frequency of false ligation products, we evaluated the activity of exonucleases at different 
enzyme concentrations (Figure 2_3) and chose Tth-derived ligase to increase ligation specificity 
(Figure 2_4). With optimized conditions, we assembled re-TALEs possessing 12.5, 14.5, 16.5 
RVD monomers and assessed the assembly efficiency by checking the length of the cloned re-
TALE insertions. We found perfect re-TALE assemblies with the following success rates: re-
TALE-12.5, 46%; re-TALE-14.5, 32%; and re-TALE16.5, 18% (Figure 2_5). Detailed 
procedures for our robust and rapid TASA protocol can be found in the Methods.  Sequences of 
the re-TALEs and backbone vectors are listed in the sequence Information, and all cloned re-
TALE blocks and backbone vectors will be made publically available and will be deposited in 
Addgene. 
 
Comparison of re-TALEs and TALEs 
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Figure 2_2. Design and practice of TASA assembly  
(A) Schematic representation of the library of re-TALE dimer blocks for TASA assembly. There is a library of 10 
re-TALE dimer blocks encoding two RVDs. Within each block, all 16 dimers share the same DNA sequence except 
the RVD encoding sequences; Dimers in different blocks have distinct sequences but are designed such that they 
share 32bp overlaps with the adjacent blocks. DNA and amino acid sequence of one dimer (Block6_AC) are listed 
on the right.  
(B) Schematic representation of TASA assembly. The left panel illustrates the TASA assembly method: a one-pot 
incubation reaction is conducted with an enzyme mixture/re-TALE blocks/re-TALE-N/TF backbone vectors. The 
reaction product can be used directly for bacterial transformation. The right panel illustrates the mechanism of 
TASA. The destination vector is linearized by an endonuclease at 37°C to cut off ccdB counter-selection cassette; 
the exonuclease, which processes the end of blocks and linearized vectors, exposes ssDNA overhangs at the end of 
fragments to allow blocks and vector backbones to anneal in a designated order. When the temperature rises up to 50
°C, polymerases and ligases work together to seal the gap, producing the final constructs ready for transformation.   
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Figure 2_3. Optimization of  exonuclease in TASA reaction   
(A) To enable specific assembly, we sought to control the processivity of exonucleases. First, we tested whether 
phosphothioester (PT) linkage is resistant to T5 exonuclease activity so that we can use PT to stop the activity of 
exonuclease at designated sites. To this end, we embedded 3 consecutive PT bonds 30 nucleotides away from the 
ends of re-TALE blocks via PCR with PT modified primers and then incubated the re-TALE blocks with T5 
exonuclease (T5 Exo) (1 mU/ µl).  The size of digested ssDNAs was tested by running the reaction product on Urea-
PAGE gels. We found that PT linkage is not resistant to T5 Exo-. Red-arrow indicates the position of full length re-
TALE blocks.   
(B)  We next tested whether we can control the size of ssDNA overhangs by titrating the concentration of T5 Exo 
and we found 1mU/µl T5 Exo generates DNA overhangs around the size of 20-30NT at 50°C for 30min. We chose 
that condition thereafter.   
(C) We then tested whether we can increase the reaction temperature to enhance the specificity of downstream DNA 
annealing and ligation while not compromising the T5 Exo activity. To this end, we tested the activity of T5 at 
different temperature and we found it is active within 30°C- 50°C, so we adhere to 50°C as the reaction condition.  
(D) We then tested the activity of T7 exonuclease at 50°C and did not see any activity under such a condition.  
(E) We tested the activity of Exonuclease III with different incubation times and we chose 1min as the reaction 
condition as Exonuclease III digests 10-30 nucleotides under such condition.  
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Figure  2_4. Optimization of  ligases in TASA reaction   
(A)  Schematic representation of the experimental design for Optimization of ligases and polymerases in the TASA 
reaction. The diagram illustrates a GFP reporter which can be constructed with 6 pieces of DNA fragments and a 
destination vector using assembly reactions. We utilized the quick readout of colony numbers and GFP+ colony 
percentages of this reporter system to optimize the ligases and polymerases for the TASA reaction. pL:  phage λ 
PL promoter.  
(B) Test of efficiency and specificity of different assembly reactions. We tested different assembly enzyme mixtures 
(below), transformed enzyme mixture to E.coli and calculated the GFP+/GFP- colonies one day after transformation 
(above). We found that reaction containing Ampligase and Taq DNA polymerase yielded the most GFP+ colonies, 
suggesting the high efficiency and specificity of this enzyme mixture. The detailed enzyme protocol can be found in 
the Methods.  
 
29 
 
Figure 2_5. TASA assembly efficiency  
TASA assembly efficiency for re-TALEs possessing different monomer lengths. The blocks used for assembly are 
illustrated on the left and the assembly efficiency is presented on the right. 
equivalent levels of protein expression and activity. A re-TALE-TF (14.5mer) and re-TALE-TF  
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We next compared the activities of re-TALE-TFs and re-TALE-Ns against TALEs 
generated with non-recoded sequence in human cells. First, we constructed re-TALE-TF-2A-
GFP and TALE-TF-2A-GFP plasmids coding for identical amino acid sequences, but where the 
latter was generated with non-recoded TALE components (26). These plasmids were transfected 
along with a mCherry reporter into 293T cells (Figure 2_6 A). We did not observe a significant 
difference in either GFP or mCherry expression between the two samples (Figure 2_6 C), 
indicating ses in (16.5mer) generated with longer sequence  
recognition arrays to the same DNA target demonstrated similar levels of protein expression and 
transcriptional activation activity (Figure 2_6 B). DNA target demonstrated similar levels of 
protein expression and transcriptional activation activity (Figure 2_6 B).  
Similarly, we constructed a pair of re-TALENs targeting the PPP1R12C (AAVS1) gene 
with the same amino acid sequences as previously published TALENs (19). To quantify the gene 
targeting efficiency, we built a 293T reporter cell line in which a chromosomally integrated 
mutant GFP gene can be repaired by nuclease-mediated HDR (20) (Figure 2_7 A)  using this re-
TALEN pair. re-TALEN-mediated HDR, as indicated by the percentage of GFP+ cells, exhibited 
an efficiency of 1.4%, similar to that of non-recoded TALENs (1.2%) (Figure 2_7 B).  We next 
sought to verify the activity of re-TALENs on a native locus. To this end, we transfected PGP1 
hiPSCs and 293T cells with the AAVS1 re-TALEN expression plasmids described above and a 
donor plasmid containing puromycin resistance and EGFP gene flanked by homologous 
sequence to the endogenous PPP1R12C gene (19) (Figure 2_7 C).  We successfully obtained 
hiPSCs  
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Figure  2_6. Expression level and activity of re-TALE-TFs  
(A) Schematic representation of the fluorescence reporter system for testing re-TALE expression and activity. The 
diagram illustrates the structure of TALE- and re-TALE-TF-2A-GFP constructs and their mCherry reporters. VP64, 
synthetic transcription activation domain; 2A, self-cleavage peptides.   Corresponding TALE-TF-2A-GFP constructs 
based on non-recoded TALE sequences were also constructed that coded for identical protein sequences. 
(B) Expression level and activity of re-TALE-TFs: the binding site sequences of re-TALEs are shown on the left. 
The GFP and mCherry reporter expression levels of the corresponding re-TALE-TF-2A-GFP constructs were 
measured by flow cytometry (Methods).  Fluorescent signal intensities are presented in arbitrary fluorescence units.  
(C) Cells co-transfected with re-TALE-TF-2A-GFP plasmids and the reporter plasmid showed equivalent GFP and 
mCherry expression compared with the TALE-TF containing the same amino acid sequence.  Scale bar, 100 µm.  
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Figure 2_7. Efficiency of re-TALENs   
(A) Schematic representation of experimental design for testing genome targeting efficiency.  A genomically 
integrated GFP coding sequence is disrupted by the insertion of a stop codon and a 68bp genomic fragment derived 
from the AAVS1 locus (bottom). Restoration of the GFP sequence by nuclease-mediated homologous 
recombination with tGFP donor (top) results in GFP+ cells that can be quantitated by FACS. Re-TALENs and 
TALENs target identical sequences within AAVS1 fragments.  
(B) Bar graph depicting GFP+ cell percentage introduced by tGFP donor alone, TALENs with tGFP donor, and re-
TALENs with tGFP donor at the target locus, as measured by FACS. (N=3, error bar =SD) Representative FACS 
plots are shown below.  
(C) Schematic overview depicting the targeting strategy for the native AAVS1 locus. The donor plasmid, containing 
splicing acceptor (SA)- 2A (self-cleaving peptides), puromycin resistant gene (PURO) and GFP were described 
before (Hockemeyer et al., 2011). The location of PCR primers used to detect successful editing events is depicted 
as blue arrows.  
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 (Figure 2_7 D) from the pool of transfected cells after one week of puromycin selection and 
verified the specific genomic integration in hiPSCs by PCR and Sanger sequencing (Figure 2_7 
E, F). Taken together, we concluded that re-TALE-N/TFs, despite their recoded DNA sequence, 
can effectively introduce genomic modifications in both somatic and pluripotent cells, at levels 
equivalent to TALENs and TALE-TFs with non-recoded sequences. 
 Next, we hypothesized that the removal of repeat sequences in re-TALEs would be 
beneficial for virus production. Lentiviral particles are powerful gene delivery vehicles for many 
cell types and in vivo animal studies (38, 39). However, no study to date has reported generation 
of lentivirus carrying TALEs, probably due to the difficulty of generating functional viral 
particles encoding the repetitive TALE sequences. To test whether re-TALEs can improve the 
generation of functional lentivirus, we packaged lentiviral particles encoding re-TALE-2A-GFP 
or TALE-2A-GFP, and measured the viral titer based on GFP fluorescence. Re-TALE-TF-2A-
GFP produced viral particles with titer of 1.4*10
6
 IFU/ml, 350X more than that of TALE-TF-
2A-GFP (4*10
3 
IFU) (Figure 2_8). To test the activity of re-TALE-TF encoded by viral particles, 
we transduced 293T cells with re-TALE-TF-GFP viral particles and transfected a mCherry 
reporter to the transduced 293T cell line 3 days after transduction. 293T cells transduced by 
lenti-re-TALE-TF showed considerably greater mCherry expression activation (Figure 2_8) 
compared with lenti-TALE-TF with equivalent titration.  
 
Genome Editing Assessment System (GEAS)  
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Figure 2_8. reTALEN activity and lentivirus generation potential 
Images of lentivirus-transduced 293T cells transfected with mCherry reporter plasmid  
We transduced 293T cells with lentiviral particles encoding re-TALE-TF-2A-GFP or TALE-TF-2A-GFP using 250 
or 25 µl of lentiviral suspension. Three days after transduction, we transfected the transduced cells with the 
corresponding mCherry reporter to verify the activity of lenti-TALE-TF/lenti-re-TALE-TF. Scale bar, 100 µm.  
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Having validated the activity of re-TALENs, we next sought to build a sensitive and 
quantitatively accurate platform for simultaneously assessing re-TALEN-mediated NHEJ and 
HDR gene editing efficiencies, which we call GEAS (Genome Editing Assessment System).   
The idea is to deliver a pair of re-TALENs and an ssODN that matches the region of the re-
TALEN target site except for a central 2bp mismatch, to allow re-TALEN dsDNA cutting and 
genomic repair to proceed, and then to conduct paired-end deep sequencing on the genomic 
region containing the target.  HDR efficiency was measured by the percentage of reads 
containing exactly and only the 2bp mismatch within a 12bp window center of the re-TALENs 
target site. NHEJ efficiency was measured by the percentage of reads carrying indels.  We 
developed a bioinformatics package in R to perform this analysis. To assess this system, we 
designed and constructed a pair of re-TALENs targeting the upstream region of CCR5 (re-
TALEN pair #9 in Table S3) and a 90nt ssODN donor according to the specifications above 
(Figure 2_9 A), we then delivered the re-TALENs and ssODN into hiPSCs and K562 cells.  
Delivery of ssODN alone into hiPSCs resulted in minimal HDR and NHEJ rates while 
the combination of re-TALENs with ssODN induced HDR with a rate of 0.67% and NHEJ with 
a rate of 0.73% (Figure 2_9 B). Gene editing is much more efficient in K562 cells, where we 
observed a 15% HDR rate and a 12% NHEJ rate, ~100X higher than the ssODN-only group 
(Figure 2_9 B). Notably, we observed that in both cell lines, the rate of genomic deletions and 
insertions, products of NHEJ, peaked in the middle of the spacer region between the two TALEN 
monomer sites for each of our re-TALENs (Figure 2_9 B), as would be expected from the fact 
that the DSB takes place in this region.  We observed a median deletion size of 4bp and insertion 
of 3bp in hiPSCs and a  
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Figure 2_9. Sensitive and comprehensive genome editing assessment system (GEAS) 
(A) Schematic representation of the genome engineering experimental design. At the re-TALEs pair targeting site, a 
90mer ssODN carrying a 2bp mismatch against genomic DNA was delivered along with re-TALEN constructs into 
PGP1 iPSCs and K562 cells.  
(B) Deep sequencing analysis of HDR and NHEJ efficiencies for re-TALEN pair and ssODN #9 from Table S3.   
Alterations in the genome of hiPSCs (top panel) and K562 cells (bottom panel) were analyzed from high-throughput 
sequence data by GEAS.  HDR was quantified from the fraction of reads that contained a 2bp point mutation built 
into the center of the ssODN (pink), and NHEJ activity (blue) was quantified from the fraction of 
deletions/Insertions. We delivered the ssODN DNA donor alone (left panels) to the two cell types as the control. 
The gray dash lines mark the outer boundary of the re-TALEN pair’s binding sites, which are at positions -26bp 
and +26bp relative to the center of the two re-TALEN binding sites.  NHEJ-mediated genomic deletion frequencies 
at each nucleotide position are plotted in blue, HDR frequency is plotted in pink 
.  All reads analyzed as containing NHEJ insertions and deletions are included in the NHEJ percentage quoted in the 
figure, but only deletions are profiled in the graph.   See Methods for details.  
(C) Deletion/Insertion size distribution in hiPSCs (top) and K562 cells (Bottom) analyzed from the entire NHEJ 
population.  
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median deletion size of 6bp and insertion of 3bp in K562 cells (Figure 2_9 C), consistent with 
DNA lesion patterns usually generated by NHEJ (40). GEAS provides a convenient and accurate 
view of both NHEJ and HDR genome editing efficiencies.  Moreover, unlike mismatch-
endonuclease-based measures of NHEJ, our sequencing-based analysis gives a precise and 
immediate measure of the size profile of NHEJ indels generated by the nuclease-induced DSB.  
Finally, with GEAS, we observed levels of gene editing events in the hiPSCs that would be at or 
below the limit of detection of mismatch sensitive endonucleases (3%) (41).   
We undertook several analyses to estimate the specificity, sensitivity and reproducibility 
of our platform.  First, using the dataset of re-TALENs/ssODN experiment in hiPSCs, we 
computed the probabilities of observing the 2bp mismatch that signifies HDR by sequencing 
errors. Assuming that errors in different nucleotide positions and in forward versus reverse reads 
are independent, the probabilities for observed datasets were <= 10
-4
 even for seeing a single 
HDR event among 7 X10
5
 reads (Methods). These results indicate an extremely low false 
positive rate for HDR detection such that even seeing a single read with the targeted 2bp 
mismatch is a strong evidence of the presence of an HDR event.  However this does not indicate 
the numerical accuracy of the measured HDR rate, or estimate the minimal HDR rate that could 
be reliably detected using this method.  To estimate the latter, we performed an information- 
based analysis (Figure 2_10 A) that computationally spiked ‘corrected’ sequences into real reads, 
and assessed the signal of corrected reads relative to noise, namely the occurrence of any two bp 
mutations outside the target site (Methods). We found the HDR detection limit to be ~.007% for 
the hiPSCs data set, ~100 times lower than 0.67% HDR detected. Thereafter,  
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Figure 2_10. GEAS sensitivity and reproducibility test 
(A) Information-based analysis of HDR detection limit. Given the dataset of re-TALENs (#3)/ssODN, we identified 
the reads containing the expected editing (HDR) and systematically removed these HDR reads to generate different 
artificial datasets with a "diluted" editing signal. We generated datasets with 100, 99.8, 99.9, 98.9, 97.8, 89.2, 78.4, 
64.9, 21.6, 10.8, 2.2, 1.1, 0.2, 0.1, 0.02, and 0% removal of HDR reads to generate artificial datasets with HR 
efficiency ranging from 0~0.67%. For each individual dataset, we estimated mutual information (MI) of the 
background signal (in purple) and the signal obtained in the targeting site (in green). We observe that MI at the 
targeting site is remarkably higher than the background when the HDR efficiency is above 0.0014%. We estimated a 
limit of HDR detection between 0.0014% and 0.0071%. MI calculation is described in the Methods.  
(B) The test of reproducibility of genome editing assessment system. The pairs of plots (Top and Bottom) show the 
HDR and NHEJ assessment results of two replicates with re-TALENs pair and cell type indicated above.  For each 
experiment, we conducted nucleofection, targeted genome amplification, deep-sequencing and data analysis 
independently. We calculated the genome editing assessment variation of replicates as (|HDR1-HDR2|)/2 
/((HDR+HDR2)/2) =ΔHDR/HDR and (|NHEJ1-NHEJ2|) /((NHEJ1+NHEJ2)/2) =ΔNHEJ/NHEJ and listed the 
variation results below the plots. We calculated the average variation of our system by 
(13.5%+7.5%+3%+7%+22.5%+2%+7.5%+25%)/8=10%. Factors that may contribute to the variations include the 
status of cells under nucleofection, nucleofection efficiency, and sequencing coverage and quality.   
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we performed the information-based measure of sensitivity for every individual data set to 
examine the reliability of our HDR measurement.  Finally, over the course of our work, we 
performed replicate genome editing assessment analyses of four samples (Figure 2_10 B), 
finding that the relative degree of variation to be ~10% between the replicates.  Among these 
datasets can be found two replicate measures of HDR at levels of ~0.07% (Figure 2_10 B), 
indicating that observation of rates of this magnitude are reproducible.  The information-based 
measure of sensitivity and the p-value computation for specificity have been built into the R 
package for GEAS. An additional test of the accuracy of GEAS can be found below in our 
comparison of HDR rates measured from sequencing against rates measured from cloning 
(Figure 2_11 B, C). 
 
Platform for isolation and clonal outgrowth of precisely edited hiPSCs 
 
GEAS revealed that the re-TALEN pair #9 achieved precise genome editing with an efficiency 
of ~0.6~0.7% in hiPSCs, a level at which correctly edited cells can usually be isolated by 
growing out single cells in a few 96 well plates. Outgrowth of hiPSCs from single cells is 
generally difficult, but protocols were recently published that describe media that facilitate this 
procedure (42). We optimized these protocols along with single-cell sorting procedures to 
establish a robust platform for single hiPSCs sorting and maintenance, that enables scalable 
monoclonal hiPSC recovery with efficiencies of >25% (see Methods). We combined this with a 
rapid and efficient genotyping system with which we can conduct chromosomal DNA extraction 
outgrowths of our sorted, edited hiPSCs to be genotyped on a large scale. Together these 
components comprise a pipeline for robustly obtaining genome-edited hiPSCs without selection.   
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To demonstrate this pipeline (Figure 2_11 A), we first transfected PGP1 hiPSCs with a 
pair of re-TALENs and an ssODN targeting CCR5 at site #3 (see Table S3) and we performed 
GEAS with a portion of the transfected cells, finding an HDR frequency of 1.7% (Figure 2_11 
B).  This information along with the 25% recovery efficiency allowed us to estimate that we 
could obtain at least one single cell clone of correctly edited cells from five 96-well plate with 
Poisson probability 98% (assuming =                  ).  We then FACS-sorted 
transfected single cells into 5 96-well plates 6 days after transfection and screened 100 
monoclonal hiPSCs 8 days after sorting. Sanger sequencing revealed that 2 out of 100 of these 
unselected hiPSC colonies contained a heterozygous genotype possessing the 2bp mutation 
introduced by the ssODN donor (Figure 2_11 C). The efficiency (1%=2/2*100) was consistent 
with the next-generation sequencing analysis (1.7%) (Figure 2_11 B). The pluripotency of the 
resulting hiPSCs was confirmed with immunostaining for SSEA4 and TRA-1-60 (Figure 2_11 
D). The cloned hiPSCs with desired genome editing generated mature teratomas with features of  
all three germ layers (Figure 2_11 E). To our knowledge, this is the first demonstration of using 
TALENs and ssODNs to obtain monoclonal hiPSCs with specific and scarless genetic alterations 
without any selection. 
 
Application of the toolkit to alteration of 15 CCR5 cis sites 
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Figure 2_11. Using re-TALENs/ssODN to obtain monoclonal genome edited human iPS cells without selection 
 (A) Timeline of the experiment. 
(B) Genome engineering efficiency of re-TALENs pair and ssODN (#3) assessed by the NGS platform described in 
Figure 5B 
(C) Sanger sequencing results of monoclonal hiPS colonies after genome editing. Of note, the 2bp heterogeneous 
genotype (CT/CTTA/CT) was successfully introduced into the genome of PGP1-iPS-5-11, PGP1-iPS-5-13 
colonies.   
(D) Immunofluorescence staining of targeted PGP1-iPS-5-11. Cells were stained for the pluripotency markers Tra-
1-60 and SSEA4.   
(E) Hematoxylin and eosin staining of teratoma sections generated from monoclonal PGP1-iPS-5-11 cells.  
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We next sought to test the scalability of our tools for building and assessing re-TALENs 
on 15 targeting sites cis to the CCR5 gene (Figure 2_12 A, Table S3).   Anticipating that editing  
efficiency might depend on chromatin state, these sites were selected to represent a wide range of 
DNaseI sensitivities (43).  Using our design and assembly tools above, we generated the re-
TALEN pairs targeting these sites and transfected them with corresponding ssODNs into PGP1 
hiPSCs and K562 cells.  Six days after transfection, we profiled the genome editing efficiencies 
at these sites in both cell lines.  
We detected NHEJ and HDR at levels above our statistical detection and sensitivity 
thresholds for 13/15 of our re-TALEN pair and ssODN in both hiPSC and K562 (see Table S4).  
In addition, in more than half of the re-TALENs pairs, the measured efficiency of HDR was > 
0.3% in hiPSC and > 3% in K562 cells.  Despite the fact that HDR & NHEJ efficiencies in K562 
cells are on average 21X higher than those in hiPSCs (Figure 2_12 B,C), we observed many 
similarities across the cell types.  A large and statistically significant positive 0.66  Pearson 
correlation coefficient is found between HR and NHEJ efficiency at the same targeting loci in 
both cell types (P=8X 10
-5
) (Figure 2_12 D),  consistent with the hypothesis that  DSB 
generation, the common upstream step of both HDR and NHEJ, is a rate limiting step for 
genome editing.   HDR rates are also very strongly correlated between the cell types (r=0.913, 
P= 2X10
-6
). Factors contributing to the ~21x difference in rates between the cell types might 
include lower expression level of re-TALEs in hiPSCs (Figure 2_13), or the activity of DNA 
repair pathways. While a strong correlation in DNase I hypersensitivity (DNaseI HS) (43) 
between the cell types at the target sites (r=0.732, p=0) indicates similar chromatin states,  
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Figure 2_12. Re-TALENs/ssODNs genome editing activity on CCR5 in hiPSCs and K562 cells  
(A) Schematic representation of the targeted genome editing sites on CCR5.  The 15 targeting sites are illustrated by 
blue arrows below. For each site, cells were co-transfected with a pair of re-TALENs and its corresponding ssODNs 
donor carrying 2bp mismatch against the genomic DNA. The genome editing efficiencies were assayed 6 days after 
transfection.  
(B) The HDR and NHEJ efficiencies of 15 pairs of re-TALENs/ssODNs targeting CCR5 in PGP1 hiPSCs genome. 
Top, NHEJ efficiencies were calculated by the frequency of genomic alleles carrying deletions or insertions at the 
targeting region. Middle, HDR efficiencies were calculated by the frequency of genomic alleles carrying 2bp 
mismatch introduced by ssODNs. Bottom, the DNaseI HS profile of hiPS cell line from ENCODE database (Duke 
DNase HS, iPS NIHi7 DS). The X-axis indicates the corresponding genomic position on chromosome 3.  
(C) The HDR and NHEJ efficiencies of 15 pairs of re-TALENs/ssODNs on CCR5 in K562 cells. Panel1, NHEJ 
efficiencies were calculated by the frequency of genomic alleles carrying deletions or insertions at the targeting 
region. Panel2, HDR efficiencies were calculated by the frequency of genomic alleles carrying the 2bp mismatch 
introduced by ssODNs. Panel3, the nucleosome occupancy data of K562 cells from ENCODE (Stanf Nucleosome 
K562 Sig). Panel 4, DNaseI HS profile of K562 cells from ENCODE (Duke DNase HS K562 DS). The X-axis 
indicates the corresponding genomic position on Chromosome 3 
(D) The correlation of HR and NHEJ efficiencies at identical sites in both iPSCs and K562 cells (r=0.68, P=8X 10-
5).  
(E) The inverse correlation of HR and nucleosome occupancy in K562 cells (r=-0.48, P=0.03) 
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Figure 12_13. reTALE expression level and acitivities in K562 cells and hiPSCs 
(A) Increased dosage of re-TALENs/ssODN increase the genome editing efficiency. We delivered re-TALENs pair 
(#3)/ssODNs into PGP1 hiPSCs with standardized condition (Top)  (1μg of each re-TALENs plasmid, 2μl of 100
μM ssODN ) or  twice as much of re-TALENs and ssODN (Bottom) (2μg of each re-TALENs plasmid, 4μl of 
100μM ssODN ). We observed increased HDR and NHEJ efficiency when we doubled the amount of DNA, 
although severe cell death was also observed in this group.  
(B) The top panel illustrates the constructs we tested in the expression experiment. NC-re-TALE-GFP is a truncated 
form of re-TALE-GFP without the middle DNA recognition domain. M-re-TALE-GFP is a truncated form of re-
TALE-GFP without the re-TALE’s N and C termini. GFP is the control plasmid only encoding GFP. All the 
constructs were built in the same vector backbones. The bar graph indicates GFP expression level as measured by 
flow cytometry.  
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this correlation does not exclude the possibility of large differences in the scale of DNaseI HS 
between the cell types, which could thus also contribute to the 21x difference.  The differences in 
HDR rates across sites in the same cell type may be attributed to different binding affinities 
between the re-TALENs and their target sites (22, 44) or, again, to epigenetic status. 
Interestingly, while we did not observe any correlation between the genome editing efficiency 
and DNaseI HS (Figure 2_12 B,C Figure 2_14),  we did observe an inverse correlation (r=-0.48, 
P=0.03) between nucleosome occupancy and HDR rates in K562 cells (Figure 2_12 E), for 
which (unlike hiPSC) these data are available  (ENCODE/Stanford/BYU, (45)).  
In this set of experiments, we leveraged the multiplicity and scalability of our methods to 
efficiently synthesize and assess genome editing at 15 sites cis to CCR5 gene in both hiPSCs and 
K562s.  We assembled re-TALENs in parallel in one 96-well plate using the one-hour TASA 
assembly reactions, and constructs were delivered into cell lines in parallel using 16-well 
nucleofector strips (Methods). Subsequently, we amplified targeting regions directly from cells 
in a 96-well plate using single-tube thermocycle reactions (Methods); and barcoded and pooled 
samples together for MiSeq sequencing runs.  
 
Use of the toolkit to assess factors affecting genome editing with ssODNs  
While ssODNs have been found to be effective as donor DNA in genome editing (see 
above,  (29, 30)), the mechanisms by which they participate in HDR are not understood and 
many questions remain regarding how to optimize their performance.  To date ssODN  
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Figure 12_14. The correlation analysis of genome editing efficiency and epigenetic state 
Left panel: we plotted the genome editing efficiencies (HDR or NHEJ) with the epigenetic parameters (DNaseI HS 
marker or Nucleosome occupancy).  
Middle panel: we used Pearson correlation to study possible associations between epigenetic parameters (DNase I 
sensitivity, nucleosome occupancy) and genome engineering efficiencies (HR, NHEJ). We compared the observed 
correlation to a randomized set (N=100000). Observed correlations higher than the 95th percentile, or lower than the 
5th percentile of the simulated distribution were considered as potential associations. We observed remarkable 
correlation between nucleosome occupancy and HR efficiency in K562 cells (r=-0.47).  
Right panel: overlay of epigenetic parameters (DNase I sensitivity, nucleosome occupancy) and genome engineering 
efficiencies (HR, NHEJ) along the CCR5 in the genome.    
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incorporation has been assayed by methods that give limited information about incorporation 
outcomes, including mismatch sensitive endonuclease assays, generation of restriction sites 
(Chen et.al. 2011), and low throughput cloning and sequencing (30). To demonstrate the utility 
of the more comprehensive information provided by GEAS, we used it to analyze ssODN design 
and targeting parameters with re-TALENs in hiPSCs. First we designed a set of ssODNs of 
different lengths (50-170nt), all carrying the same 2bp mismatch in the middle of the spacer 
region of the CCR5 re-TALEN pair #3 target site.  We observed that 90nt ssODN achieved the 
optimal HDR efficiency of ~1.8% and that longer ssODN declined in efficiency (Figure 2_15 A).  
Since it has been long established that longer homology regions improve HDR rates when 
dsDNA donors are used with nucleases (46), possible reasons for this result include that ssODNs 
are used in an alternative genome repair process, or longer ssODNs are less available to the DNA 
repair machinery, or that longer ssODNs incur negative effects that offset any improvements 
gained by longer homology, compared to dsDNA donors (47).  However, if either of the former 
two hypothesis were the case, NHEJ rates would be unaffected with longer ssODNs.  NHEJ 
induced insertion and deletion rates were observed to decline with HDR however (Figure 2_15 
A), suggesting that the longer ssODNs present offsetting effects.  Possible hypotheses would be 
that longer ssODNs are toxic to the cell (48), or that transfection of longer ssODNs saturates 
DNA processing machinery by causing decrease molar DNA uptake and so dilutes the capacity 
of the cells to take up or express re-TALEN plasmids.  
Assuming that our 90nt ssODNs interact with genomic targeting site through homology 
directed pairing, we then explored whether there might be an optimal  
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Figure  2_15. Functional parameters governing ssODN-mediated HDR with re-TALENs in iPSCs 
(A) PGP1 iPSCs were co-transfected with re-TALENs pair (#3) and ssODNs of different lengths (50, 70, 
90,110, 130,150,170 nts). All ssODNs possessed an identical 2bp mismatch against the genomic DNA in 
the middle of their sequence. A 90mer ssODN achieved optimal HDR in the targeted genome. The 
assessment of HDR, NHEJ-incurred deletion and insertion efficiency is described in the Methods.  
(B) A set of 90nt sense and anti-sense ssODNs were delivered into PGP1 iPSCs with re-TALEN pair (#3). These 
ssODNs were designed so that the distance between the middle of ssODNs and the middle of re-TALENs cutting 
site varied from -40bp ~ 40bp while specifying the same 2bp mismatch against the genome at the center of the re-
TALEN pair spacer region. ssODNs that were shifted to the 3’ side of target site achieved higher HDR efficiencies 
than their 5’ shifted counterparts; e.g., the sense ssODN at distance +10 (top half)achieved 3.3% HDR while that at 
distance -10 achieved 1.1% HDR. This asymmetry was also present when antisense ssODNs were used (bottom 
half).  
(C) Ninety bp ssODNs corresponding to re-TALEN pair #3 each containing a 2bp mismatch (A) in the center and an 
additional 2bp mismatch (B) at different positions offset from A (where offsets varied from -30bp30bp) were used 
to test the effects of deviations from homology along the ssODN. Genome editing efficiency of each ssODN was 
assessed in PGP1 hiPSC. The bottom bar graph shows the incorporation frequency of A only, B only, and A + B in 
the targeted genome. HDR rates decrease as the distance of homology deviations from the center increase  
(D) ssODNs targeted to sites with varying distances (-620bp~ 480bp) away from the target site of re-TALEN pair #3 
were tested to assess the maximum distance within which we can place ssODNs to introduce mutations. All ssODNs 
carried a 2bp mismatch in the middle of their sequences. We observed minimal HDR efficiency (<=0.06%) when 
the ssODN mismatch was positioned 40bp away from the middle of re-TALEN pair’s binding site.   
A B 
C D 
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homology pairing arrangement of the ssODN design.   To this end, we designed a set of 
90nt sense ssODNs that maintained their identical 2bp mismatch against the center of the re-
TALENs target site but asymmetrically shifted 5’ or 3’ with respect to the target region (Figure 
2_15 B). We found that HDR rates remained elevated when the ssODNs were shifted to have 
more base pairing of their 3’ ends against the complementary genomic DNA at the break 
compared to shifting an equivalent degree to have more pairing at the ssODN’s 5’ end. (Figure 
2_15 B)  However, this elevated HDR rate asymmetry vanishes when shifts reached ~25-30nt, at 
which point 5’ and 3’ shifts had similarly lower efficiencies.  A similar asymmetrical preference 
for ssODN 3’ pairing was seen when we used a set of antisense ssODNs.  These results suggest 
that the HDR rates are improved when there is longer pairing up to 25-30nt of the 3’ end of the 
ssODN against the chromosomal complement at the break, regardless of the strand polarity of 
the ssODN.  This asymmetry of ssODN performance with placement accords with the structure 
of resected genomic DSBs (40), where 3’ end ssDNA overhangs are exposed at DSB to ensure 
homologous recombination (HR).  This suggests that ssODNs utilize resected genomic 3’ 
overhangs DNA in a fashion similar to dsDNA donors to mediate genome editing. The fact that 
HDR rates drop off and become equivalent beyond that range may be due to the fact that 
increasing these shifts leaves less and less of the 5’ end of the ssODN to pair against the indented 
chromosomal complement on the other side of the DSB, resulting in failure of the HDR.  
Notably, we see that NHEJ rates are unaffected by these shifts of the ssODN (Figure 2_15 B), 
suggesting that ssODN relative position and content do not have offsetting impacts on cellular 
NHEJ at a dsDNA break in the way that longer ssODNs appear to (above). 
Next, we sought to examine the impact of imprecise homology in the pairing regions on 
HDR efficiency.  Here we designed 90nt sense ssODNs all positioned symmetrically with 
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respect to the central 2bp mismatch (A) in the center of the spacer region of re-TALEN pair #3, 
where each also had a second 2bp mismatch (B) at a different offset from the center (Figure 2_15 
C).  A sense ssODN possessing only the center 2bp mismatch was used as a control.  Each of 
these ssODNs was introduced individually with re-TALEN pair #3 and the outcomes were 
analyzed with GEAS.  We found that overall HDR as measured by the rate at which the A 
mismatch was incorporated (A+B, A) decreased as the B mismatches increased their distance 
from the A mismatch (Figure 2_15 C, S7A).  The higher HDR rate observed when B is only 
10bp away from A may reflect a lesser need for pairing of the ssODN against genomic DNA 
proximal to the dsDNA break.  We observe that at each distance of B to A, a fraction of HDR 
events only incorporate A, while another fraction incorporate both A and B (Figure 2_15 C (A 
and A+B)),  These two events might also be interpretable in terms of gene conversion tracts (49) 
along the length of the ssDNA oligo, whereby A+B events represent long conversion tracts that 
extend beyond B, and A-only events represent shorter ones that do not reach to B.  Under this 
interpretation, a distribution of gene conversion lengths in both directions along the ssODN can 
be estimated (Figure 2_16 B).  The estimated distribution implies that gene conversion tracts 
progressively decrease in incidence as their lengths increase, a result very similar to gene 
conversion tract distributions seen with dsDNA donors, but on a highly compressed distance 
scale of tens of bp for the ssDNA donor vs. hundreds of bases for dsDNA donors.  Consistent 
with this result, an experiment with an ssODN with three pairs of 2bp mismatches spaced at  
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Figure 2_16. Study of ssODN designs and theoretical models underlying re-TALENs/ssODN mediated HDR 
(A) Impact of homology pairing in the ssODN-mediated genome editing. Bar graph shows the rates of overall HDR 
as measured by the rate at which the middle 2b mismatch (A) was incorporated.  Each bar represents the sum of the 
A+B and A values of the bars platted in Figure 2_15 C.  Overall HDR decreases as the secondary mismatches B 
increase their distances from the A, where the relative position of B to A varies from -30bp to +30bp.  The higher 
rates of incorporation when B is only 10bp away from A (-10bp and +10b) may reflect a lesser need for pairing of 
the ssODN against genomic DNA proximal to the dsDNA break.  
(B) Distribution of gene conversion lengths along the ssODN.  For each bar except the 0 bar in Figure 8C, the value 
(A+B)/(A + (A+B)) is interpreted as indicating the fraction of HDR events for which gene conversion extended at 
least as far as offset of B. These values are plotted here.  The A-only events then represent shorter gene conversion 
tracts that do not extend as far as B.  Gene conversion tracts progressively decrease in incidence as their lengths 
increase, a result very similar to gene conversion tract distributions seen with dsDNA donors (Elliott et al., 1998) but 
on a highly compressed distance scale of tens of bp for the ssDNA oligo vs. hundreds of bases for dsDNA donors.   
(C) Assays for gene conversion tracts with dsDNA donors differ from experiments described in Figure 2_15 C and 
2_16A, B by using a single dsDNA donor that contains a series of mutations and measuring contiguous series of 
incorporations (Elliott et al., 1998), whereas we used different ssODNs with single B mutations at different 
distances. Here, we used an ssODN donor with three pairs of 2bp mismatches spaced at intervals of 10nt on either 
side of the central 2bp mismatch A (Top). Genome editing with this ssODN gave rise of a pattern in which A alone 
was incorporated 85% (53/62) of the time, with multiple B mismatches incorporated at other times.  Although 
numbers of B incorporation events were too low to estimate a distribution of tract lengths > 10bp, it is clear that the 
short tract region from -10-10bp predominates.   
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intervals of 10nt on either side of the central 2bp mismatch A gave rise of a pattern in 
which A alone was incorporated 86% of the time, with multiple B mismatches incorporated at 
other times (Figure 2_16 C).  Although numbers of B incorporation events were too low to 
estimate a distribution of tract lengths > 10bp, it is clear that the short tract region from -10 to 
10bp predominates (Figure 2_16 C).  In none of these experiments do we see clear signs of an 
asymmetry indicating preference for incorporation of B mismatches on the 5’ vs. the 3’ side of 
the ssODN, as we saw above (Figure 2_15 B).  Finally, in all of our experiments with single B 
mismatches, we see a small fraction of B-only incorporation events (0.04%~0.12%) that is 
roughly constant across all B distances from A (Figure 2_15 C).  The nature of these events is 
unclear.  
Finally, we sought to test how far we can place an ssODN away from the re-TALEN-
induced dsDNA break and still observe incorporation, by delivering a set of 90nt ssODNs with 
central 2bp mismatches targeting a range of larger distances (-600bp-400bp) away from the re-
TALEN-induced dsDNA break site. We observed >30x lower HDR efficiencies compared to the 
control ssODN positioned centrally over the cut region when the ssODNs matched 40bp away 
(Figure 2_15 D).  This low level of incorporation distal to the DSB may be due to processes 
unrelated to the dsDNA cut, such as seen in experiments in which genomes are altered by 
ssDNA donor alone (48).  Meanwhile, the low level of HDR seen at ~40bp may be due to the 
combination of weakened homology on the mismatch-containing side of the DSB coupled with 
insufficient ssODN oligo length on the other side of DSB that was also seen previously (Figure 
2_15 B).   
We observe that, in comparison with other methods of assessing design parameters for 
genome-editing, GEAS tool provided simultaneous information on rates of HDR, NHEJ, and 
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other mutagenic processes through a single experimental and statistical analysis method vs. 
performing different experiments and separate statistical analyses for each individually.  Through 
the power of high-throughput sequencing, we could also detect events whose incidences were 
fractions of a percent, and successfully captured even lower frequency events by simply 
increasing the depth of sequencing. These features gave us the power to deduce that ssODN 
length might impact HDR rates through toxicity or saturation of DNA uptake capacity in the cell 
through a single set of similar experiments (Figure 2_15 A), and to detect possibly distinct 
processes of dsDNA cut-induced vs. non-cut induced oligo incorporation (Figure 2_15 D). 
 
Discussion 
Here we describe an efficient and integrated pipeline for the design, synthesis, and 
assessment of re-TALENs for human cell genome engineering in general, and for isolation of 
scarlessly engineered hiPSCs without selection in 17 days.  The pipeline allowed us to address a 
number of challenging issues in genome-editing with TALENs.  By eliminating DNA repeats, 
our recoded TALE design enabled one-hour, one-pot synthesis of TALENs, and allowed us to 
generate functional lenti-virus containing TALE sequences that will open the door to using re-
TALEs and re-TALENs for a broad spectrum of cell types and in vivo models. The efficiency 
and scalability of our pipeline enabled us to investigate genome editing outcomes at 15 CCR5-
proximal sites in parallel and explore correlations between editing rates and chromatin state in 
both hiPSCs and K562 cells.   It also allowed us to explore multiple design parameters important 
for TALEN-based genome editing with ssODN donors with a single uniform experimental 
protocol and analysis method.  The components in our pipeline are modular in that re-TALENs 
can be generated and used without applying GEAS, and the latter tools can be applied to targeted 
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genome-editing conducted by other means such as ZFNs, targeted nickases, meganucleases, and 
CRISPR systems (50).  One can also simply use our recoded TALE sequences to design re-
TALENs that can be ordered directly from gene synthesis companies instead. Our pipeline is 
also extensible.  While our DNA repeat elimination algorithm was applied to a commonly used 
TALE RVD monomer and framework (51), it could just as well be applied to recoding the novel 
monomers (44, 52) and frameworks (33).  Finally, our pipeline is an open source.  We provide 
complete details on the TASA protocol for one-pot re-TALE and re-TALEN assembly, are 
making our re-TALE sequences and plasmids available on Addgene, and are making software 
code and documentation for our recoding algorithm and GEAS system available to the scientific 
community.  We envision that our pipeline will provide researchers with the means to facilitate 
and standardize their genome editing practice and extend them to additional cell lines and types. 
With >100K reads / sample, GEAS was able to detect HDR events with efficiency as low 
as 0.007%, 400-fold more sensitive than the ~3% detection power provided by the mismatch-
endonuclease method.  Moreover, it provides genome alteration information at target sites at 
single nucleotide resolution, giving direct insight into NHEJ rates and indel profiles, as well as 
ssDNA oligo errors and other random mutations in a single step. We found that NHEJ lead to 
small (<10bp) deletions in both cell lines, consistent with the typical pattern of NHEJ products 
(40). We note, however, that since we only amplified ~250bp around the targeting sites in our 
analysis, we could not observe >200bp deletions reportedly found in U2OS cells (24). It has been 
reported that non-specific ssODN insertions are prevalent at DSBs in 293 cells (31).  In our study, 
however, we found insertions generally occurred at very low incidence (Figure 2_10 C) and did 
not see evidence of overrepresentation of ssODN sequences (Figure 2_10 C), although the small 
size of the insertions we observed (median ~3bp) may have complicated this assessment. In this 
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study, we routinely pooled ~20 barcoded samples together and used the Illumina MiSeq system 
to obtain the sequence data which was analyzed with GEAS.  Under optimized conditions, 
MiSeq can deliver >10 Million paired-end 150bp reads within 27hrs, so that up to 100 sample-
barcoded targeting regions can be covered with ~100K reads each at a cost of approximately $10 
per sample.  If desired, sample throughput can be traded for higher sensitivity by reducing 
sample numbers and allotting more reads per sample.  Higher capacity sequencing systems can 
be used to further improve throughput and cost per sample.     
Our parallel analysis of genome editing in hiPSCs and K562 cells showed that despite the 
~21x difference in editing rates between them, editing profiles were similar across 15 sites.  
Since gene targeting in hiPSCs is an important strategy for gene therapy, improving hiPSC 
editing rates is a high priority.  The difference in re-TALE expression level (Figure 2_13 B), 
activity of DNA repair pathway and epigenetic status may contribute to the different genome 
editing efficiency between the two cell types.  In the course of this study, we did, in fact, find 
that the increasing the amount of transfection constructs into the hiPSC increased HDR rates 
(Figure 2_13 A).  In addition, we compared nucleosome occupancy data available for K562 cells 
(ENCODE/Stanford/BYU, (45)) with HDR rates in that cell type and we detected a strong 
correlation across targeting sites (Figure 2_12 E),  suggesting the involvement of chromatin 
organization in the genome editing process. Such data will soon become available for hiPSC and 
give us a further opportunity to test these conclusions.  Across both cell types, we also found that 
HDR and NHEJ rates were strongly correlated at all sites, which suggests that the rate of dsDNA 
cuts may be limiting for both processes.  Contrary to the conventional conceptions that NHEJ is 
much more prevalent in human stem cells (53), we did not observe significant HDR/NHEJ ratio 
difference between K562 cells and hiPSCs (Figure 2_12 D).      
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We also used GEAS to explore design parameters of donor ssODN composition and 
targeting (Figure 2_15 ).   While it has been long observed that gene targeting with long dsDNA 
donors is improved by long flanking homology regions (46), here we found that increasing 
ssODN length beyond 90 nt lowered HDR rates (Figure 2_15 A), possibly due to ssODN toxicity 
or saturation of DNA processing enzymes.  However, we saw clear evidence of the need of 
ssODN to pair against both flanks of the dsDNA cut, with some preference for increased pairing 
of the 3’ end of the ssODN.  Results were symmetrical regardless of whether the ssODN was 
provided in a sense or an antisense orientation.  Other properties of ssODN incorporation in 
HDR were similar to those of dsDNA donors, although operating on a compressed distance scale:  
For instance, we saw that deviations from homology at the flanks of the ssODN decreased 
incorporation (Figure 2_15 C), and also saw evidence that gene conversion tracts against 
ssODNs most frequently correspond to short regions around the dsDNA cut and extend outwards 
with smaller frequencies with increasing length (Figure 2_15 C, 2_16 B).  We envision that 
further analyses of other design and protocol options for genome editing with ssODNs, such as 
use of phosphorothioated ssODNs and use of compounds that suppress viral response pathways 
(48), will lead to significant improvements in genome editing rates and outcomes and clarify the 
still obscure mechanism behind ssODN/nuclease mediated genome editing (Figure 2_17).  
Finally, we note directions by which our pipeline may be extended.  After clonal 
outgrowth and identification of correctly edited cells, the pipeline could be extended to 
interrogate phenotypes of these cells, and this could also be coupled to acquisition and analysis 
of transcriptomes of these cells obtained from RNA-seq analysis of barcoded aliquoted mixtures.  
In such experiments, cells found to have NHEJ alterations or no modifications could serve as 
useful comparisons and controls.  Another direction would be to multiplex the introduction of  
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Figure 2_17. Theoretical models underlying re-TALENs/ssODN mediated HDR 
Theoretical models underlying re-TALENs/ssODN mediated HDR. In model I, DNA DSB introduced by re-
TALENs is not resolved until replication fork comes by, so that ssODN incorporates into the genome as Okazaki 
fragments to prime the synthesis of the nascent genomic DNA and also to serve as the template to repair the 
chromosomal complementary strand.  However, in this model, the presence of the gap in the sense strand may cause 
the DNA replication fork (Question mark) to collapse.  
In model II, DNA ends at DSB are digested by end processing enzymes so that 3’ ssDNA overhangs are generated 
at the re-TALENs cutting region. ssODN anneals to its chromosomal complement and invades into the genome by 
replacing the original strand. Subsequently, anti-sense strand is synthesized with the ssODN as the template and the 
replaced region at sense strand are resected. Finally, ssODN physically incorporates into the genome by the 
concerted action of DNA polymerases and ligases.  
In model III, 3’ ssDNA overhangs are generated at the re-TALENs-mediated DSB as described in model II.  The 
available chromosomal ssDNA region serves as the dock to recruit the binding of ssODN, which in turn serves as 
the template to initiate the repair of the anti-sense strand. Within the process of branch migration or template 
switching, the newly synthesized anti-sense strand re-anneals to the upstream genomic ssDNA overhangs and 
initiates the repair of sense strand. The newly synthesized sense strand displaces the ssODN from the genome and 
the genomic gap is sealed with the concerted action of DNA polymerases and ligases.  
By examining our data sets, we first found both sense and anti-sense ssODNs, in cooperation with re-TALEs, are 
able to mediate genome editing (Figure 8B), which supports DNA repair models where ssODN strand polarity is not 
relevant. Consistent with this notion, ssODNs shifting to the 3’ end of the DSB achieves higher HDR efficiency 
than its 5’ counterparts (Figure 8B), mirroring the asymmetrical structure at DSB where 3’ chromosomal DNA 
overhangs are generated, potentially enabling the 3’ end of ssODNs to anneal.  In addition, we observed a small 
window (~20bp) around DSBs where information encoded in the ssODNs can be passed to genomic DNA 
effectively, while genetic variations beyond this window cannot be effectively introduced into the genome (Figure 
8C,D). The observation of this short conversion track (~20bp) with previous biotin-labeled oligo studies (Radecke et 
al., 2006) support model III where ssODNs function as template. It is conceivable that when ssODN serves as the 
template, it can only introduce genetic alteration into the chromosomal DNA at the DSB region, whereas the 
chromosomal overhangs preserve the flanking genomic information. However, it is also possible that ssODN 
physically incorporates into the genome but the mismatches beyond the original DSB region are repaired or 
resected. Additional research using radioactive-labeled ssODN and siRNA screening of important factors may 
further pinpoint these models.  
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reTALENs and/or ssODNs into the cells, and use the pipeline to generate libraries of 
single cells with different combinations of mutations within a set of sites, or of cells with a 
variety of different programmed mutations at one or more fixed sites.  Such libraries would allow 
multilocus genetic influences on cellular phenotypes to be dissected or single nucleotide 
resolution of the bases in a regulatory element important for function.  Longer term, a critical 
issue to applications of engineered hiPSCs, not addressed in the current pipeline, is 
determination of the presence of off-target mutations caused by use of nucleases to engineer cells.  
As costs of sequencing decline, we can envision conducting whole-genome sequencing of the 
monoclonal hiPSC that have been identified as correctly engineered at the target site to identify 
off-target edits.  Using current technologies, ~50x coverage has been found to be sufficient to 
call single nucleotide variations in ~94% of the reference genome with a ~1% false positive rate 
(54), although detection of indels typically generated by NHEJ may less reliable (55). Shorter 
term, but less definitive, we could perform large-scale targeted sequencing of genomic sites that 
are similar in sequence to target sites or which have been identified as sites of off-target activity 
by in vivo (56) or in vitro (57) assays.  Application of off-target detection to monoclonal 
outgrowths engineered cells has advantages over detection of off-targets in cell populations in 
that the latter is invariably limited by sequencing depth to detecting only relatively common off-
targets, and does not reveal the distribution of high frequency vs. rare off-targets that might be 
found in single cells.  Integration of these many directions for development of our platform for 
efficiently isolating scarlessly engineered human stem cells will give the research community 
many new abilities to analyze the causal underpinnings of numerous important biological 
problems, as well as methods to prepare hiPSC and other cell lines to precise specifications that 
could be useful for disease treatment. 
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Materials and Methods 
re-TALEs design 
re-TALEs were optimized at different levels to facilitate assembly, and improve 
expression. re-TALE DNA sequences were first co-optimized for a human codon-usage, and low 
mRNA folding energy at the 5’ end (GeneGA, Bioconductor). The obtained sequence was 
evolved through several cycles to eliminate repeats (direct or inverted) longer than 11 bp. 
Specifically, the re-TALE sequence was evolved in several design cycles to eliminate repeats. In 
each cycle, synonymous sequences from each repeat are evaluated. Those with the largest 
hamming distance to the evolving DNA are selected. The final sequence with cai = 0.59 
ΔG= -9.8 kcal/mol. We provide an R package to carry out this general framework for synthetic 
protein design. The sequence of one of re-TALE possessing 16.5 monomers is listed in Sequence 
1. We provide an R package in the supplement to carry out this general framework for synthetic 
protein design.   
 
re-TALE assembly  
(1) re-TALE dimer blocks preparation  
re-TALE dimer blocks encoding two RVDs were generated by two rounds of PCR under 
standard Kapa HIFI (KPAP) PCR conditions, in which the first round of PCR introduced the 
RVD coding sequence and the second round of PCR generated the  entire dimer blocks with 
36bp overlaps with the adjacent blocks. PCR products were purified using QIAquick 96 PCR 
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Purification Kit (QIAGEN) and the concentrations were measured by Nano-drop. The primer 
and template sequences are listed in Table 2_1 and 2_ 2.   
 
(2) re-TALE destination vectors preparation 
re-TALENs and re-TALE-TF destination vectors were constructed by modifying the 
TALE-TF and TALEN cloning backbones (51). We re-coded the 0.5 RVD regions on the vectors  
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Table 2_1. re-TALE blocks sequences 
 
block0 
CGCAATGCGCTCACGGGAGCACCCCTCAACCTAACCCCTGAACAGGTAGTCGCTATAGCTTCAN
NNNNNGGGGGCAAGCAAGCACTTGAGACCGTTCAACGACTCCTGCCAGTGCTCTGCCAAGCCCA
TGGATTGACTCCGGAGCAAGTCGTCGCGATCGCGAGCNNNNNNGGGGGGAAGCAGGCGCTGGAA
ACTGTTCAGAGACTGCTGCCTGTACTTTGTCAGGCGCATGGTCTC 
block1 
AGACTGCTGCCTGTACTTTGTCAGGCGCATGGTCTCACCCCCGAACAGGTTGTCGCAATAGCAA
GTNNNNNNGGCGGTAAGCAAGCCCTAGAGACTGTGCAACGCCTGCTCCCCGTGCTGTGTCAGGC
TCACGGTCTGACACCTGAACAAGTTGTCGCGATAGCCAGTNNNNNNGGGGGAAAACAAGCTCTA
GAAACGGTTCAAAGGTTGTTGCCCGTTCTGTGCCAAGCACATGGGTTA 
block1' 
TGCGCTCACGGGAGCACCCCTCAACCTCACCCCCGAACAGGTTGTCGCAATAGCAAGTNNNNNN
GGCGGTAAGCAAGCCCTAGAGACTGTGCAACGCCTGCTCCCCGTGCTGTGTCAGGCTCACGGTC
TGACACCTGAACAAGTTGTCGCGATAGCCAGTNNNNNNGGGGGAAAACAAGCTCTAGAAACGGT
TCAAAGGTTGTTGCCCGTTCTGTGCCAAGCACATGGGTTA 
block2 
AGGTTGTTGCCCGTTCTGTGCCAAGCACATGGGTTAACACCCGAACAAGTAGTAGCGATAGCGT
CANNNNNNGGGGGTAAACAGGCTTTGGAGACGGTACAGCGGTTATTGCCGGTCCTCTGCCAGGC
CCACGGACTTACGCCAGAACAGGTGGTTGCAATTGCCTCCNNNNNNGGCGGGAAACAAGCGTTG
GAAACTGTGCAGAGACTCCTTCCTGTTTTGTGTCAAGCCCACGGCTTGACGCCT 
block3 
AGACTCCTTCCTGTTTTGTGTCAAGCCCACGGCTTGACGCCTGAGCAGGTTGTGGCCATCGCTA
GCNNNNNNGGAGGGAAGCAGGCTCTTGAAACCGTACAGCGACTTCTCCCAGTTTTGTGCCAAGC
TCACGGGCTAACCCCCGAGCAAGTAGTTGCCATAGCAAGCNNNNNNGGAGGAAAACAGGCATTA
GAAACAGTTCAGCGCTTGCTCCCGGTACTCTGTCAGGCACACGGTCTA 
block4 
CGCTTGCTCCCGGTACTCTGTCAGGCACACGGTCTAACTCCGGAACAGGTCGTAGCCATTGCTT
CCNNNNNNGGCGGCAAACAGGCGCTAGAGACCGTCCAGAGGCTCTTGCCTGTGTTATGCCAGGC
ACATGGCCTCACCCCGGAGCAGGTCGTTGCCATCGCCAGTNNNNNNGGCGGAAAGCAAGCTCTC
GAAACAGTACAACGGCTGTTGCCAGTCCTATGTCAAGCTCATGGACTG 
block5 
CGGCTGTTGCCAGTCCTATGTCAAGCTCATGGACTGACGCCCGAGCAGGTAGTGGCAATCGCAT
CTNNNNNNGGAGGTAAACAAGCACTCGAGACTGTCCAAAGATTGTTACCCGTACTATGCCAAGC
GCATGGTTTAACCCCAGAGCAAGTTGTGGCTATTGCATCTNNNNNNGGTGGCAAACAAGCCTTG
GAGACCGTGCAACGATTACTGCCTGTCTTATGTCAGGCCCATGGCCTT 
block6 
CGATTACTGCCTGTCTTATGTCAGGCCCATGGCCTTACTCCTGAGCAGGTGGTCGCTATCGCCA
GCNNNNNNGGGGGCAAGCAAGCACTGGAAACAGTCCAGCGTTTGCTTCCAGTACTTTGTCAGGC
GCATGGATTGACACCGGAACAAGTGGTGGCTATAGCCTCANNNNNNGGAGGAAAGCAGGCGCTG
GAAACCGTCCAACGTCTTTTACCGGTGCTTTGCCAGGCGCACGGGCTC 
block6' 
CGATTACTGCCTGTCTTATGTCAGGCCCATGGCCTTACTCCTGAGCAAGTCGTAGCTATCGCCA
GCNNNNNNGGTGGGAAACAGGCCCTGGAAACCGTACAACGTCTCCTCCCAGTACTTTGTCAAGC
ACACGGGTTGACACCGGAACAAGTGGTGGCGATTGCGTCCNNNNNNGGAGGCAAGCAGGCACTG
GAGACCGTCCAACGGCTTCTTCCGGTTCTTTGCCAGGCTCATGGGCTC 
block7 
CGGCTTCTTCCGGTTCTTTGCCAGGCTCATGGGCTCACGCCAGAGCAGGTGGTAGCAATAGCGT
CGNNNNNNGGTGGTAAGCAAGCGCTTGAAACGGTCCAGCGTCTTCTGCCGGTGTTGTGCCAGGC
GCACGGACTCACACCAGAACAAGTGGTTGCTATTGCTAGTNNNNNNGGTGGAAAGCAGGCCCTC
GAGACGGTGCAGAGGTTACTTCCCGTCCTCTGTCAAGCGCACGGCCTC 
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Table 2_2. re-TALE blocks primer sequences 
 
block0-F CGCAATGCGCTCACGGGAGCACCCCTCAACctAACCCCTGAACAGGT*A*G 
block0-R GAGACCATGCGCCTGACAAAGTACAGGCAGCAGTCTCTGAACAG*T*T 
block1'-F TGGCGCAATGCGCTCACGGGAGCACCCCTCA*A*C 
block1-F AGACTGCTGCCTGTACTTTGTCAGGCGCATGGTCTCACCCCCGAACA*G*G 
block1-
R/block1'-
R TAACCCATGTGCTTGGCACAGAACGGGCAACAACCTTTGAACCG*T*T 
block2-F AGGTTGTTGCCCGTTCTGTGCCAAGCACATGGGTTAACACCCgaac*a*a 
blcok2-R AGGCGTCAAGCCGTGGGCTTGACACAAAACAGGAAGGAGTCTCTGCACAG*T*t 
block3-F AGACTCCTTCCTGTTTTGTGTCAAGCCCACGGCTTGACGCCTG*A*G 
block3-R TAGACCGTGTGCCTGACAGAGTACCGGGAGCAAGCGCT*G*A 
block4-F CGCTTGCTCCCGGTACTCTGTCAGGCACACGGTCTAA*C*T 
block4-R CAGTCCATGAGCTTGACATAGGACTGGCAACAGCCGTT*G*T 
block5-F CGGCTGTTGCCAGTCCTATGTCAAGCTCATGGACTGA*C*G 
block5-R AAGGCCATGGGCCTGACATAAGACAGGCAGTAATCGTT*G*C 
block6-F CGATTACTGCCTGTCTTATGTCAGGCCCATGGCCTTA*C*T 
block6-R GAGCCCGTGCGCCTGGCAAAGCACCGGTAAAAGACGTTGGA*C*G 
block6'-F CGATTACTGCCTGTCTTATGTCAGGCCCATGGCCTTACTCCTGAGCAA*G*T 
block6'-R GAGCCCATGAGCCTGGCAAAGAACCGGAAGAAGCCGTT*G*G 
block7-F CGGCTTCTTCCGGTTCTTTGCCAGGCTCATGGGCTCACGCCAGAGCAGG*T*G 
blcok7-R GAGGCCGTGCGCTTGACAGAGGACGGGAAGTAACCTCT*G*C 
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and also incorporated SapI cutting site at the designated re-TALE cloning site.. Plasmids can be 
pre-treated with SapI (New England Biolabs) with manufacturer recommended conditions and 
purified with QIAquick PCR purification kit (QIAGEN).   
 
(3) TASA assembly 
 
We carried out the (10ul) one-pot TASA assembly reaction with 200ng of each block, 
500ng destination backbone, 1X TASA enzyme mixture (2U SapI, 100U Ampligase (Epicentre), 
10mU T5 exonuclease (Epicentre), 2.5U Phusion DNA polymerase (New England Biolabs)) and 
1X isothermal assembly reaction buffer as described before (58) (5% PEG-8000, 100 mM Tris-
HCl pH 7.5, 10 mM MgCl2, 10 mM DTT, 0.2 mM each of the four dNTPs and 1 mM NAD). 
Incubations were performed at 37°C for 5min and 50 °C for 30 min. Alternatively, >90% 
efficiency can be achieved by two-steps assembly. First, 10ul re-TALE assembly reactions were 
performed with 200ng of each block, 1X re-TALE enzyme mixture (100U Ampligase, 12.5mU 
T5 exonuclease, 2.5U Phusion DNA polymerase) and 1X isothermal assembly buffer at 50°C for 
30min, followed by standardized Kapa HIFI PCR reaction, agarose gel electrophoresis, and 
QIAquick Gel extraction (Qiagen) to enrich the full length re-TALEs. 200ng re-TALE amplicons 
can then be mixed with 500ng Sap1-pre-treated destination backbone, 1X re-TALE assembly 
mixture and 1X isothermal assembly reaction buffer and incubated at 50 °C for 30 min.  TASA 
assembly reaction and re-TALE final assembly reaction can be processed directly for bacterial 
transformation to colonize individual assemblies.  
  
Assessment of re-TALEs functionality  
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(1) Cell culture 
PGP1 iPS cells were maintained on Matrigel (BD Biosciences)-coated plates in mTeSR1 
(Stemcell Technologies). Cultures were passaged every 5–7 days with TrypLE Express 
(Invitrogen). 293T and 293FT cells were grown and maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen) high glucose supplemented with 10% fetal bovine serum (FBS, 
Invitrogen), penicillin/streptomycin (pen/strep, Invitrogen), and non-essential amino acids 
(NEAA, Invitrogen). K562 cells were grown and maintained in RPMI (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS, Invitrogen 15%) and penicillin/streptomycin (pen/strep, 
Invitrogen).  All cells were maintained at 37°C and 5% CO2 in a humidified incubator. 
 
(2) re-TALE-TF activity assessment  
 re-TALE-TF activity assessment experiments were conducted as described before (26). 
Briefly, 293T cells were seeded onto 24-well plates the day before transfection at densities of 2 × 
105 cells well. Approximately 24 h after initial seeding, cells were co-transfected with 500ng 
plasmids carrying re-TALE-TF-2A-GFP and 30ng mCherry reporters using Lipofectamine 2000 
(Invitrogen) following the manufacturer’s protocols. Cells were harvested using TrypLE Express 
(Invitrogen) ~18 h after transfection and resuspended in 200 µl of media for flow cytometry 
analysis using an LSRFortessa cell analyzer (BD Biosciences). The flow cytometry data were 
analyzed using BD FACSDiva (BD Biosciences). At least 25,000 events were analyzed for each 
transfection sample.  
 
(3) re-TALENs activity assessment  
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We established a stable 293T cell line for detecting HDR efficiency as described before 
(20). Specifically, the reporter cell lines bear genomically integrated GFP coding sequences 
disrupted by the insertion of a stop codon and a 68bp genomic fragment derived from the 
AAVS1 locus. We seeded reporter cells at densities of 2 × 105 cells per well in 24-well plate and 
transfected them with 1μg of each re-TALENs plasmid and 2μg DNA donor plasmid using 
Lipofectamine 2000 following the manufacturer’s protocols. Cells were harvested using TrypLE 
Express (Invitrogen) ~18 h after transfection and resuspended in 200 µl of media for flow 
cytometry analysis using an LSRFortessa cell analyzer (BD Biosciences). The flow cytometry 
data were analyzed using FlowJo (FlowJo). At least 25,000 events were analyzed for each 
transfection sample. For endogenous AAVS1 locus targeting experiment in 293T, the 
transfection procedures were identical as described above and we conducted puromycin selection 
with drug concentration at 3μg/ml 1 week after transfection.   
 
(4) Functional lentivirus generation assessment   
The lentiviral vectors were created by standard PCR and cloning techniques. The 
lentiviral plasmids were transfected by Lipofectamine 2000 with Lentiviral Packaging Mix 
(Invitrogen) into cultured 293FT cells (Invitrogen) to produce lentivirus. Supernatant was 
collected 48 and 72h post-transfection, sterile filtered, concentrated with the Amicon Ultra-15 
Centrifugal Filter Units (Millipore) and added at different dilutions to fresh 293T cells with 
polybrene. Cells were harvested using TrypLE Express (Invitrogen) and resuspended in 200 µl 
of media for flow cytometry analysis using an LSRFortessa cell analyzer (BD Biosciences). The 
flow cytometry data were analyzed using BD FACSDiva (BD Biosciences). At least 25,000 
events were analyzed for each transfection sample. Lentivirus titration was calculated based on 
66 
 
the following formula: virus titration = (percentage of GFP+ 293T cell * initial cell numbers 
under transduction) / (the volume of original virus collecting supernatant used in the transduction 
experiment). To test the functionality of lentivirus, 3 days after transduction, we transfected 2 × 
105 lentivirus transduced 293T cells with 30 ng plasmids carrying mCherry reporter and 500ng 
pUC19 plasmids using Lipofectamine 2000 (Invitrogen). Cell images were analyzed using Axio 
Observer Z.1 (Zeiss) 18 hours after transfection and harvested using TrypLE Express (Invitrogen) 
and resuspended in 200 µl of media for flow cytometry analysis using a LSRFortessa cell 
analyzer (BD Biosciences). The flow cytometry data were analyzed using BD FACSDiva (BD 
Biosciences). 
 
Test of re-TALENs/ssODNs genome editing efficiency  
(1)  re-TALENs/ssODNs nucleofection in PGP1 hiPSCs and K562 cells  
PGP1 iPSCs were cultured in Rho kinase (ROCK) inhibitor Y-27632 (Calbiochem) 2h 
before nucleofection.  Transfections were done using P3 Primary Cell 4D-Nucleofector X Kit 
(Lonza).  Specifically, cells were harvested using TrypLE Express (Invitrogen) and 2×106 cells 
were resuspended in 20 μl nucleofection mixture containing 16.4 μl P3 Nucleofector solution, 
3.6 μl supplement, 1μg of each re-TALENs plasmid, 2μl of 100 μM ssODN. Subsequently, we 
transferred the mixtures to 20µl Nucleocuvette strips and conducted nucleofection using CB150 
program. Cells were plated on Matrigel-coated plates in mTeSR1 medium supplemented with 
ROCK inhibitor for the first 24 hrs.  For endogenous AAVS1 locus targeting experiment with 
dsDNA donor, we utilized the identical procedure except we used 2 μg dsDNA donor and we 
supplement the mTeSR1 media with puromycin at the concentration of 0.5ug/mL 1 week after 
transfection.  
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K562 cells were nucleofected with re-TALENs/ssODNs using SF Cell Line 4D-
Nucleofector X Kit. Specifically, 2×106 cells were resuspended in 20 μl nucleofection mixture 
containing 16.4 μl SF Nucleofector solution, 3.6 μl supplement, 1 μg of each re-TALENs 
plasmid, and 2 μg of corresponding ssODN donor. Subsequently, we transferred the mixtures to 
20 µl Nucleocuvette strips and conducted nucleofection using FF120 program. Cells were 
transferred to pre-warmed medium.  
The information of reTALENs and ssODNs used in this study are listed in Table 2_3 to 
2_6.  
(2) Amplicon library preparation of the targeting regions  
Cells were harvested 6 days after nucleofection and 0.1 μl prepGEM tissue protease enzyme 
(ZyGEM) and 1 μl prepGEM gold buffer (ZyGEM) were added to 8.9 µl of the 2~5 X 105 cells 
in the medium. 1ul of the reactions were then added to 9 µl of PCR mix containing 5ul 2X 
KAPA Hifi Hotstart Readymix (KAPA Biosystems) and 100nM corresponding amplification 
primer pairs. Reactions were incubated at 95°C for 5 min followed by 15 cycles of 98°C, 20 s; 
65°C, 20 s and 72°C, 20 s. To add the Illumina  
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Table 2_3. Information of re-TALEN pairs/ssODN targeting CCR5 
# 
targeting 
site 
re-TALENs  
pair targeting 
site (start) 
/chr3: 
re-TALENs  
pair 
targeting site (end) 
/chr3: 
re-TALEN-L 
targeting 
sequence 
re-TALE-R 
targeting 
sequence 
ssODN donor sequence 
1 46409942 46409993 
TCCCCACTTTCTT
GTGAA 
TAACCACTCAGGACA
GGG 
CTGAAGAATTTCCCATGGGTCCCCACTTTCTTGT
GAATCCTTGGAGTGAACCCCCCTGTCCTGAGTGG
TTACTAGAACACACCTCTGGAC 
2 46410227 46410278 
TCACACAGCAAGT
CAGCA 
TAGCGGAGCAGGCTC
GGA 
TGGAAGTATCTTGCCGAGGTCACACAGCAAGTCA
GCAGCACAGCCAGTGTGACTCCGAGCCTGCTCCG
CTAGCCCACATTGCCCTCTGGG 
3 46411260 46411311 
TACCCAGACGAGA
AAGCT 
TCAGACTGCCAAGCT
TGA 
CTACTGTCATTCAGCCCAATACCCAGACGAGAAA
GCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTC
TGACTACAGAGGCCACTGGCTT 
4 46411464 46411515 
TCTTGTGGCTCGG
GAGTA 
TATTGTCAGCAGAGC
TGA 
GGAAGCCCAGAGGGCATCTTGTGGCTCGGGAGTA
GCTCTCTGCTACCTTCTCAGCTCTGCTGACAATA
CTTGAGATTTTCAGATGTCACC 
5 46411517 46411568 
TTGAGATTTTCAG
ATGTC 
TATACAGTCATATCA
AGC 
TCAGCTCTGCTGACAATACTTGAGATTTTCAGAT
GTCACCAACGCCCAAGAGAGCTTGATATGACTGT
ATATAGTATAGTCATAAAGAAC 
6 46411634 46411685 
TTCAGATAGATTA
TATCT 
TGCCAGATACATAGG
TGG 
GTGGAAAATTTCTCATAGCTTCAGATAGATTATA
TCTGGAGTGAGCAATCCTGCCACCTATGTATCTG
GCATAGTGTGAGTCCTCATAAA 
7 46412396 46412447 
TTATACTGTCTAT
ATGAT 
TCAGCTCTTCTGGCC
AGA 
GAAACAGCATTTCCTACTTTTATACTGTCTATAT
GATTGATTTGGTCAGCTCATCTGGCCAGAAGAGC
TGAGACATCCGTTCCCCTACAA 
8 46412432 46412483 
TGGCCAGAAGAGC
TGAGA 
TTACCGGGGAGAGTT
TCT 
TTGATTTGCACAGCTCATCTGGCCAGAAGAGCTG
AGACATCCGTATCCCTACAAGAAACTCTCCCCGG
TAAGTAACCTCTCAGCTGCTTG 
9 46412750 46412801 
TTTGCAGAGAGAT
GAGTC 
TTAGCAGAAGATAAG
ATT 
GGAGAGGGTTTAGTTCTCCTTAGCAGAAGATAAG
ATTTCAAGATGAGAGCTAAGACTCATCTCTCTGC
AAATCTTTCTTTTGAGAGGTAA 
10 46413152 46413203 
TATAAGACTAAAC
TACCC 
TCGTCTGCCACCACA
GAT 
TAATATAATAAAAAATGTTTCGTCTGCCACCACA
GATGAATGTCGAGCATTCTGGGTAGTTTAGTCTT
ATAACCAGCTGTCTTGCCTAGT 
11 46414305 46414356 
TAAAACAGTTTGC
ATTCA 
TATAAAGTCCTAGAA
TGT 
TTAAAAACCTATTGATGTATAAAACAGTTTGCAT
TCATGGAGGGTGACTAAATACATTCTAGGACTTT
ATAAAAGATCACTTTTTATTTA 
12 46414608 46414659 
TGGCCATCTCTGA
CCTGT 
TAGTGAGCCCAGAAG
GGG 
GACATCTACCTGCTCAACCTGGCCATCTCTGACC
TGTTTTTCCTATTTACTGTCCCCTTCTGGGCTCA
CTATGCTGCCGCCCAGTGGGAC 
13 46414768 46414820 
TAGGTACCTGGCT
GTCGT 
TGACCGTCCTGGCTT
TTA 
TCATCCTCCTGACAATCGATAGGTACCTGGCTGT
CGTCCATGCTACGTTTGCTTTAAAAGCCAGGACG
GTCACCTTTGGGGTGGTGACAA 
14 46415017 46415068 
TGTCATGGTCATC
TGCTA 
TCGACACCGAAGCAG
AGT 
GGCTGGTCCTGCCGCTGCTTGTCATGGTCATCTG
CTACTCGGGAGACCTAAAAACTCTGCTTCGGTGT
CGAAATGAGAAGAAGAGGCACA 
15 46420034 46420084 
TGCCCCCGCGAGG
CCACA 
TCTGGAAGTTGAACA
CCC 
GGCAAGCCTTGGGTCATACTGCCCCCGCGAGGCC
ACATTGGCAAGTCAGCAAGGGTGTTCAACTTCCA
GACTTGGCCATGGAGAAGACAT 
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Table 2_4. HDR and NHEJ efficiency of re-TALEN/ssODN targeting CCR5  
 
# 
targeting 
site 
cell type HDR NHEJ 
HDR detection limit based on 
Information analysis 
1 PGP1-iPS 0.06% 0.26% 0.04% 
2 PGP1-iPS 0.48% 0.07% 0.01% 
3 PGP1-iPS 1.71% 0.41% 0.03% 
4 PGP1-iPS 0.02% 0.04% 0.02%* 
5 PGP1-iPS 0.52% 0.73% 0.00% 
6 PGP1-iPS 0.06% 0.15% 0.00% 
7 PGP1-iPS 0.01% 0.00% 0.01%* 
8 PGP1-iPS 0.03% 0.06% 0.00% 
9 PGP1-iPS 0.27% 1.25% 0.00% 
10 PGP1-iPS 0.68% 0.27% 0.01% 
11 PGP1-iPS 0.06% 0.03% 0.00% 
12 PGP1-iPS 0.38% 1.47% 0.04% 
13 PGP1-iPS 0.00% 0.13% 0.00% 
14 PGP1-iPS 0.47% 0.37% 0.02% 
15 PGP1-iPS 0.80% 0.14% 0.08% 
1 K562 2.01% 0.89% 0.10% 
2 K562 18.50% 12.82% 0.00% 
3 K562 38.58% 67.93% 0.55% 
4 K562 0.80% 2.47% 0.08% 
5 K562 2.69% 64.74% 0.15% 
6 K562 0.78% 1.34% 0.02% 
7 K562 0.06% 0.77% 0.01% 
8 K562 3.93% 12.34% 0.19% 
9 K562 2.54% 2.96% 0.00% 
10 K562 17.97% 6.08% 0.30% 
11 K562 0.68% 0.24% 0.07% 
12 K562 1.88% 0.46% 0.00% 
13 K562 1.85% 0.26% 0.00% 
14 K562 12.04% 0.83% 1.10% 
15 K562 11.41% 4.14% 0.21% 
* The group where HDR detection limit exceeds the real HDR detected 
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Table 2_5. CCR5 targeting site PCR primer sequences 
# targeting in CCR5 name primer sequence 
1 
site1-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATTTTGCAGTGTGCGTTACTCC 
site1-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGTTTGCAGTGTGCGTTACTCC 
site1-F3 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCCTAATTTGCAGTGTGCGTTACTCC 
site1-F4 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGGTCATTTGCAGTGTGCGTTACTCC 
site1-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTCCAAGCAACTAAGTCACAGCA 
2 
Site2-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATATGAGGAAATGGAAGCTTG 
Site2-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGATGAGGAAATGGAAGCTTG 
Site2-F3 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCCTAAATGAGGAAATGGAAGCTTG 
Site2-F4 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGGTCAATGAGGAAATGGAAGCTTG 
Site2-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTCATTAGGGTATTGGAGGA 
3 
site3-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATAATCCTCCCAACAACTCAT 
site3-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGAATCCTCCCAACAACTCAT 
site3-F3 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCCTAAAATCCTCCCAACAACTCAT 
site3-F4 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGGTCAAATCCTCCCAACAACTCAT 
site3_R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTCCCAATCCTACAGAGGCAG 
4 
site4-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATAAGCCAAAGCTTTTTATTC 
site4-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGAAGCCAAAGCTTTTTATTC 
site4-F3 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCCTAAAAGCCAAAGCTTTTTATTC 
site4-F4 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGGTCAAAGCCAAAGCTTTTTATTC 
site4_R ACACTCTTTCCCTACACGACGCTCTTCCGATCTAAGCCAAAGCTTTTTATTCT 
5 
site5-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATATCTTGTGGCTCGGGAGTAG 
site5-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGATCTTGTGGCTCGGGAGTAG 
site5-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTGGCAGGATTCTTCACTCCA 
6 
site6-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATCTATTTTGTTGCCCTTCAAA 
site6-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGCTATTTTGTTGCCCTTCAAA 
site6-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTAACCTGAACTTGACCATATACT 
7 
site7-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATCAGCTGAGAGGTTACTTACC 
site7-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGCAGCTGAGAGGTTACTTACC 
site7-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTAATGATTTAACTCCACCCTC 
8 
site8-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATACTCCACCCTCCTTCAAAAGA 
site8-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGACTCCACCCTCCTTCAAAAGA 
site8-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTGGTGTTTGCCAAATGTCT 
9 
site9_F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATGGGCACATATTCAGAAGGCA 
site9_F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGGGGCACATATTCAGAAGGCA 
site9_R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTAGTGAAAGACTTTAAAGGGAGCA 
10 
site10-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATCACAATTAAGAGTTGTCATA 
site10-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGCACAATTAAGAGTTGTCATA 
site10-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTCTCAGCTAGAGCAGCTGAAC 
11 
site11-F1 CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTGACACTTGATAATCCATC 
site11-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGTCAATGTAGACATCTATGTAG 
site11-R ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATTCAATGTAGACATCTATGTAG 
12 
site12-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATACTGCAAAAGGCTGAAGAGC 
site12-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGACTGCAAAAGGCTGAAGAGC 
site12-F3 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCCTAAACTGCAAAAGGCTGAAGAGC 
site12-F4 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGGTCAACTGCAAAAGGCTGAAGAGC 
site12-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTGCCTATAAAATAGAGCCCTGTCAA 
13 
site13-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATCTCTATTTTATAGGCTTCTTC 
site13-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGCTCTATTTTATAGGCTTCTTC 
site13-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTAGCCACCACCCAAGTGATC 
14 
site14-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGTTCCAGACATTAAAGATAGTC 
site14-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATTTCCAGACATTAAAGATAGTC 
site14-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTAATCATGATGGTGAAGATAAG 
15 
site15-F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATCCGGCAGAGACAAACATTAAA 
site15-F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCCGGCAGAGACAAACATTAAA 
site15-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTAGCTAGGAAGCCATGGCAAG 
illumina adaptor 
PE-PCR-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACAcgac*g*c 
PE-PCR-R CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACc*g*c 
Multiplex sequencing PCR primer 
3 
site3-M-F ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGTGCATAGTATGTGCTAGATGCTG 
site3-M-R GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTGATCTCTAAGAAGGCAAATGAGAC 
illumina adaptor 
Index-PCR CAAGCAGAAGACGGCATACGAGATN1N2N3N4N5N6GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
universal-PCR AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
 
*index-PCR primers are purchased from epicentre (ScriptSeq™ Index PCR 
Primers 
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Table 2_6. ssODN design for studying ssODN-mediated genome editing  
Used in 
Figure 
variation ssODN name ssODN sequence 
Figure 
7A 
length of the 
ssODN 
50 CCTCTGTAGTCAGACTGCCAAGCTTGAAACCTGTTATACCCTCAGCTTTCTCGTCTGGGTATTGGGCTGA 
70 CTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTT 
90 CATGAAATGACTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTTAGCCCCTGGG 
110 
CCCAACAACTCATGAAATGACTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTTAGC
CCCTGGGTTAGTCTGCC 
130 
ATAGAATCCTCCCAACAACTCATGAAATGACTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCA
CTGGCTTAGCCCCTGGGTTAGTCTGCCTCTGTAGGAT 
150 
TGGATGCCTCATAGAATCCTCCCAACAACTCATGAAATGACTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACT
ACAGAGGCCACTGGCTTAGCCCCTGGGTTAGTCTGCCTCTGTAGGATTGGGGGCACG 
Figure 
7B 
Distance 
between 
middle of 
ssODN and 
DSB 
-40 TGGATGCCTCATAGAATCCTCCCAACAACTCATGAAATGACTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAG 
-30 ATAGAATCCTCCCAACAACTCATGAAATGACTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCT 
-20 CCCAACAACTCATGAAATGACTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTG 
-10 CATGAAATGACTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGG 
0 CTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTT 
10 TCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTTAGCCCCTGGG 
20 ACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTTAGCCCCTGGGTTAGTCTGCC 
30 GAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTTAGCCCCTGGGTTAGTCTGCCTCTGTAGGAT 
40 GGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTTAGCCCCTGGGTTAGTCTGCCTCTGTAGGATTGGGGGCACG 
-40 CTGTTATACCCTCAGCTTTCTCGTCTGGGTATTGGGCTGAATGACAGTAGTCATTTCATGAGTTGTTGGGAGGATTCTATGAGGCATCCA 
-30 AGCTTGAAACCTGTTATACCCTCAGCTTTCTCGTCTGGGTATTGGGCTGAATGACAGTAGTCATTTCATGAGTTGTTGGGAGGATTCTAT 
-20 CAGACTGCCAAGCTTGAAACCTGTTATACCCTCAGCTTTCTCGTCTGGGTATTGGGCTGAATGACAGTAGTCATTTCATGAGTTGTTGGG 
-10 CCTCTGTAGTCAGACTGCCAAGCTTGAAACCTGTTATACCCTCAGCTTTCTCGTCTGGGTATTGGGCTGAATGACAGTAGTCATTTCATG 
0 AAGCCAGTGGCCTCTGTAGTCAGACTGCCAAGCTTGAAACCTGTTATACCCTCAGCTTTCTCGTCTGGGTATTGGGCTGAATGACAGTAG 
10 CCCAGGGGCTAAGCCAGTGGCCTCTGTAGTCAGACTGCCAAGCTTGAAACCTGTTATACCCTCAGCTTTCTCGTCTGGGTATTGGGCTGA 
20 GGCAGACTAACCCAGGGGCTAAGCCAGTGGCCTCTGTAGTCAGACTGCCAAGCTTGAAACCTGTTATACCCTCAGCTTTCTCGTCTGGGT 
30 ATCCTACAGAGGCAGACTAACCCAGGGGCTAAGCCAGTGGCCTCTGTAGTCAGACTGCCAAGCTTGAAACCTGTTATACCCTCAGCTTTC 
40 CGTGCCCCCAATCCTACAGAGGCAGACTAACCCAGGGGCTAAGCCAGTGGCCTCTGTAGTCAGACTGCCAAGCTTGAAACCTGTTATACC 
Figure 
7C 
Distance 
between the 
secondary 
mutation and 
DSB 
90-*1 CTACTGTCATTCAGGGCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTT 
90-*2 CTACTGTCATTCAGCCCAATACCCTAACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTT 
90-*3 CTACTGTCATTCAGCCCAATACCCAGACGAGAAAAGTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTT 
90M-0 CTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTT 
90-*4 CTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTGTAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTT 
90-*5 CTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCTCTCTGACTACAGAGGCCACTGGCTT 
90-*6 CTACTGTCATTCAGCCCAATACCCAGACGAGAAAGCTGAGGGTATAACAGGTTTCAAGCTTGGCAGTCTGACTAGTGAGGCCACTGGCTT 
Figure 
7D 
distance 
between 
ssODN and 
the DSB 
L670bp_90M CACTTTATATTTCCCTGCTTAAACAGTCCCCCGAGGGTGGGTGCGGAAAAGGCTCTACACTTGTTATCATTCCCTCTCCACCACAGGCAT 
L570bp_90M TTTGTATTTGGGTTTTTTTAAAACCTCCACTCTACAGTTAAGAATTCTAAGGCACAGAGCTTCAATAATTTGGTCAGAGCCAAGTAGCAG 
L480bp_90M GGAGGTTAAACCCAGCAGCATGACTGCAGTTCTTAATCAATGCCCCTTGAATTGCACATATGGGATGAACTAGAACATTTTCTCGATGAT 
L394bp_90M CTCGATGATTCGCTGTCCTTGTTATGATTATGTTACTGAGCTCTACTGTAGCACAGACATATGTCCCTATATGGGGCGGGGGTGGGGGTG 
L290bp_90M GGTGTCTTGATCGCTGGGCTATTTCTATACTGTTCTGGCTTTTCGGAAGCAGTCATTTCTTTCTATTCTCCAAGCACCAGCAATTAGCTT 
L200bp_90M GCTTCTAGTTTGCTGAAACTAATCTGCTATAGACAGAGACTCCGACGAACCAATTTTATTAGGATTTGATCAAATAAACTCTCTCTGACA 
L114bp_90M GAAAGAGTAACTAAGAGTTTGATGTTTACTGAGTGCATAGTATGCACTAGATGCTGGCCGTGGATGCCTCATAGAATCCTCCCAACAACT 
L45bp_90M GCTAGATGCTGGCCGTGGATGCCTCATAGAATCCTCCCAACAACCGATGAAATGACTACTGTCATTCAGCCCAATACCCAGACGAGAAAG 
R40bp_90M ACAGGTTTCAAGCTTGGCAGTCTGACTACAGAGGCCACTGGCTTTACCCCTGGGTTAGTCTGCCTCTGTAGGATTGGGGGCACGTAATTT 
R100bp_90M TTAGTCTGCCTCTGTAGGATTGGGGGCACGTAATTTTGCTGTTTAAGGTCTCATTTGCCTTCTTAGAGATCACAAGCCAAAGCTTTTTAT 
R200bp_90M GGAAGCCCAGAGGGCATCTTGTGGCTCGGGAGTAGCTCTCTGCTACCTTCTCAGCTCTGCTGACAATACTTGAGATTTTCAGATGTCACC 
R261bp_90M TCAGCTCTGCTGACAATACTTGAGATTTTCAGATGTCACCAACCAGCAAGAGAGCTTGATATGACTGTATATAGTATAGTCATAAAGAAC 
R322bp_90M CATAAAGAACCTGAACTTGACCATATACTTATGTCATGTGGAAATCTTCTCATAGCTTCAGATAGATTATATCTGGAGTGAAGAATCCTG 
R375M_90M GTGGAAAATTTCTCATAGCTTCAGATAGATTATATCTGGAGTGAGCAATCCTGCCACCTATGTATCTGGCATAGTGTGAGTCCTCATAAA 
R448bp_90M GGTTTGAAGGGCAACAAAATAGTGAACAGAGTGAAAATCCCCACCTAGATCCTGGGTCCAGAAAAAGATGGGAAACCTGTTTAGCTCACC 
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sequence adaptor, 5 µl reaction products were then added to 20 µl  of  PCR mix 
containing 12.5 µl 2X KAPA HIFI Hotstart Readymix (KAPA Biosystems) and 200 nM primers 
carrying Illumina sequence adaptors. Reactions were incubated at 95°C for 5min followed by 25 
cycles of 98°C, 20s; 65°C, 20s and 72°C, 20s. PCR products were purified by QIAquick PCR 
purification kit, mixed at roughly the same concentration, and sequenced with MiSeq Personal 
Sequencer. All the PCR primers can be found in the Table 2_5.  
 
(3) Genome editing assessment system (GEAS) 
We wrote a pipeline to analyze the genome engineering data. This pipeline is integrated 
in one single Unix module, which uses different tools such as R, BLAT, and FASTX Toolkit.  
Barcode splitting: Groups of samples were pooled together and sequenced using MiSeq 
150bp paired end (PE150) (Illumina Next Gen Sequencing), and later separated based on DNA 
barcodes using FASTX Toolkit. 
 Quality filtering: We trimmed nucleotides with lower sequence quality (phred 
score<20).  After trimming, reads shorter than 80 nucleotides were discarded. 
 Mapping: We used BLAT to map the paired reads independently to the reference 
genome and we generated .psl files as output. 
 Indel calling: We defined indels as the full length reads containing 2 blocks of 
matches in the alignment. Only reads following this pattern in both paired end reads were  
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 considered. As a quality control, we required the indel reads to possess minimal 
70nt matching with the reference genome and both blocks to be at least 20 nt long. Size and 
position of indels were calculated by the positions of each block to the reference genome. Non-
homologous end joining (NHEJ) has been estimated as the percentage of reads containing indels 
(see equation 1). The majority of NHEJ event have been detected at the targeting site vicinity. 
 Homology directed recombination (HDR) efficiency: Pattern matching (grep) 
within a 12bp window centering over DSB was used to count specific signatures corresponding 
to reads containing the reference sequence, modifications of the reference sequence (2bp 
intended mismatches), and reads containing only 1bp mutation within the 2bp intended 
mismatches (see equation 1). 
 
Equation 1. Estimation of NHEJ and HDR 
 
A= reads identical to the reference:  XXXXXABXXXXX 
B= reads containing 2bp mismatch programed by ssODN:  XXXXXabXXXXX 
C= reads containing only 1 bp mutation in the target site: such as XXXXXaBXXXXX or 
XXXXXAbXXXXX  
D = reads containing indels as described above 
                     
 
       
   
                    
 
       
   
 
Statistical analysis of genome editing NGS data  
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(1) HDR specificity analysis 
We used an exact binomial test to compute the probabilities of observing various 
numbers of sequence reads containing the 2bp mismatch.  Based on the sequencing results of 
10bp windows before and after the targeting site, we estimated the maximum base change rates 
of the two windows (P1 and P2). Using the null hypothesis that the changes of each of the two 
target bp were independent, we computed the expected probability of observing 2bp mismatch at 
the targeting site by chance as the product of these two probabilities (P1*P2). Given a dataset 
containing N numbers of total reads and n number of HDR reads, we calculated the p-value of 
the observed HDR efficiency.  
 
(2) HDR sensitivity analysis  
In our experimental design, the ssODN DNA donors contained a 2bp mismatch against 
the targeting genome, so that we expected co-presence of the base changes in the two target bp if 
the ssODN was incorporated into the targeting genome. Other non-intended observed sequence 
changes would not likely change at the same time. Thus, we predicted non-intended changes to 
be much less interdependent.  Based on these assumptions, we used mutual information (MI) to 
measure the mutual dependence of simultaneous two base pair changes in all other pairs of 
positions, and we estimated the HDR detection limit as the smallest HDR where MI of the 
targeting 2bp site is higher than MI of all the other position pairs.  For a given experiment, we 
first identified HDR reads with intended 2bp mismatch from the original fastq file and we 
simulated a set of fastq files with diluted HDR efficiencies by systematically removing different 
numbers of HDR reads from the original data set. Mutual information (MI) was computed 
between all pairs of positions within a 20bp window centered on the targeting site.  In these 
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calculations, the mutual information of the base composition between any two positions is 
computed. Thus, unlike our HDR specificity measure above, this measure does not assess the 
tendency of position pairs to change to any particular pairs of target bases, only their tendency to 
change at the same time. We coded our analysis in R and MI was computed using the package 
infotheo. 
 
(3) Correlations between genome editing efficiency and epigenetic state 
We computed Pearson correlation coefficients to study possible associations between 
epigenetic parameters (DNase I HS or nucleosome occupancy) and genome engineering 
efficiencies (HDR, NHEJ).  Dataset of epigenetic parameters for both cell types were 
downloaded from UCSC genome browser. 
K562 cells HS: /gbdb/hg19/bbi/wgEncodeOpenChromDnaseK562SigV2.bigWig 
hiPSCs DNase I HS: /gbdb/hg19/bbi/wgEncodeOpenChromDnaseIpsnihi7Sig.bigWig 
K562 cells nucleosome occupancy: 
/gbdb/hg19/bbi/wgEncodeSydhNsomeK562Sig.bigWig 
To compute P-values, we compared the observed correlation to a simulated distribution 
which was built by randomizing the position of the epigenetic parameter (N=100000). Observed 
correlations higher than the 95th percentile, or lower than the 5th percentile of the simulated 
distribution were considered as potential associations.  
 
(4) Insertion composition analysis  
We analyzed whether inserted fragments tend to contain ssODN sequence. We mapped 
the insertion sequence to the ssODN and counted the mapping occurrence at specific positions in 
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the ssODN. As the control, we generate a set of randomized DNA sequence with the same size 
profile of insertions and conducted the same mapping analysis (Figure S9).    
 
Genotype screening of colonized hiPSCs 
(1) FACS sorting of single-hiPSCs 
Human iPS cells on feeder-free cultures were pre-treated with mTesr-1 media 
supplemented with SMC4 (5 uM thiazovivin,1 uM CHIR99021, 0.4 uM PD0325901, 2 uM 
SB431542) (42)  for at least 2 hrs prior to FACS sorting.  Cultures were dissociated using 
Accutase (Millipore) and resuspended in mTesr-1 media supplemented with SMC4 and the 
viability dye ToPro-3 (Invitrogen) at concentration of 1~2 X107 /mL.  Live hiPS cells were 
single-cell sorted using a BD FACSAria II SORP UV (BD Biosciences) with 100um nozzle 
under sterile conditions into 96-well plates coated with irradiated CF-1 mouse embryonic 
fibroblasts (Global Stem).  Each well contained hES cell medium (59) with 100 ng / ml 
recombinant human basic Fibroblast Growth Factor (bFGF) (Millipore) supplemented with 
SMC4 and 5 ug / ml fibronectin (Sigma).  After sorting, plates were centrifuged at 70 x g for 3 
min.  Colony formation was seen 4 days post sorting, and the culture media was replaced with 
hES cell medium with SMC4. SMC4 can be removed from hES cell medium 8 days after sorting.  
 
(2) Genotyping monoclonal hiPSCs 
A few thousand cells were harvested 8 days after Fluorescence-activated cell sorting 
(FACS) and 0.1ul prepGEM tissue protease enzyme (ZyGEM) and 1ul prepGEM gold buffer 
(ZyGEM) were added to 8.9 µl of cells in the medium. The reactions were then added to 40 µl of 
PCR mix containing 35.5ml platinum 1.1X Supermix (Invitrogen), 250nM of each dNTP and 
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400nM primers. Reactions were incubated at 95°C for 3min followed by 30 cycles of 95°C, 20s; 
65°C, 30s and 72°C, 20s. Products were Sanger sequenced using either one of the PCR primers 
(Table S5) and sequences were analyzed using DNASTAR (DNASTAR).  
 
(3) Immunostaining 
Cells were incubated in the KnockOut DMEM/F-12 medium at 37˚C for 60 minutes 
using the following antibody: Anti-SSEA-4 PE (Millipore) (1: 500 diluted); Tra-1-60 (BD 
Pharmingen) (1:100 diluted). After the incubation, cells were washed three times with KnockOut 
DMEM/F-12 and imaged on the Axio Observer Z.1 (ZIESS).  
 
(4) Teratoma Formation and Analysis 
Human iPSCs were harvested using collagenase type IV (Invitrogen) and resuspended 
into 200 µl of Matrigel and injected intramuscularly into the hind limbs of Rag2gamma knockout 
mice. Teratomas were isolated and fixed in formalin between 4 - 8 weeks after the injection. The 
teratomas were subsequently analyzed by hematoxylin and eosin staining. 
 
Sequence used in the study 
Sequence 2_1 
re-TALE (16.5) sequence 
CTAACCCCTGAACAGGTAGTCGCTATAGCTTCAAATATCGGGGGCAAGCAAGCACTTGAGACCGTTCAACGACTCCT
GCCAGTGCTCTGCCAAGCCCATGGATTGACTCCGGAGCAAGTCGTCGCGATCGCGAGCAACGGCGGGGGGAAGCAGG
CGCTGGAAACTGTTCAGAGACTGCTGCCTGTACTTTGTCAGGCGCATGGTCTCACCCCCGAACAGGTTGTCGCAATA
GCAAGTAATATAGGCGGTAAGCAAGCCCTAGAGACTGTGCAACGCCTGCTCCCCGTGCTGTGTCAGGCTCACGGTCT
GACACCTGAACAAGTTGTCGCGATAGCCAGTCACGACGGGGGAAAACAAGCTCTAGAAACGGTTCAAAGGTTGTTGC
CCGTTCTGTGCCAAGCACATGGGTTAACACCCGAACAAGTAGTAGCGATAGCGTCAAATAACGGGGGTAAACAGGCT
TTGGAGACGGTACAGCGGTTATTGCCGGTCCTCTGCCAGGCCCACGGACTTACGCCAGAACAGGTGGTTGCAATTGC
CTCCAACATCGGCGGGAAACAAGCGTTGGAAACTGTGCAGAGACTCCTTCCTGTTTTGTGTCAAGCCCACGGCTTGA
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CGCCTGAGCAGGTTGTGGCCATCGCTAGCCACGACGGAGGGAAGCAGGCTCTTGAAACCGTACAGCGACTTCTCCCA
GTTTTGTGCCAAGCTCACGGGCTAACCCCCGAGCAAGTAGTTGCCATAGCAAGCAACGGAGGAGGAAAACAGGCATT
AGAAACAGTTCAGCGCTTGCTCCCGGTACTCTGTCAGGCACACGGTCTAACTCCGGAACAGGTCGTAGCCATTGCTT
CCCATGATGGCGGCAAACAGGCGCTAGAGACAGTCCAGAGGCTCTTGCCTGTGTTATGCCAGGCACATGGCCTCACC
CCGGAGCAGGTCGTTGCCATCGCCAGTAATATCGGCGGAAAGCAAGCTCTCGAAACAGTACAACGGCTGTTGCCAGT
CCTATGTCAAGCTCATGGACTGACGCCCGAGCAGGTAGTGGCAATCGCATCTCACGATGGAGGTAAACAAGCACTCG
AGACTGTCCAAAGATTGTTACCCGTACTATGCCAAGCGCATGGTTTAACCCCAGAGCAAGTTGTGGCTATTGCATCT
AACGGCGGTGGCAAACAAGCCTTGGAGACAGTGCAACGATTACTGCCTGTCTTATGTCAGGCCCATGGCCTTACTCC
TGAGCAAGTCGTAGCTATCGCCAGCAACATAGGTGGGAAACAGGCCCTGGAAACCGTACAACGTCTCCTCCCAGTAC
TTTGTCAAGCACACGGGTTGACACCGGAACAAGTGGTGGCGATTGCGTCCAACGGCGGAGGCAAGCAGGCACTGGAG
ACCGTCCAACGGCTTCTTCCGGTTCTTTGCCAGGCTCATGGGCTCACGCCAGAGCAGGTGGTAGCAATAGCGTCGAA
CATCGGTGGTAAGCAAGCGCTTGAAACGGTCCAGCGTCTTCTGCCGGTGTTGTGCCAGGCGCACGGACTCACACCAG
AACAAGTGGTTGCTATTGCTAGTAACAACGGTGGAAAGCAGGCCCTCGAGACGGTGCAGAGGTTACTTCCCGTCCTC
TGTCAAGCGCACGGCCTCACTCCAGAGCAAGTGGTTGCGATCGCTTCAAACAATGGTGGAAGACCTGCCCTGGAA 
Sequence 2_2 
re-TALEN-backbone sequence 
( purple: re-TALE-N; red: SapI site; green: 0.5 monomer; blue: re-TALEN-C; orange: Fok I) 
ATGTCGCGGACCCGGCTCCCTTCCCCACCCGCACCCAGCCCAGCGTTTTCGGCCGACTCGTTCTCAGACCTGCTTAG
GCAGTTCGACCCCTCACTGTTTAACACATCGTTGTTCGACTCCCTTCCTCCGTTTGGGGCGCACCATACGGAGGCGG
CCACCGGGGAGTGGGATGAGGTGCAGTCGGGATTGAGAGCTGCGGATGCACCACCCCCAACCATGCGGGTGGCCGTC
ACCGCTGCCCGACCGCCGAGGGCGAAGCCCGCACCAAGGCGGAGGGCAGCGCAACCGTCCGACGCAAGCCCCGCAGC
GCAAGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAAGCCCAAAGTGAGGTCGACAGTCG
CGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACATGCCCACATCGTAGCCTTGTCGCAGCACCCTGCAGCC
CTTGGCACGGTCGCCGTCAAGTACCAGGACATGATTGCGGCGTTGCCGGAAGCCACACATGAGGCGATCGTCGGTGT
GGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGGGCCTCCCCTTC
AGCTGGACACGGGCCAGTTGCTGAAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGTGCACGCGTGGCGC
AATGCGCTCACGGGAGCACCCCTCAACAGTTCACGCTGACAGAGACCGCGGCCGCATTAGGCACCCCAGGCTTTACA
CTTTATGCTTCCGGCTCGTATAATGTGTGGATTTTGAGTTAGGATCCGTCGAGATTTTCAGGAGCTAAGGAAGCTAA
AATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTC
AGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAAT
AAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAAT
GAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTT
CATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGT
GAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCAC
CAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAG
GCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTT
AATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAAAGATCTGGATCCGGCTTACTAAAAGCCAGATA
ACAGTATGCGTATTTGCGCGCTGATTTTTGCGGTATAAGAATATATACTGATATGTATACCCGAAGTATGTCAAAAA
GAGGTATGCTATGAAGCAGCGTATTACAGTGACAGTTGACAGCGACAGCTATCAGTTGCTCAAGGCATATATGATGT
CAATATCTCCGGTCTGGTAAGCACAACCATGCAGAATGAAGCCCGTCGTCTGCGTGCCGAACGCTGGAAAGCGGAAA
ATCAGGAAGGGATGGCTGAGGTCGCCCGGTTTATTGAAATGAACGGCTCTTTTGCTGACGAGAACAGGGGCTGGTGA
AATGCAGTTTAAGGTTTACACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTG
ACACGCCCGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAAAGTCTCCCGTGAACTTTAC
CCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGG
GGAAGAAGTGGCTGATCTCAGCCACCGCGAAAATGACATCAAAAACGCCATTAACCTGATGTTCTGGGGAATATAAA
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TGTCAGGCTCCCTTATACACAGCCAGTCTGCAGGTCGACGGTCTCGCTCTTCGAAGGTTACTTCCCGTCCTCTGTCA
AGCGCACGGCCTCACTCCAGAGCAAGTGGTTGCGATCGCTTCAAACAACGGTGGAAGACCTGCCCTGGAATCAATCG
TGGCCCAGCTTTCGAGGCCGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGC
GGACGACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAGCGGACCAACAGAAGGAT
TCCCGAGAGGACATCACATCGAGTGGCAGGTTCCCAACTCGTGAAGAGTGAACTTGAGGAGAAAAAGTCGGAGCTGC
GGCACAAATTGAAATACGTACCGCATGAATACATCGAACTTATCGAAATTGCTAGGAACTCGACTCAAGACAGAATC
CTTGAGATGAAGGTAATGGAGTTCTTTATGAAGGTTTATGGATACCGAGGGAAGCATCTCGGTGGATCACGAAAACC
CGACGGAGCAATCTATACGGTGGGGAGCCCGATTGATTACGGAGTGATCGTCGACACGAAAGCCTACAGCGGTGGGT
ACAATCTTCCCATCGGGCAGGCAGATGAGATGCAACGTTATGTCGAAGAAAATCAGACCAGGAACAAACACATCAAT
CCAAATGAGTGGTGGAAAGTGTATCCTTCATCAGTGACCGAGTTTAAGTTTTTGTTTGTCTCTGGGCATTTCAAAGG
CAACTATAAGGCCCAGCTCACACGGTTGAATCACATTACGAACTGCAATGGTGCGGTTTTGTCCGTAGAGGAACTGC
TCATTGGTGGAGAAATGATCAAAGCGGGAACTCTGACACTGGAAGAAGTCAGACGCAAGTTTAACAATGGCGAGATC
AATTTCCGC 
 
re-TALE-TF backbone sequence 
( purple: re-TALE-N; red: SapI site; green: 0.5 monomer; blue: re-TALEN-C; orange: NLS-VP64; 2A-GFP 
is highlighted in green) 
ATGTCGCGGACCCGGCTCCCTTCCCCACCCGCACCCAGCCCAGCGTTTTCGGCCGACTCGTTCTCAGACCTGCTTAG
GCAGTTCGACCCCTCACTGTTTAACACATCGTTGTTCGACTCCCTTCCTCCGTTTGGGGCGCACCATACGGAGGCGG
CCACCGGGGAGTGGGATGAGGTGCAGTCGGGATTGAGAGCTGCGGATGCACCACCCCCAACCATGCGGGTGGCCGTC
ACCGCTGCCCGACCGCCGAGGGCGAAGCCCGCACCAAGGCGGAGGGCAGCGCAACCGTCCGACGCAAGCCCCGCAGC
GCAAGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAAGCCCAAAGTGAGGTCGACAGTCG
CGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACATGCCCACATCGTAGCCTTGTCGCAGCACCCTGCAGCC
CTTGGCACGGTCGCCGTCAAGTACCAGGACATGATTGCGGCGTTGCCGGAAGCCACACATGAGGCGATCGTCGGTGT
GGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGGGCCTCCCCTTC
AGCTGGACACGGGCCAGTTGCTGAAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGTGCACGCGTGGCGC
AATGCGCTCACGGGAGCACCCCTCAACAGTTCACGCTGACAGAGACCGCGGCCGCATTAGGCACCCCAGGCTTTACA
CTTTATGCTTCCGGCTCGTATAATGTGTGGATTTTGAGTTAGGATCCGTCGAGATTTTCAGGAGCTAAGGAAGCTAA
AATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTC
AGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAAT
AAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAAT
GAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTT
CATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGT
GAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCAC
CAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAG
GCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTT
AATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAAAGATCTGGATCCGGCTTACTAAAAGCCAGATA
ACAGTATGCGTATTTGCGCGCTGATTTTTGCGGTATAAGAATATATACTGATATGTATACCCGAAGTATGTCAAAAA
GAGGTATGCTATGAAGCAGCGTATTACAGTGACAGTTGACAGCGACAGCTATCAGTTGCTCAAGGCATATATGATGT
CAATATCTCCGGTCTGGTAAGCACAACCATGCAGAATGAAGCCCGTCGTCTGCGTGCCGAACGCTGGAAAGCGGAAA
ATCAGGAAGGGATGGCTGAGGTCGCCCGGTTTATTGAAATGAACGGCTCTTTTGCTGACGAGAACAGGGGCTGGTGA
AATGCAGTTTAAGGTTTACACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTG
ACACGCCCGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAAAGTCTCCCGTGAACTTTAC
CCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGG
GGAAGAAGTGGCTGATCTCAGCCACCGCGAAAATGACATCAAAAACGCCATTAACCTGATGTTCTGGGGAATATAAA
TGTCAGGCTCCCTTATACACAGCCAGTCTGCAGGTCGACGGTCTCGCTCTTCGAAGGTTACTTCCCGTCCTCTGTCA
AGCGCACGGCCTCACTCCAGAGCAAGTGGTTGCGATCGCTTCAAACAACGGTGGAAGACCTGCCCTGGAATCAATCG
TGGCCCAGCTTTCGAGGCCGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGC
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GGACGACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAGCGGACCAACAGAAGGAT
TCCCGAGAGGACATAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCGGTTCCGGACGGGCTGACGCATTGGACGAT
TTTGATCTGGATATGCTGGGAAGTGACGCCCTCGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCTTGATGA
CTTTGACCTCGACATGCTCGGCAGTGACGCCCTTGATGATTTCGACCTGGACATGCTGATTAACTCTAGAGGCAGTG
GAGAGGGCAGAGGAAGTCTGCTAACATGCGGTGACGTCGAGGAGAATCCTGGCCCAGTGAGCAAGGGCGAGGAGCTG
TTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGG
CGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCA
CCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTC
AAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGC
CGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACA
TCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATC
AAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCC
CATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACG
AGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG 
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Summary 
Bacteria and archaea have evolved adaptive immune defenses, termed clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems, that use 
short RNA to direct degradation of foreign nucleic acids. Here, we engineer the type II bacterial 
CRISPR system to function with custom guide RNA (gRNA) in human cells and build a 
genome-wide resource of ~190 K unique gRNAs targeting ~40.5% of human exons. In addition, 
we investigated off-target binding by Cas9-gRNA complexes and compared them with TAL 
effector (TALE) proteins and demonstrate methods to mitigate off-target phenomena by 
engineering a requirement for cooperatively through offset nicking for genome editing. Our 
results establish an RNA-guided editing tool for facile, robust, and multiplexable human genome 
engineering. 
 
Introduction 
Bacteria and archaea have evolved adaptive immune defenses termed clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems that use short 
RNA to direct degradation of foreign nucleic acids. CRISPR defense involves acquisition and 
integration of new targeting “spacers” from invading virus or plasmid DNA into the CRISPR 
locus, expression and processing of short guiding CRISPR RNAs (crRNAs) consisting of spacer-
repeat units, and cleavage of nucleic acids (most commonly DNA) complementary to the spacer.  
Three classes of CRISPR systems have been described thus far (Type I, II and III). Here 
we focus on the Type II CRISPR system, which utilizes a single effector enzyme, Cas9, to cleave 
dsDNA, whereas Type I and Type III systems require multiple distinct effectors acting as a 
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complex (for a detailed review of CRISPR classification, see reference (1)). As a consequence, 
Type II systems are more likely to function in alternative contexts such as eukaryotic cells. The 
Type II effector system consists of a long pre-crRNA transcribed from the spacer-containing 
CRISPR locus, the multifunctional Cas9 protein, and a tracrRNA important for gRNA 
processing.  The tracrRNAs hybridize to the repeat regions separating the spacers of the pre-
crRNA, initiating dsRNA cleavage by endogenous RNase III, which is followed by a second 
cleavage event within each spacer by Cas9, producing mature crRNAs that remain associated 
with the tracrRNA and Cas9.  Jinek et al. demonstrated that a tracrRNA-crRNA fusion, termed a 
guide RNA (gRNA) in this work, is functional in vitro, obviating the need for RNase III and the 
crRNA processing in general (2). 
Type II CRISPR interference is a result of Cas9 unwinding the DNA duplex and 
searching for sequences matching the crRNA to cleave.  Target recognition occurs upon 
detection of complementarity between a “protospacer” sequence in the target DNA and the 
remaining spacer sequence in the crRNA. Importantly, Cas9 cuts the DNA only if a correct 
protospacer-adjacent motif (PAM) is also present at the 3’ end. Different Type II systems have 
differing PAM requirements.  The S. pyogenes system utilized in this work requires an NGG 
sequence, where N can be any nucleotide. S. thermophilus Type II systems require NGGNG (3) 
and NNAGAAW (4), respectively, while different S. mutans systems tolerate NGG or NAAR 
(5). Bioinformatic analyses have generated extensive databases of CRISPR loci in a variety of 
bacteria that may serve to identify new PAMs and expand the set of CRISPR-targetable 
sequences (6, 7). In S. thermophilus, Cas9 generates a blunt-ended double-stranded break 3bp 
prior to the 3’ end of the protospacer (8), a process mediated by two catalytic domains in the 
Cas9 protein: an HNH domain that cleaves the complementary strand of the DNA and a RuvC-
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like domain that cleaves the non-complementary strand. While the S. pyogenes system has not 
been characterized to the same level of precision, DSB formation also occurs towards the 3’ end 
of the protospacer.  If one of the two nuclease domains is inactivated, Cas9 will function as a 
nickase in vitro (2) and in human cells.  
As a genome engineering tool, the specificity of gRNA-directed Cas9 cleavage will be of 
the utmost importance. Significant off-target activity could cause unwanted double-strand breaks 
at other regions of the genome, resulting in toxicity and possibly oncogenesis in gene therapy 
applications. The S. pyogenes system tolerates mismatches in the first 6 bases out of the 20bp 
mature spacer sequence in vitro. However, it is entirely possible that greater stringency is 
required in vivo given the low toxicity we observed in human cell lines, as potential off-target 
sites matching (last 14 bp) NGG exist within the human reference genome for our gRNAs. 
Mismatches towards the 3’ end of the spacer, known as the “seed sequence” (9), are less well 
tolerated.  Jinek et al. found that single mismatches in the PAM at positions -3 through -7 
abolished interference in vitro, though a mismatch at position -10 did not (2).  In S. 
thermophilus, single mutations in the PAM or at positions -1, -3 through -5, and -7 through -8 
abolished interference. When transplanted into E. coli, the S. thermophilus system did not 
tolerate single mutations in the PAM or in positions -3, -6, or -8. As a caveat, Garneau et al. 
found that spacers acquired from plasmid DNA tolerated greater degeneracy in both the PAM 
and seed sequence while sufficing to block plasmid acquisition in S. thermophiles (10); however, 
similar degeneracy was not sufficient to block phage infection (11), emphasizing the importance 
of the assay utilized. Taken together, these results point towards the urgent need to assay 
specificity in the context of interest.  
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Here, we sought to test whether we can engineer Cas9 system in human setting to 
conduct sequence specific genome engineering.  
Results 
Design of Cas9-gRNA system in human cells 
First, we engineer the protein and RNA components of this bacterial type II CRISPR 
system in human cells. We began by synthesizing a human codon optimized version of the Cas9 
protein bearing a C-terminal SV40 nuclear localization signal and cloning it into a mammalian 
expres- sion system (Figure 3_1 A, Figure 3_2 A).To direct Cas9 to cleave sequences of interest, 
we expressed crRNA-tracrRNA fusion transcripts, hereafter referred to as guide RNAs (gRNAs), 
from the human U6 polymerase III promoter. Directly transcribing gRNAs allowed us to avoid 
reconstituting the RNA-processing machinery used by bacterial CRISPR systems (Figure 3_1 A 
and Figure 3_2 B) (2, 12), Constrained only by U6 transcription initiating with G and the 
requirement for the PAM (protospacer-adjacent motif) sequence –NGG following the 20–base 
pair (bp) crRNA target, our highly versatile approach can, in principle, target any genomic site of 
the form GN20GG (Figure 3_2C). 
 
Functional test of Cas9-gRNA system in human cells 
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Figure 3-1. Genome editing in human cells using an engineered type II CRISPR system.  
(A) RNA-guided gene targeting in human cells involves co-expression of the Cas9 protein bearing a C-
terminus SV40 nuclear localization signal with one or more defined-length guide RNAs expressed from the human 
U6 polymerase III promoter. Cas9 unwinds the DNA duplex and cleaves both strands upon recognition of a target 
sequence by the guide RNA, but only if the correct protospacer-associated motif (PAM) is present at the 3’ end. Any 
genomic sequence of the form GN20GG can in principle be targeted.  
(B) A genomically integrated GFP coding sequence is disrupted by the insertion of a stop codon and a 68bp 
genomic fragment derived from the AAVS1 locus. Restoration of the GFP sequence by homologous recombination 
with an appropriate donor sequence results in GFP+ cells that can be quantitated by FACS. T1 and T2 gRNAs target 
sequences within the AAVS1 fragment. Binding sites for the two halves of the TAL effector nuclease heterodimer 
(TALEN) are underlined.  
(C) Bar graph depicting homologous recombination efficiencies induced by T1, T2, and TALEN-mediated 
nuclease activity at the target locus, as measured by FACS. Representative FACS plots and microscopy images of 
the targeted cells are depicted below (scale bar is 100 microns). 
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Figure 3_2. The engineered type II CRISPR system for human cells. (continued) 
(A) Expression format and full sequence of the cas9 gene insert. The RuvC-like and HNH motifs, and the C-
terminus SV40 NLS are respectively highlighted by blue, brown and orange colors.  
(B) U6 promoter based expression scheme for the guide RNAs and predicted RNA transcript secondary 
structure. The use of the U6 promoter constrains the 1st position in the RNA transcript to be a ‘G’ and thus all 
genomic sites of the form GN20GG can be targeted using this approach.  
(C) A list of the 4 gRNAs used in this study for targeting GFP and the AAVS1 locus is provided. 
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To test the functionality of our implementation for genome engineering, we developed a 
green fluorescent protein (GFP) reporter assay (Figure 3_1 B) in human embryonic kidney HEK 
293T cells similar to one previously described (13). Specifically, we established a stable cell line 
bearing a genomically integrated GFP coding sequence disrupted by the insertion of a stop codon 
and a 68-bp genomic fragment fromtheAAVS1 locus that renders the expressed protein fragment 
non- fluorescent. Homologous recombination (HR) using an appropriate repair donor can restore 
the normal GFP sequence, which enabled us to quantify the resulting GFP+ cells by flow-
activated cell sorting (FACS). 
To test the efficiency of our system at stimulating HR, we constructed two gRNAs, T1 
and T2, that target the intervening AAVS1 fragment (Figure 3_2 B) and compared their activity 
to that of a previously described TAL effector nuclease heterodimer (TALEN) targeting the same 
region (14).We observed successful HR events using all three targeting reagents, with gene 
correction rates using the T1 andT2 gRNAs approaching 3%and 8%, respectively (Figure 3_2 
C). This RNA-mediated editing process was notably rapid, with the first detectable GFP+ cells 
appearing ~20 hours post transfection compared with ~40 hours for the AAVS1 TALENs. We 
observed HR only upon simultaneous introduction of the repair donor, Cas9 protein, and gRNA, 
which confirmed that all components are required for genome editing (Figure 3_3). Although we 
noted no apparent toxicity associated with Cas9/gRNA expression, work with zinc finger 
nucleases (ZFNs) and TALENs has shown that nicking only one strand further reduces toxicity. 
Accordingly, we also tested a Cas9D10A mutant that is known to function as a nickase in vitro, 
which yielded similar HR but lower non homologous end  
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Figure 3_3. RNA-guided genome editing requires both Cas9 and guide RNA for successful targeting. Using the 
GFP reporter assay described in Fig. 1B, all possible combinations of the repair DNA donor, Cas9 protein, and 
gRNA were tested for their ability to effect successful HR. GFP+ cells were observed only when all the 3 
components were present, validating that these CRISPR components are essential for RNA-guided genome editing.  
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joining (NHEJ) rates (Figure 3_4) (2), Consistent with (2), in which a related Cas9 protein is 
shown to cut both strands 3 bp upstream of the PAM, our NHEJ data confirmed that most 
deletions or insertions occurred at the 3′ end of the target sequence (Figure 3_4 B). We also 
confirmed that mutating the target genomic site prevents the gRNA from effecting HR at that 
locus, which demonstrates that CRISPR- mediated genome editing is sequence-specific (Figure 
3_5). Finally, we showed that two gRNAs targeting sites in the GFP gene, and also three 
additional gRNAs targeting fragments from homologous regions of the DNA methyl transferase 
3a (DNMT3a) and DNMT3b genes could sequence-specifically induce significant HR in the 
engineered reporter cell lines (Figure 3_6 and Figure 3_7). Together, these results confirm that 
RNA- guided genome targeting in human cells is simple to execute and induces 
robustHRacrossmultiple target sites. 
Having successfully targeted an integrated reporter, we next turned to modifying a native 
locus. We used the gRNAs described above to target theAAVS1 locus located in the PPP1R12C 
gene on chromosome 19, which is ubiquitously expressed across most tissues (Figure 3_8 A).We 
targeted 293Ts, human chronic myelogenous leukemia K562 cells, and PGP1 human induced 
pluripotent stem (iPS) cells (15) and analyzed the results by next-generation sequencing of the 
targeted locus. Consistent with our results for the GFP reporter assay, we observed high numbers 
of NHEJ events at the endogenous locus for all three cell types. The two gRNAs T1 and T2 
achieved NHEJ rates of 10 and 25%in 293Ts, 13 and 38% in K562s, and 2 and 4% in PGP1- iPS 
cells, respectively (Figure 3_8). We observed no overt toxicity from the Cas9 and gRNA 
expression required to induce NHEJ in any of these cell types. As expected, NHEJ-mediated 
deletions for T1 and T2 were centered around the target site positions, which further validated 
the  
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Figure 3_4.  Analysis of gRNA and Cas9 mediated genome editing. We closely examined the CRISPR mediated 
genome editing process using either  
(A) a GFP reporter assay as described earlier, and  
(B) deep sequencing of the targeted loci. As comparison we also tested a D10A mutant for Cas9 that has been shown 
in earlier reports to function as a nickase in in vitro assays. Our data shows that both Cas9 and Cas9D10A can effect 
successful HR at nearly similar rates. Deep sequencing however confirms that while Cas9 shows robust NHEJ at the 
targeted loci, the D10A mutant has significantly diminished NHEJ rates (as would be expected from its putative 
ability to only nick DNA). Also, consistent with the known biochemistry of the Cas9 protein, our NHEJ data 
confirms that most base-pair deletions or insertions occurred near the 3’ end of the target sequence: the peak is ~3-
4 bases upstream of the PAM site, with a median deletion frequency of ~9-10bp. Data is mean +/- SEM (N=3). 
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Figure 3_5. RNA-guided genome editing is target sequence specific.  
we developed 3 293T stable lines each bearing a distinct GFP reporter construct. These are distinguished by the 
sequence of the AAVS1 fragment insert (as indicated in the figure). One line harbored the wild-type fragment while 
the two other lines were 6 mutated bases away (highlighted in red). Each of the lines was then targeted by one of the 
following 4 reagents: a GFP-ZFN pair that can target all cell types since its targeted sequence was in the flanking 
GFP fragments and hence present in along cell lines; a AAVS1 TALEN that could potentially target only the wt-
AAVS1 fragment since the mutations in the other two lines should render the left TALEN unable to bind their sites; 
the T1 gRNA which can also potentially target only the wt-AAVS1 fragment, since its target site is also disrupted in 
the two mutant lines; and finally the T2 gRNA which should be able to target all the 3 cell lines since unlike the T1 
gRNA its target site is unaltered among the 3 lines. Consistent with these predictions, the ZFN modified all 3 cell 
types, the AAVS1 TALENs and the T1 gRNA only targeted the wt-AAVS1 cell type, and the T2 gRNA 
successfully targets all 3 cell types. These results together confirm that the guide RNA mediated editing is target 
sequence specific. 
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Figure 3_6. Guide RNAs targeted to the GFP sequence enable robust genome editing.  
In addition to the 2 gRNAs targeting the AAVS1 insert, we also tested two additional gRNAs targeting the flanking 
GFP sequences of the reporter described in Fig. 1B. These gRNAs were also able to effect robust HR at this 
engineered locus. 
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Figure 3_7. RNA-guided genome editing is target sequence specific, and demonstrates similar targeting efficiencies 
as ZFNs or TALENs.  
Similar to the GFP reporter assay described in Fig. 1B, we developed 2 293T stable lines each bearing a distinct 
GFP reporter construct. These are distinguished by the sequence of the fragment insert (as indicated in the figure). 
One line harbored a 58bp fragment from the DNMT3a gene while the other line bore a homologous 58bp fragment 
from the DNMT3b gene. The sequence differences are highlighted in red. Each of the lines was then targeted by one 
of the following 6 reagents: a GFP-ZFN pair that can target all cell types since its targeted sequence was in the 
flanking GFP fragments and hence present in along cell lines; a pair of TALENs that potentially target either 
DNMT3a or DNMT3b fragments; a pair of gRNAs that can potentially target only the DNMT3a fragment; and 
finally a gRNA that should potentially only target the DNMT3b fragment. Consistent with these predictions, the 
ZFN modified all 3 cell types, and the TALENs and gRNAs only their respective targets. Furthermore the 
efficiencies of targeting were comparable across the 6 targeting reagents. These results together confirm that RNA-
guided editing is target sequence specific and demonstrates similar targeting efficiencies as ZFNs or TALENs. Data 
is mean +/- SEM (N=3). 
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Figure 3_8. RNA-guided genome editing of the native AAVS1 locus in multiple cell types. 
(A) Sequences targeted by T1 (red) and T2 (green) gRNAs are located inside an intron of PPP1R12C gene 
within the AAVS1 locus on chromosome 19.  
(B) T1 and T2 gRNAs induced Cas9 to cleave target sequences within 293Ts, K562s, and PGP1 human iPS 
cells, resulting in NHEJ-mediated deletions that were pinpointed and quantified using next-generation sequencing.  
NHEJ frequencies for T1 and T2 gRNAs were 10% and 25% in 293T, 13% and 38% in K562, and 2% and 4% in 
PGP1 iPS cells, respectively. Red dash lines demarcate the boundary of the T1 gRNA targeting site; green dash lines 
demarcate the boundary of the T2 gRNA targeting site. Deletion incidences at each nucleotide position are plotted in 
black lines. The sequence of the whole targeting region which was used as the reference for NGS mapping is listed 
in supplement. As expected (refer Fig. 1A), the peak of frequency of NHEJ based base-pair deletions occurs at the 3
’ end of the target sequence.  
(C) DNA donor architecture for HR at the AAVS1 locus, and location of the sequencing primers (arrows) to 
detect successful targeted events is depicted.  
(D) PCR assay three days post transfection demonstrates that only cells expressing the donor, Cas9 and T2 
gRNA show evidence of successful HR events.  
(E) Successful HR was confirmed by Sanger sequencing of the PCR amplicon showing that the expected DNA 
bases at both the genome-donor and donor-insert boundary are present.  
(F) Successfully targeted clones of 293T cells were also selected with puromycin for 2 weeks. Microscope 
images of two representative GFP+ clones is shown (scale bar is 100 microns). 
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sequence- specificity of this targeting process (Figure 3_9-11). Simultaneous introduction of 
both T1 and T2 gRNAs resulted in high-efficiency deletion of the intervening 19-bp fragment 
(Figure 3_10), which demonstrated that multiplexed editing of genomic loci is feasible using this 
approach. Last, we attempted to use HR to integrate either a double-stranded DNA donor 
construct (16) or an oligo donor into the native AAVS1 locus (Figure 3_8 and Figure 3_12).We 
confirmed HR- mediated integration, using both approaches, by polymerase chain reaction 
(PCR) (Figure 3_8 D and Figure 3_12) and Sanger sequencing (Figure 3_8 E). We also readily 
derived 293T or iPS clones from the pool ofmodified cells using puromycin selection over 2 
weeks (Figure 3_8 E and Figure 3_12). These results demonstrate that this approach enables 
efficient integration of foreign DNA at endogenous loci in human cells.  
 
Comparison of  Cas9-gRNA system with reTALENs system in human stem cells 
After confirming activity of Cas9-gRNA, we next sought to compare the efficiency 
reTALENs V.S. Cas9-gRNA . To do that, we design and constructed reTALENs and Cas9-
gRNAs targeted to fifteen sites at the CCR5 genomic locus (Figure 3_13 A).  Anticipating that 
editing efficiency might depend on chromatin state, these sites were selected to represent a wide 
range of DNaseI sensitivities (17).  The nuclease constructs were transfected with the 
corresponding ssODNs donors (Supplementary Table 3) into PGP1 hiPSCs.  Six days after 
transfection, we profiled the genome editing efficiencies at these sites (Supplementary Table 4). 
For 13 out of 15 re-TALEN pairs with ssODN donors, we detected NHEJ and HDR at levels 
above our statistical detection thresholds, with an average NHEJ efficiency of 0.4% and an 
average HDR efficiency of  
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Figure 3_9. RNA-guided NHEJ in human iPS cells.  
we measured NHEJ rate by assessing genomic deletion and insertion rate at double-strand breaks (DSBs) by deep 
sequencing. Panel 1: Deletion rate detected at targeting region.  Red dash lines: boundary of T1 RNA targeting site; 
green dash lines: boundary of T2 RNA targeting site. We plot the deletion incidence at each nucleotide position in 
black lines and we calculated the deletion rate as the percentage of reads carrying deletions. Panel 2: Insertion rate 
detected at targeting region. Red dash lines: boundary of T1 RNA targeting site; green dash lines: boundary of T2 
RNA targeting site. We plot the incidence of insertion at the genomic location where the first insertion junction was 
detected in black lines and we calculated the insertion rate as the percentage of reads carrying insertions. Panel 3: 
Deletion size distribution. We plot the frequencies of different size deletions among the whole NHEJ population. 
Panel 4: insertion size distribution. We plot the frequencies of different sizes insertions among the whole NHEJ 
population.  
(Continued) 
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Figure 3_9 (Continued) 
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Figure 3_10.  RNA-guided NHEJ in K562 cells. 
 K562 targeting by both gRNAs is efficient (13-38%) and sequence specific (as shown by the shift in position of the 
NHEJ deletion distributions). Importantly, as evidenced by the peaks in the histogram of observed frequencies of 
deletion sizes, simultaneous introduction of both T1 and T2 guide RNAs resulted in high efficiency deletion of the 
intervening 19bp fragment, demonstrating that multiplexed editing of genomic loci is also feasible using this 
approach.  
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Figure 3_11.  RNA-guided NHEJ in 293cells. 
293T targeting by both gRNAs is efficient (10-24%) and sequence specific (as shown by the shift in position of the 
NHEJ deletion distributions).  
  
105 
 
 
Figure 3_12. HR at the endogenous AAVS1 locus using either a dsDNA donor or a short oligonucleotide donor.  
(A) PCR screen (refer Fig. 2C) confirmed that 21/24 randomly picked 293T clones were successfully targeted. 
(B) Similar PCR screen confirmed 3/7 randomly picked PGP1-iPS clones were also successfully targeted.  
(C) Finally short 90mer oligos could also effect robust targeting at the endogenous AAVS1 locus (shown here for 
K562 cells). 
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0.6% (Figure 3_13). In addition, a statistically significant positive correlation (r
2
 =0.81) was 
found between HR and NHEJ efficiency at the same targeting loci (P<1 X 10
-4
) , suggesting that 
DSB generation, the common upstream step of both HDR and NHEJ, is a rate-limiting step for 
reTALEN-mediated genome editing.  
In contrast, all 15 Cas9-gRNA pairs showed significant levels of NHEJ and HR, with an 
average NHEJ efficiency of 3% and an average HDR efficiency of 1.0% (Figure 3_13 A). In 
addition, a positive correlation was also detected between the NHEJ and HDR efficiency 
introduced by Cas9-gRNA (r
2
=0.52, p=0.003), consistent with what we had observed with our 
reTALENs. The NHEJ efficiency achieved by Cas9-gRNA was significantly higher than that 
achieved by reTALENs (t-test, paired-end, P=0.02). Interestingly, we observed a moderate but 
statistically significant correlation between NHEJ efficiency and the melting temperature of the 
gRNA targeting sequence (Figure 3_13 B) (r
2
=0.28, p=0.04), suggesting that the strength of 
base-pairing between the gRNA and its genomic target could explain as much as 28% of the 
variation in the efficiency of Cas9-gRNA-mediated DSB generation. Even though Cas9-gRNA 
produced NHEJ levels at an average of 7 times higher than the corresponding reTALEN, Cas9-
gRNA only achieved HDR levels (average=1.0%) similar to that of the corresponding 
reTALENs (average = 0.6%), suggesting either that the ssODN concentration at the DSB is the 
limiting factor for HDR or that the genomic break structure created by the Cas9-gRNA is not 
favorable for effective HDR (See discussion). Of note, within our data, we did not observe any 
correlation between DNaseI HS and the genome targeting efficiencies achieved by either 
method.  
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Figure 3_13. Comparison of the reTALEN and CRISPR activity  
(A) The genome editing efficiency of re-TALENs and Cas9-gRNAs targeting CCR5 in PGP1 hiPSCs. 
Top: schematic representation of the targeted genome editing sites in CCR5.  The 15 targeting sites are illustrated by 
blue arrows below. For each site, cells were co-transfected with a pair of re-TALENs and their corresponding 
ssODN donor carrying 2bp mismatches against the genomic DNA. Genome editing efficiencies were assayed 6 days 
after transfection.  Similarly, we transfected 15 Cas9-gRNAs with their corresponding ssODNs individually into 
PGP1-hiPSCs to target the same 15 sites and analyzed the efficiency 6 days after transfection. Bottom: the genome 
editing efficiency of re-TALENs and Cas9-gRNAs targeting CCR5 in PGP1 hiPSCs. Panel 1 and 2 indicate NHEJ 
and HDR efficiencies mediated by reTALENs. Panel 3 and 4 indicate NHEJ and HDR efficiencies mediated by 
Cas9-gRNAs. NHEJ rates were calculated by the frequency of genomic alleles carrying deletions or insertions at the 
targeting region; HDR rates were calculated by the frequency of genomic alleles carrying 2bp mismatches. Panel 5, 
the DNaseI HS profile of a hiPSC cell line from ENCODE database (Duke DNase HS, iPS NIHi7 DS). Of note, the 
scales of different panels are different.  
(B) The correlation of NHEJ efficiencies mediated by Cas9-gRNA and the Tm temperature of gRNA targeting site 
in iPSCs (r=0.52, P=0.04) 
 
B 
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Computational design of gRNA array targeting the whole exome of human genome 
Our versatile RNA-guided genome-editing system can be readily adapted to modify other 
genomic sites by simply modifying the sequence of our gRNA expression vector to match a 
compatible sequence in the locus of interest. To facilitate this process, we bioinformatically 
generated ~190,000 specific gRNA-targetable sequences targeting ~40.5% exons of genes in the 
human genome. We also incorporated these target sequences into a 200-bp format compatible 
with multiplex synthesis on DNA arrays (18) (Figure 3_14). This resource provides a ready 
genome-wide reference of potential target sites in the human genome and amethodology 
formultiplex gRNA synthesis. 
 
Investigate the specificity of Cas9-gRNA and reTALEN 
The ability to both edit and regulate genes using the above RNA-guided system opens the 
door to versatile multiplex genetic and epigenetic engineering of human cells. However, an 
increasingly recognized constraint on Cas9-mediated engineering is the apparently limited 
specificity of Cas9-gRNA targeting (19).  Resolution of this issue will require in-depth 
interrogation of Cas9 affinity for a very large space of target sequence variations. We adapted 
our RNA-guided transcriptional activation system (hCRISPR-TF) we published recently to serve 
this purpose. This system provides a direct high-throughput readout of Cas9 targeting in human 
cells, avoids complications introduced by dsDNA cut toxicity and mutagenic repair incurred by 
specificity testing with native nuclease-active Cas9, and additionally can be adapted to any 
programmable DNA binding system. To illustrate this latter point, we also applied this system to 
evaluate TALE specificity. The methodology of our approach is outlined in Figure 3_15. Briefly,  
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Figure 3_14. Methodology for multiplex synthesis, retrieval and U6 expression vector cloning of guide RNAs 
targeting genes in the human genome.  
We established a resource of ~190k bioinformatically computed unique gRNA sites targeting ~40.5% of all exons of 
genes in the human genome (list in Supplementary Table 1). Furthermore, we incorporated these into a 200bp 
format (list in Supplementary Table 2) that is compatible for multiplex synthesis on DNA arrays. Specifically, our 
design allows for (i) targeted retrieval of a specific or pools of gRNA targets from the DNA array oligonucleotide 
pool (through 3 sequential rounds of nested PCR as indicated in the figure schematic); and (ii) its rapid cloning into 
a common expression vector which upon linearization using an AflII site serves as a recipient for Gibson assembly 
mediated incorporation of the gRNA insert fragment. 
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Figure 3_15. Continued) Figure 3_15. Evaluating the landscape of targeting by Cas9-gRNA complexes and TALEs.  
(A)        The methodology of our approach is outlined:  
(B) Construct libraries are generated with a biased distribution of binding site sequences and random sequence 
24bp tags that will be incorporated into reporter gene transcripts (top).  The transcribed tags are highly degenerate so 
that they should map many-to-one to Cas9 or TALE binding sequences.  The construct libraries are sequenced (3
rd
 
level, left) to establish which tags co-occur with binding sites, resulting in an association table of binding sites vs. 
transcribed tags (4
th
 level, left).  Multiple construct libraries built for different binding sites may be sequenced at 
once using library barcodes (indicated here by the light blue and light yellow colors; levels 1-4, left). A construct 
library is then transfected into a cell population and a set of different Cas9/gRNA or TALE transcription factors are 
induced in samples of the populations (2
nd
 level, right).  One sample is always induced with a fixed TALE activator 
targeted to a fixed binding site sequence  within the construct (top level, green box); this sample serves as a positive 
control (green sample, also indicated by a + sign). cDNAs generated from the reporter mRNA molecules in the 
induced samples are then sequenced and analyzed to obtain tag counts for each tag in a sample (3
rd
 and 4
th
 level, 
right). As with the construct library sequencing, multiple samples, including the positive control, are sequenced and 
analyzed together by appending sample barcodes.  Here the light red color indicates one non-control sample that has 
been sequenced and analyzed with the positive control (green).  Because only the transcribed tags and not the 
construct binding sites appear in each read, the binding site vs. tag association table obtained from construct library 
sequencing is then used to tally up total counts of tags expressed from each binding site in each sample (5
th
 level). 
The tallies for each non-positive control sample are then converted to normalized expression levels for each binding 
site by dividing them by the tallies obtained in the positive control sample.  
(C) The targeting landscape of a Cas9-gRNA complex reveals that it is on average tolerant to 1-3 mutations in 
its target sequences.  
(D) The Cas9-gRNA complex is also largely insensitive to point mutations, except those localized to the PAM 
sequence. Notably this data reveals that the predicted PAM for the S. pyogenes Cas9 is not just NGG but also NAG.  
(E) Introduction of 2 base mismatches significantly impairs the Cas9-gRNA complex activity, however only 
when these are localized to the 8-10 bases nearer the 3’ end of the gRNA target sequence (in the heat plot the target 
sequence positions are labeled from 1-23 starting from the 5’ end).  
(F) Similarly examining the TALE off-targeting data for an 18-mer TALE reveals that it can tolerate on 
average 1-2 mutations in its target sequence, and fails to activate a large majority of 3 base mismatch variants in its 
targets. 
(G) The 18-mer TALE is, similar to the Cas9-gRNA complexes, largely insensitive to single base mismatched 
in its target. Introduction of 2 base mismatches significantly impairs the 18-mer TALE activity. Notably we observe 
that TALE activity is more sensitive to mismatches nearer the 5’ end of its target sequence (in the heat plot the target 
sequence positions are labeled from 1-18 starting from the 5’ end). 
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Figure 3_15. (Continued) 
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we design a construct library in which each element of the library comprises a minimal promoter 
driving a dTomato fluorescent protein. Downstream of the transcription start site a 24bp (A/C/G) 
random transcript tag is inserted, while two TF binding sites are placed upstream of the 
promoter: one is a constant DNA sequence shared by all library elements, and the second is a 
variable feature that bears a ‘biased’ library of binding sites which are engineered to span a huge 
collection of sequences that present many combinations of mutations away from the target 
sequence the programmable DNA targeting complex was designed to bind. We achieved this 
using degenerate oligonucleotides engineered to bear nucleotide frequencies at each position 
such that the target sequence nucleotide appears at a 79% frequency and each other nucleotide 
occurs at 7% frequency. The reporter library is then sequenced to reveal the associations between 
the 24bp dTomato transcript tags and their corresponding ‘biased’ target site in the library 
element. The huge diversity of the transcript tags assures that sharing of tags between different 
targets will be extremely rare, while the biased construction of the target sequences means that 
sites with few mutations will be associated with more tags than sites with more mutations. Next 
we stimulate transcription of the dTomato reporter genes with either a control-TF engineered to 
bind the shared DNA site, or the target-TF that was engineered to bind the target site. As assayed 
by dTomato fluorescence, protein expression was observed to peak by ~ 48 hours and thus to 
prevent over-stimulation of the library total RNA was harvested within 24 hours. We then 
measure the abundance of each expressed transcript tag in each sample by conducting RNAseq 
on the stimulated cells, and then map these back to their corresponding binding sites using the 
association table established earlier. Note that one would expect the control-TF to excite all 
library members equally since its binding site is shared across all library elements, while the 
target-TF will skew the distribution of the expressed members to those that are preferentially 
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targeted by it. This assumption is used in step 5 to compute a normalized expression level for 
each binding site by dividing the tag counts obtained for the target-TF by those obtained for the 
control-TF. 
We used the above approach to analyze the targeting landscape of multiple Cas9-gRNA 
complexes. These complexes on average tolerate 1-3 mutations in their target sequences (Figure 
3_15 B). They are also largely insensitive to point mutations, except those localized to the PAM 
sequence (Figure 3_15 C). Introduction of 2 base mismatches significantly impairs activity, but 
only when these are localized to the 8-10 bases nearer the 3’ end of the gRNA target sequence 
(Figure 3_15 D). These results are further reaffirmed by specificity data generated using two 
different Cas9-gRNA complexes (Figure 3_16). Notably we found that different gRNAs can 
have vastly different specificity profiles (Figure 3_16 A, B), specifically, gRNA2 here tolerates 
up to 3 mismatches and gRNA3 only up to 1. We next ran an array of experiments to validate 
these results. We also confirmed via targeted experiments that single-base mismatches within 
12bp of the 3’ end of the spacer in the assayed gRNAs indeed still result in detectable targeting, 
however 2bp mismatches in this region result in rapid loss of activity (Figure 3_17). An 
interesting aspect of the single-base mismatch data from both these experiments was that the 
predicted PAM for the S. pyogenes Cas9 is not just NGG but also NAG
20
. We confirmed this 
result with targeted experiments using the wild-type Cas9 in a nuclease assay (Figure 3_18). 
Taken together, our data demonstrate that the Cas9- 
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Figure 3_16.  Evaluating the landscape of targeting by Cas9-gRNA complexes.  
Using the approach described in Figure 3_15 we analyzed the targeting landscape of two additional Cas9-gRNA 
complexes (A-C) and (D-F). Notably we find that these two gRNAs have vastly different specificity profiles with 
gRNA2 tolerating up to 2-3 mismatches and gRNA3 only up to 1. These aspects are reflected in both the one base 
mismatch (B,E) and two base mismatch plots (C,F). To improve display, data outliers highlighted by ‘x’ symbols 
were not displayed in (C,F). 
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Figure 3_17 Validations, single and double-base gRNA mismatches. Using a nuclease assay we tested 2 
independent gRNAs: gRNA2 (A,B) and gRNA3 (C,D) bearing single or double-base mismatches (highlighted in 
red) in the spacer sequence versus the target. These experiments confirmed that single-base mismatches within 12bp 
of the 3’ end of the spacer in the assayed gRNAs indeed still result in detectable targeting, however 2bp mismatches 
in this regions result in rapid loss of activity. These results further highlight the differences in specificity profiles 
between different gRNAs consistent with the results in Figure 3_16 
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gRNA system can tolerate multiple mismatches in its target sequence. Consequently, achieving 
high targeting specificity with current experimental formats will likely require  
judicious and potentially complicated bioinformatic choice of gRNAs. Indeed, when we 
rescanned a previously generated set of ~190K Cas9 targets in human exons that had no alternate 
NGG targets sharing the last 13nt of the targeting sequence for the absence of alternate NGG and 
NAG sites at least one mismatch away, only .04% were specific at this level. 
We next applied our transcriptional specificity assay to examine the mutational tolerance 
of another widely used genome editing tool, TALE domains. Examining the TALE off-targeting 
data (Figure 3_15) reveals that 18-mer TALEs tolerate 1-2 mutations in their target sequences, 
but fail to activate a large majority of 3 base mismatch variants in their targets. They are also 
particularly sensitive to mismatches nearer the 5’ end of their target sequences. Intriguingly 
certain mutations in the middle of the target lead to higher TALE activity, an aspect that needs 
further evaluation. We also observed that shorter TALEs (14-mer and 10-mer) are progressively 
more specific in their targeting but also reduced in activity by nearly an order of magnitude 
(Figure 3_18). Taken together, these data imply that engineering shorter TALEs or TALEs 
bearing a judicious composition of high and low affinity monomers can potentially yield higher 
specificity in genome engineering applications, while the requirement for FokI dimerization in 
nuclease applications is essential to avoid off-target effects for the shorter TALEs (20–22).  
Unlike TALEs where direct control of the TALE size or monomer composition is a ready 
approach to modulating specificity, there are limited current avenues for  
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Figure 3_18. Validations, TALE mutations. 
Using a nuclease mediated HR assay (A,B) we confirmed that 18-mer TALEs indeed tolerate multiple mutations in 
their target sequences.  
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engineering the Cas9-gRNA complex towards lower binding affinity (and hence higher 
specificity) for their targets (23, 24). We therefore focused on exploiting cooperativity 
requirements to improve specificity. In the context of genome-editing, we chose to focus on 
creating off-set nicks. Our motivation stems from the observation that a large majority of nicks 
seldom result in NHEJ events (25), thus minimizing the effects of off-target nicking. Towards 
this we found that inducing off-set nicks to generate DSBs is highly effective at inducing gene 
disruption at both integrated reporter constructs and at native genomic loci (Figure 3_19). 
Interestingly we noted that consistent with the standard model for HR mediated repair (26) 
engineering of 5’ overhangs via off-set nicks generated more robust NHEJ events as opposed to 
3’ overhangs (Figure 3_19 B). Intriguingly generation of 3’ overhangs did not result in 
improvement of HR rates (Figure 3_19 C). It remains to be determined if Cas9 biochemistry or 
chromatin state and nucleotide composition of the genomic loci also contributed to the observed 
asymmetry in targeting rates at the two loci tested above. Taken together, we conclude that use 
of nicks for HR and off-set nicks for generating DSBs offers a promising route for mitigating the 
effects of off-target Cas9-gRNA activity. 
 
Discussion 
Our results demonstrate the promise of CRISPR-mediated gene targeting for RNA- 
guided, robust, and multiplexable mammalian genome engineering. The ease of retargeting our 
system to modify genomic sequences greatly exceeds that of comparable ZFNs and TALENs, 
while offering similar or greater efficiencies (27). Existing studies of type II CRISPR specificity 
efficiencies (27) suggest that target sites must perfectly match  
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Figure 3_19. off-set nicking 
(A) We employed the traffic light reporter to simultaneously assay for HR and NHEJ events upon introduction of 
targeted nicks or breaks: DNA cleavage events resolved through the HDR pathway restore the GFP sequence, 
whereas mutagenic NHEJ causes frame-shifts rendering the GFP out of frame and the downstream mCherry 
sequence in frame. For the assay, we designed 14 gRNAs covering a 200bp stretch of DNA: 7 targeting the sense 
strand (U1-7) and 7 the antisense strand (D1-7). Using the Cas9D10A mutant, which nicks the complementary 
strand, we used different two-way combinations of the gRNAs to induce a range of programmed 5’ or 3’ overhangs 
(the nicking sites for the 14 gRNAs are indicated).  
(B) Inducing off-set nicks to generate DSBs is highly effective at inducing gene disruption. Notably off-set nicks 
leading to 5’ overhangs result in more NHEJ events as opposed to 3’ overhangs.  
(C) Similarly, generating 3’ overhangs also favors the ratio of HR over NHEJ events, but the total number of HR 
events is significantly lower than when a 5’ overhang is generated.  In (b,c) the predicted overhang lengths are 
indicated below the corresponding x-axis legends. 
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the PAM sequence NGG and the 8- to 12-base “seed sequence” at the 3′ end of the 
gRNA. The importance of the remaining 8 to 12 bases is less well understood and may depend 
on the binding strength of the matching gRNAs or on the inherent tolerance of Cas9 itself. 
Indeed, Cas9 will tolerate single mismatches at the 5′ end in bacteria and in vitro, which suggests 
that the 5′ G is not required. Moreover, it is likely that the target locus’s underlying chromatin 
structure and epigenetic state will also affect the efficiency of genome editing in eukaryotic cells 
(16), although we suspect that Cas9’s helicase activity may render it more robust to these factors, 
but this remains to be evaluated. In addition, the range of CRISPR-targetable sequences could be 
expanded through the use of homologs with different PAM requirements (28) or by directed 
evolution. Finally, inactivating one of the Cas9 nuclease domains increases the ratio of HR to 
NHEJ and may reduce toxicity (29, 30), whereas inactivating both domains may enableCas9 to 
function as a retargetable DNA binding protein. 
To illustrate and improve the specific of genome targeting tools is uppermost important 
for its application in biomedical research and gene therapy. Here, we observed that the Ca9-
gRNA system can result in significant off-targeting events. Interestingly we note that there are 
huge differences in specificity between evaluated gRNAs. Based on this we speculate that likely 
the Cas9 protein contributes primarily to PAM recognition, but gRNA-DNA binding (and 
associated thermodynamic parameters) are a prominent determinant of specificity. Thus 
judicious choice of gRNAs will be a productive route to improved target specificity, albeit rules 
governing their design such as Tm, nucleotide composition, secondary structure of gRNA spacer 
versus scaffold, and role of underlying chromatin structure of the target loci remain to be 
determined. Controlling the dose and duration of Cas9 and gRNA expression will also be critical 
for engineering high specificity, and thus RNA based delivery will be an attractive genome 
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editing route (31, 32). While structure-guided design and directed evolution may eventually 
improve the specificity of individual Cas9 proteins, we have also shown here that engineering a 
requirement for cooperativity via off-set nicking to generate DSBs can potentially ameliorate off-
target activity, and may be an important avenue for exploring therapeutic applications. The 
improved ease and efficacy of editing and regulating genomes using this RNA-guided genome 
engineering approach will have broad implications for our ability to tune and program complex 
biological systems. 
With enhanced activity and specificity, we expect that RNA- guided genome targeting 
will have broad implications for synthetic biology (13, 33), the direct and multiplexed 
perturbation of gene networks (16, 34), and targeted ex vivo (35, 36) and in vivo gene therapy 
(37). 
 
Materials and Methods 
Plasmid construction 
The Cas9 gene sequence was human codon optimized and assembled by hierarchical 
fusion PCR assembly of 9 500bp gBlocks ordered from IDT (sequence in fig. S1A). Cas9_D10A 
was similarly constructed. The resulting full-length products were cloned into the pcDNA3.3-
TOPO vector (Invitrogen). The target gRNA expression constructs were directly ordered as 
individual 455bp gBlocks from IDT and either cloned into the pCR-BluntII-TOPO vector 
(Invitrogen) or pcr amplified. The vectors for the HR reporter assay involving a broken GFP 
were constructed by fusion PCR assembly of the GFP sequence bearing the stop codon and 68bp 
AAVS1 fragment, or 58bp fragments from the DNMT3a and DNMT3b genomic loci assembled 
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into the EGIP lentivector from Addgene (plasmid #26777). These lentivectors were then used to 
establish the GFP reporter stable lines. TALENs used in this study were constructed using the 
protocols described in (14). All DNA reagents developed in this study are available at Addgene. 
Cell culture 
PGP1 iPS cells were maintained on Matrigel (BD Biosciences)-coated plates in mTeSR1 
(Stemcell Technologies). Cultures were passaged every 5–7 d with TrypLE Express (Invitrogen). 
K562 cells were grown and maintained in RPMI (Invitrogen) containing 15% FBS. HEK 293T 
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) high glucose 
supplemented with 10% fetal bovine serum (FBS, Invitrogen), penicillin/streptomycin (pen/strep, 
Invitrogen), and non-essential amino acids (NEAA, Invitrogen). All cells were maintained at 
37°C and 5% CO2 in a humidified incubator.  
 
Gene targeting of PGP1 iPS, K562 and 293Ts 
PGP1 iPS cells were cultured in Rho kinase (ROCK) inhibitor (Calbiochem) 2h before 
nucleofection.  Cells were harvest using TrypLE Express (Invitrogen) and 2×10
6
 cells were 
resuspended in P3 reagent (Lonza) with 1μg Cas9 plasmid, 1μg gRNA and/or 1μg DNA donor 
plasmid, and nucleofected according to manufacturer’s instruction (Lonza). Cells were 
subsequently plated on an mTeSR1-coated plate in mTeSR1 medium supplemented with ROCK 
inhibitor for the first 24h. For K562s, 2×10
6
 cells were resuspended in SF reagent (Lonza) with 
1μg Cas9 plasmid, 1μg gRNA and/or 1μg DNA donor plasmid, and nucleofected according to 
manufacturer’s instruction (Lonza). For 293Ts, 0.1×106 cells were transfected with 1μg Cas9 
plasmid, 1μg gRNA and/or 1μg DNA donor plasmid using Lipofectamine 2000 as per the 
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manufacturer’s protocols. The DNA donors used for endogenous AAVS1 targeting were either a 
dsDNA donor (Figure 3_2) or a 90mer oligonucleotide. The former has flanking short homology 
arms and a SA-2A-puromycin-CaGGS-eGFP cassette to enrich for successfully targeted cells.  
 
Assess the targeting efficiency  
Cells were harvested 3 days after nucleofection and the genomic DNA of ~1 X 10
6
 cells 
was extracted using prepGEM (ZyGEM). PCR was conducted to amplify the targeting region 
with genomic DNA derived from the
 
cells and amplicons were deep sequenced by MiSeq 
Personal Sequencer (Illumina) with coverage >200,000 reads. The sequencing data was analyzed 
to estimate NHEJ efficiencies. The reference AAVS1 sequence analyzed is: 
CACTTCAGGACAGCATGTTTGCTGCCTCCAGGGATCCTGTGTCCCCGAGCTGGGACCACCTTATATTCCCAGGGCCG
GTTAATGTGGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCCACTAGGGACAGGATTGGT
GACAGAAAAGCCCCATCCTTAGGCCTCCTCCTTCCTAGTCTCCTGATATTGGGTCTAACCCCCACCTCCTGTTAGGC
AGATTCCTTATCTGGTGACACACCCCCATTTCCTGGA 
The PCR primers for amplifying the targeting regions in the human genome are: 
AAVS1-R CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTacaggaggtgggggttagac 
AAVS1-F.1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATtatattcccagggccggtta 
AAVS1-F.2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACATCGtatattcccagggccggtta 
AAVS1-F.3 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCCTAAtatattcccagggccggtta 
AAVS1-F.4 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGGTCAtatattcccagggccggtta 
AAVS1-F.5 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACTGTtatattcccagggccggtta 
AAVS1-F.6 ACACTCTTTCCCTACACGACGCTCTTCCGATCTATTGGCtatattcccagggccggtta 
AAVS1-F.7 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGATCTGtatattcccagggccggtta 
AAVS1-F.8 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCAAGTtatattcccagggccggtta 
AAVS1-F.9 ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTGATCtatattcccagggccggtta 
124 
 
AAVS1-F.10 ACACTCTTTCCCTACACGACGCTCTTCCGATCTAAGCTAtatattcccagggccggtta 
AAVS1-F.11 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTAGCCtatattcccagggccggtta 
AAVS1-F.12 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTACAAGtatattcccagggccggtta 
To analyze the HR events using the DNA donor in Fig. 2C the primers used were: 
HR_AAVS1-F CTGCCGTCTCTCTCCTGAGT 
HR_Puro-R GTGGGCTTGTACTCGGTCAT 
 
Bioinformatics approach for computing human exon CRISPR targets and methodology for their 
multiplexed synthesis 
We sought to generate a set of gRNA gene sequences that maximally target specific 
locations in human exons but minimally target other locations in the genome. Maximally 
efficient targeting by a gRNA is achieved by 23nt sequences, the 5’-most 20nt of which exactly 
complement a desired location, while the three 3’-most bases must be of the form NGG.  
Additionally, the 5’-most nt must be a G to establish a pol-III transcription start site. However, 
according to (38), mispairing of the six 5’-most nt of a 20bp gRNA against its genomic target 
does not abrogate Cas9-mediated cleavage so long as the last 14nt pairs properly, but mispairing 
of the eight 5’-most nt along with pairing of the last 12 nt does, while the case of the seven 5-
most nt mispairs and 13 3’ pairs was not tested.  To be conservative regarding off-target effects, 
we therefore assumed that the case of the seven 5’-most mispairs is, like the case of six, 
permissive of cleavage, so that pairing of the 3’-most 13nt is sufficient for cleavage. To identify 
CRISPR target sites within human exons that should be cleavable without off-target cuts, we 
therefore examined all 23bp sequences of the form 5’-GBBBB BBBBB BBBBB BBBBB NGG-
3’ (form 1), where the B’s represent the bases at the exon location, for which no sequence of the 
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form 5’-NNNNN NNBBB BBBBB BBBBB NGG-3’ (form 2) existed at any other location in the 
human genome.  Specifically, we (i) downloaded a BED file of locations of coding regions of all 
RefSeq genes the GRCh37/hg19 human genome from the UCSC Genome Browser (39–41).  
Coding exon locations in this BED file comprised a set of 346089 mappings of RefSeq mRNA 
accessions to the hg19 genome.  However, some RefSeq mRNA accessions mapped to multiple 
genomic locations (probable gene duplications), and many accessions mapped to subsets of the 
same set of exon locations (multiple isoforms of the same genes).  To distinguish apparently 
duplicated gene instances and consolidate multiple references to the same genomic exon instance 
by multiple RefSeq isoform accessions, we therefore  (ii) added unique numerical suffixes to 705 
RefSeq accession numbers that had multiple genomic locations, and (iii) used the mergeBed 
function of BEDTools (42) (v2.16.2-zip-87e3926) to consolidate overlapping exon locations into 
merged exon regions.  These steps reduced the initial set of 346089 RefSeq exon locations to 
192783 distinct genomic regions. We then downloaded the hg19 sequence for all merged exon 
regions using the UCSC Table Browser, adding 20bp of padding on each end. (iv) Using custom 
perl code, we identified 1657793 instances of form 1 within this exonic sequence. (v) We then 
filtered these sequences for the existence of off-target occurrences of form 2: For each merged 
exon form 1 target, we extracted the 3’-most 13bp specific (B) “core” sequences and, for each 
core generated the four 16bp sequences 5’-BBB BBBBB BBBBB NGG-3’  (N = A, C, G, and 
T), and searched the entire hg19 genome for exact matches to these 6631172 sequences using 
Bowtie version 0.12.8 (43) using the parameters -l 16 -v 0 -k 2. We rejected any exon target site 
for which there was more than a single match. Note that because any specific 13bp core 
sequence followed by the sequence NGG confers only 15bp of specificity, there should be on 
average ~5.6 matches to an extended core sequence in a random ~3Gb sequence (both strands). 
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Therefore, most of the 1657793 initially identified targets were rejected; however 189864 
sequences passed this filter. These comprise our set of CRISPR-targetable exonic locations in the 
human genome. The 189864 sequences target locations in 78028 merged exonic regions (~40.5% 
of the total of 192783 merged human exon regions) at a multiplicity of ~2.4 sites per targeted 
exonic region.  To assess targeting at a gene level, we clustered RefSeq mRNA mappings so that 
any two RefSeq accessions (including the gene duplicates we distinguished in (ii)) that overlap a 
merged exon region are counted as a single gene cluster, the 189864 exonic specific CRISPR 
sites target 17104 out of 18872 gene clusters (~90.6% of all gene clusters) at a multiplicity of 
~11.1 per targeted gene cluster.  (Note that while these gene clusters collapse RefSeq mRNA 
accessions that represent multiple isoforms of a single transcribed gene into a single entity, they 
will also collapse overlapping distinct genes as well as genes with antisense transcripts.)  At the 
level of original RefSeq accessions, the 189864 sequences targeted exonic regions in 30563 out 
of a total of 43726 (~69.9%) mapped RefSeq accessions (including our distinguished gene 
duplicates) at a multiplicity of ~6.2 sites per targeted mapped RefSeq accession. 
As we gather information on CRISPR performance at our computationally predicted 
human exon CRISPR target sites, we plan to refine our database by correlating performance with 
factors we expect to be important, such as base composition and secondary structure of both 
gRNAs and genomic targets (44), and the epigenetic state of these targets in human cell lines for 
which this information is available.       
Finally, we also incorporated these target sequences into a 200bp format that is 
compatible for multiplex synthesis on DNA arrays. Our design allows for targeted retrieval of a 
specific or pools of gRNA sequences from the DNA array based oligonucleotide pool and its 
rapid cloning into a common expression vector. Specifically we tested this approach by 
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synthesizing a 12k oligonucleotide pool from CustomArray Inc. Furthermore, as per our 
approach we were able to successfully retrieve gRNAs of choice from this library (Figure 3_14). 
We observed an error rate of ~4 mutations per 1000bp of synthesized DNA. 
 
Cell culture and transfections 
HEK 293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen) high glucose supplemented with 10% fetal bovine serum (FBS, Invitrogen), 
penicillin/streptomycin (pen/strep, Invitrogen), and non-essential amino acids (NEAA, 
Invitrogen). Cells were maintained at 37°C and 5% CO2 in a humidified incubator.  
Transfections involving nuclease assays were as follows: 0.4×10
6 
cells were transfected 
with 2μg Cas9 plasmid, 2μg gRNA and/or 2μg DNA donor plasmid using Lipofectamine 2000 as 
per the manufacturer’s protocols. Cells were harvested 3 days after transfection and either 
analyzed by FACS, or for direct assay of genomic cuts the genomic DNA of ~1 X 10
6
 cells was 
extracted using DNAeasy kit (Qiagen). For these PCR was conducted to amplify the targeting 
region with genomic DNA derived from the
 
cells and amplicons were deep sequenced by MiSeq 
Personal Sequencer (Illumina) with coverage >200,000 reads. The sequencing data was analyzed 
to estimate NHEJ efficiencies.  
For transfections involving transcriptional activation assays: 0.4×10
6 
cells were 
transfected with (1) 2μg Cas9N-VP64 plasmid, 2μg gRNA and/or 0.25μg of reporter construct; or 
(2) 2μg Cas9N- plasmid, 2μg MS2-VP64, 2μg gRNA-2XMS2aptamer and/or 0.25μg of reporter 
construct. Cells were harvested 24-48hrs post transfection and assayed using FACS or 
immunofluorescence methods, or their total RNA was extracted and these were subsequently 
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analyzed by RT-PCR. Here standard taqman probes from Invitrogen for REX1, OCT4, SOX2 
and NANOG were used, with normalization for each sample performed against GAPDH. 
For transfections involving transcriptional activation assays for specificity profile of 
Cas9-gRNA complexes and TALEs: 0.4×10
6 cells were transfected with (1) 2μg Cas9N-VP64 
plasmid, 2μg gRNA and 0.25μg of reporter library; or (2) 2μg TALE-TF plasmid and 0.25μg of 
reporter library; or (3) 2μg control-TF plasmid and 0.25μg of reporter library. Cells were 
harvested 24hrs post transfection (to avoid the stimulation of reporters being in saturation mode). 
Total RNA extraction was performed using RNAeasy-plus kit (Qiagen), and standard RT-pcr 
performed using Superscript-III (Invitrogen). Libraries for next-generation sequencing were 
generated by targeted pcr amplification of the transcript-tags. 
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Summary 
Tools for efficient and precise genome editing facilitate functional studies and advance gene 
therapies. Current nucleases-based methods that employ homologous recombination at sites of 
targeted double-strand breaks (DSBs) are limited by competing DNA repair pathways (1) and 
cytotoxicity (2).   Here we present targeted cytidine deaminases, consisting of DNA deaminases 
(3) fused with programmable DNA-binding modules (4, 5), that perform sequence-specific 
genome editing without generating DSBs and the need to simultaneously provide replacement 
(i.e., donor) DNA. Targeted deaminases are both efficient and specific in Escherichia coli, 
converting a targeted cytidine to thymidine with 13% efficiency and 95% accuracy. Edited cells 
do not exhibit random hypermutation or aberrant genomic structural changes. These novel 
enzymes also function in human cells, causing a site-specific C:G->T:A transition in 2.5% of 
cells, with significantly less toxicity than nucleases. Targeted deaminases therefore represent a 
platform for safer and effective genome editing in prokaryotes and eukaryotes. The 
independence from DSBs and donor DNA suggests applications of this tool in multiplexed 
editing (including repetitive elements) and inducible genome editing in whole animals. 
Introduction 
Genome editing in mammalian cells has been greatly facilitated by the development of 
customized zinc finger (ZF)- and transcription activator-like effectors (TALEs)- (4) nucleases 
(ZFNs) (5, 6) and TALENs (7, 8) that create DSBs at specifically targeted sites in the genome.  
When exogenous donor DNA has been provided with arms homologous to the targeted sites, 
cells repair the DSB at high rates and with high precision through homologous recombination 
(HR) with the donor DNA. However, the use of targeted DSBs also imposes limitations; first, 
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during DSB repair, HR competes with non-homologous end joining (NHEJ) which does not 
require donor DNA and often introduces mutations at the repair site. In the absence of In the 
absence of nuclease-based methods, NHEJ occurs 30-fold to 40,000-fold more frequently than 
HR in human cells, so that effective use of targeted nucleases requires coordinating their 
expression with high levels of donor DNA (1). Second, DSBs are toxic to the cell and can 
introduce genome instability, placing further constraints on targeted nuclease expression.  These 
conditions make it unlikely that that targeted nucleases can be used safely and effectively to 
make highly multiplexed changes to a genome, or to perform efficient gene targeting within 
multi-cellular organisms where delivery of donor DNA into cells at high copy numbers would be 
challenging.  However, an accurate genome editing method that did not create DSBs or require 
donor DNA should escape these limitations. 
Single-nucleotide genome editing independent of DSBs and DNA donor occurs naturally. 
Activation induced deaminase (AID) and apolipoprotein B mRNA editing enzyme catalytic 
polypeptide-like family proteins (APOBECs) (3) are cytidine deaminases expressed in 
vertebrates that act in the antibody diversification process or in the innate immune system as an 
agent that targets retroviruses (3). These enzymes can convert cytidines to uracils in DNA. If 
DNA replication occurs before uracil repair, the replication machinery will treat the uracil as 
thymine, leading to a C:G to T:A base pair conversion (9). This elegant editing mechanism 
suggests a potentially simple and effective genome editing approach that circumvents the 
limitations associated with nucleases. Here, we sought to test whether combining deaminases 
with DNA-binding proteins could target cytidine deamination to specific positions in the genome 
and thus enable targeted genome C:GT:A editing.  
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Results 
Design and functional test of targeted deaminase 
As a first step, we engineered targeted deaminases by fusing the deaminases (APOBEC1, 
APOBEC3F, APOBEC3G (2K3A) (10) and AID) with a ZF recognizing the 9bp DNA sequence 
5’-GCCGCAGTG-3’ (11) (Figure 4_1 A). Based on the available structures of the deaminases 
(12), we inferred that the enzymes’ domains reside at the C-terminus. We therefore tethered the 
ZF DNA-binding domains by a four amino-acid linker to the N-terminus of the deaminases to 
generate ZF-APOBEC1, 3F, 3G and ZF-AID (Figure 4_1 C). To determine whether these fusion 
enzymes can convert a single genomic cytidine to thymidine in vivo, we integrated a single-copy 
GFP reporter into the E. coli bacterial genome by recombineering (13) (Figure 4_1 B) in which 
an impaired start codon (ACG) was designed upstream of the ZF binding sequence and the GFP 
coding sequence. Correction of the genomic ACG to ATG by targeted deamination should result 
in translatable GFP transcripts and GFP-positive cells, allowing successful targeted deaminase 
activity to be measured by flow cytometry.   
Among the four chimeric deaminases we tested, one (ZF-AID) led to robust GFP 
expression in the reporter population; 10 hours after ZF-AID induction 0.1% of the cell were 
GFP+ (Figure 4_1 C).  This frequency was more than fifteen-fold higher than when ZF or AID 
was expressed alone (t-test, two-tailed, P(ZF-AID, ZF) =0.0015, P(ZF-AID, AID) =0.0016; n=4) (Figure 
4_1 C). We confirmed with sequencing that the broken start codon ACG was permanently 
changed to ATG in the gfp gene of 20/20 randomly chosen GFP+ colonies. We conclude that 
AID can effectively introduce CT mutations at a sequence specified by a fused DNA-binding 
module, and so we used AID as the deaminase module in all subsequent experiments.   
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Figure 4_1 Design and targeted deaminase activity of chimeric deaminases in E.coli.  
(A)  Schematic representation of the design of targeted deaminases. The DNA binding domain (DBD), either ZF or 
TALE, was fused to N-terminus of the deaminase with a certain linker.  
(B)  Experimental overview: we integrated a GFP cassette (top) consisting of a broken start codon ACG, DNA 
binding sequence, and the GFP coding sequence into the bacterial genome. We subsequently transformed targeted 
deaminases (middle) in pTrc-kan plasmid (Supplementary Method1) into the strain and induced protein expression. 
Targeted deamination of the C in the broken start codon leads to a ACGATG transition (bottom), rescuing GFP 
translation which is quantifiable via flow cytometry.  
(C)  ZF-deaminases were tested for targeted deaminase activity by measuring GFP rescue. ZF, ZF-APOBECs (ZF-
APOBEC1, ZF-APOBEC3F, ZF-APOBEC3G) or ZF-AID indicate cells transformed with plasmids that express ZF, 
ZF-APOBECs or ZF-AID respectively. All error bars indicate s.d. (All t-tests compare ZF-deaminases against the 
ZF control. Pvalue < 0.05 *, Pvalue < 0.01 **, Pvalue < 0.001 ***, n=4).  
(D)  GFP rescue by ZF-AID and TALE-AID in the ZF-reporter and TALE-reporter strains.(All t-tests compare the 
fusion deaminases against the AID control. Pvalue < 0.05 *, Pvalue < 0.01 **, Pvalue < 0.001 ***, n=4).   
A 
B
  A 
C 
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Figure 4_2 Test of targeted deaminase frequency on the reporter with two ZF binding sites.  
(A) Schematic representation of the modified GFP reporters with two ZF binding sites. In the monomer reporter, a 
ZF binding site (ZFB) lies 9bp downstream of the start codon (in blue). In the dimer reporter constructs, an 
additional ZFB lies either 9bp (dimer1 and dimer3), 6bp (dimer2), or 14bp (dimer4) upstream of the start codon. 
Arrows indicate promoter, RBS indicate position of ribosome binding site.  
(B) Overlap histogram of GFP expression level from the different reporters. Dimer1, 2 and 3 exhibited significant 
overlaps with the negative control (uninduced monomer ACG reporter), suggesting that the alterations to the length 
or sequence between the RBS and start codon compromised the translation of GFP. In contrast, the dimer4 reporter 
showed distinct GFP fluorescence, so we chose it for the following test.  
(C)Targeted deamination frequency on dimer and monomer reporters. ZF-4aa-AID expression led to similar GFP 
rescue frequency in both the dimer4 ACG and monomer ACG GFP reporter systems. Conversely, AID expression 
alone did not result in any detectable GFP rescue signal, indicating that the ZF-4aa-ZFP monomer was able to 
specifically target the genomic site. Targeted deamination frequency was quantified via percentage of GFP-
expressing cells in the population. 
 
A 
B 
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We then tested whether if we could program the DNA-binding specificity of targeted 
deaminases by changing the DNA-binding modules. To this end, we constructed a TALE-AID 
fusion, using a TALE reported to recognize the 14bp sequence 5’-TCACGATTCTTCCC-3’ (14) 
and built a corresponding reporter strain with the TALE binding site downstream of the GFP 
broken start codon (ACG) (Figure 4_1C).  Induction of TALE- AID for 10 hours led to 
successful GFP expression in 0.02% of the reporter population (Figure 4_1 D), lower than in the 
ZF-AID experiment but still significantly higher than with TALE or AID expression alone (t-test, 
two-tailed, P(TALE-AID, TALE) =0.0069, P(TALE-AID, AID) =0.0186; n=4) (Figure 4_1 D). In addition, 
both TALE-AID and ZF-AID caused minimal GFP expression when their recognition sites were 
absent (Figure 4_1 D). Thus, both ZF and TALE DNA-binding modules can direct deaminase 
activity to a sequence-defined locus in the genome.  Additionally, we tested whether an 
additional binding sequence might enhance targeting frequency by inserting a second binding 
site upstream of the targeted cytidine.  However, we did not observe an increase (Figure 4_2).  
 
Optimization of genome editing efficiency of targeted deaminase in bacteria 
Our initial tests demonstrated the feasibility of using targeted deaminases for genome 
editing, but the editing efficiency was low. We reasoned that native uracil repair pathway might 
prevent targeted cytidine deamination from leading to a C:GT:A transition. Therefore, we 
knocked out mutS and ung, two genes known to be involved in AID-initiated deamination repair. 
GFP rescue frequency by ZF-AID increased to 0.5% (5-fold) in the ΔmutS knockout, and to 
3.5% (35-fold) in the ΔmutS Δung double knockout (Figure 4_3). Similarly, GFP rescue by 
TALE-AID induction was increased to 0.1% (7-fold increase) in the ΔmutS Δung knockout 
(Figure 4_3). We confirmed the GFP fluorescence signal by microscopy (Figure 4_3) and  
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Figure 4_3. Modified genetic banckground spurs the genome editing efficiency 
(A) GFP rescue by ZF-AIDs and TALE-AID in (wild type), (Δung), and (ΔmutS Δung) strains. All error bars 
indicate s.d.. (All t-tests compare the fusion deaminases against the AID control. Pvalue < 0.05 *, Pvalue < 0.01 **, 
Pvalue < 0.001 ***, n=4).   
(B) E.coli (ΔmutS Δung) cells imaged under fluorescence(upper) and phase contrast(lower) after expression of ZF-
AID or AID for 10 hours.  Top, Scale bar: 20m.  
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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 confirmed the C:GT:A transitions by sequencing the gfp gene of 20 randomly chosen GFP+ 
colonies from both the ZF-AID- and TALE-AID-induced population. We conclude that 
suppression of uracil repair led to an increase in the resulting rate of C:GT:A transitions 
caused by targeted deaminase. Hence, all subsequent experiments with E.coli were done in the 
ΔmutS Δung background. 
As genome engineering requires both efficiency and specificity, we then set out to 
increase editing efficiency via structural optimization of the fusion enzymes. First, we compared 
the ZF-AID described above with three alternatives carrying modified linkers previously used in 
zinc finger fusion proteins (15, 16) (an alternative four amino-acid linker, 4aa2, to examine the 
effect of linker sequence, and 8aa and 11aa linkers to examine the importance of linker length). 
(Figure 4_4). While expression of all four ZF-AIDs led to robust GFP rescue, improvements 
were observed with ZF-8-aa-AID achieving 7.5% GFP+ frequency after 10 hours (Figure 4_5), 
and 13% after 30 hours of induction. While linker length is clearly an important design 
consideration, interestingly, rescue efficiencies by ZF-4-aa-AID and ZF-4-aa2-AID were also 
slightly different (t-test, two tailed, p=0.0032, n=4), suggesting that besides linker length (4 
amino acids in both), linker sequence also influences performance of the overall construct.  
The initial test with TALE –AID (hereafter referred to as TALE-C1-AID) did not rescue 
GFP with as a high frequency as the ZF-AIDs.  Given the critical importance of linker length 
observed with our ZF-AID fusion constructs (Figure 4_4), we proceeded to examine whether 
truncation of some or all of the 178aa
 
 region in the C-terminus of the TALE protein could 
enable a higher GFP rescue frequency. To this end, we tested the activity of TALE-AIDs 
carrying various truncated TALE C-termini (referred as TALE-C2-AID, TALE-C3-AID, TALE-
C4-AID, and TALE-C5-AID (Figure 4_6)). Truncations were chosen at loop regions predicted  
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Figure 4_4.  Optimization of ZF-deamination s frequency in E.coli.   
Schematic representation of ZF-AIDs variants tested for targeted deaminase activity (upper) and the reporter (lower) 
with the ZF-recognition sequence in blue. b, GFP rescue by expression of the four ZF-AIDs variants and ZF or AID 
domains alone. All error bars indicate s.d..  
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Figure 4_5. Secondary mutations led to the decline of GFP rescue efficiency  
(A) Targeted deamination frequency peaked following 30 hours of ZF-AID induction and dropped after that. The 
targeted deaminase frequencies were measured by flow cytometry analysis of GFP expression. Bacterial culture was 
diluted 1:100 every 10 h to maintain continuous cell proliferation.   
(B) Targeted deamination frequency as measured by GFP+ cell fraction peaked following 20 hours of TALE-AID 
induction and dropped after that. Bacterial culture was diluted 1:100 every 10hrs to maintain continuous cell 
proliferation.  
(C) Time line depicting the experiment design to capture secondary mutations.  
(D) Sanger DNA sequencing revealed that prolonged ZF-AID induction led to secondary mutations that abolished 
the expression of GFP. 1kb of the gfp gene was sequenced over 20 GFP- colonies; only the mutated part is shown in 
the table.  The original sequence is listed below and the schematic graph of the GFP cassette shows the 
corresponding positions of this sequence.  “*” indicates positions where the sequence is identical with the wild type 
gfp.  Red letters indicate the mutated bases.  
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using protein secondary structure by the software LASERGENE. Changes in TALE C-
terminus length could affect targeted deaminase activity at a particular target locus either by 
affecting intrinsic protein activity or simply by making the protein optimal for a different length 
of DNA between the DNA binding and deamination target sites. To investigate these possibilities, 
we also constructed five bacterial GFP reporter strains, each with a genomic gfp locus carrying a 
broken start codon 2, 5, 8, 11, or 14bps upstream of the TALE binding site (Figure 4_6). 
Targeted deamination frequencies were then measured by GFP rescue frequency and compared 
in a 5-by-5 matrix of TALE-AIDs and reporters (Figure 4_6). TALE-AID truncations showed 
significantly higher GFP rescue over that of TALE-C1-AID (Figure 4_6). Notably, induction of 
TALE-C3-AID achieved a genomic editing frequency of 2.5% on the 8bp-spacer reporter after 
10 hours of induction (Figure 4_6), and peaked at 8% following 20 hours of induction (Figure 
4_5 B). Interestingly, TALE-C3-AID outperformed all other constructs regardless of the spacer 
length of the reporter, suggesting that this chimeric protein has an intrinsically optimal structure 
out of the TALE-AIDs tested. Taking together the optimization results for ZF-AIDs and TALE-
AIDs, we suggest important design considerations for engineering of efficient targeted 
deaminases.  
Test of the specify of targeted deaminase in bacteria 
Having investigated and improved deaminase targeting frequency, we next characterized 
targeting specificity using the following three methods: 1) investigating the effect of point-
mutations in the recognized DNA sequence on editing frequency 2) sequencing the GFP locus in 
many cells after expression of targeted deaminase; and 3) whole-genome sequencing of three 
GFP+ clones. 
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Figure 4_6.  Optimization of TALE-deamination s frequency in E.coli.   
Schematic representation of TALE-AIDs and the reporters tested for targeted deaminase activity. Five TALE-AIDs 
(upper) with different TALE C-terminus truncations (C1 to C5) were constructed, with the remaining C-terminus 
lengths shown in parentheses. Full TALE-AID protein sequences can be found in Supplementary Sequence 2. Five 
reporters were constructed (lower) with different spacer lengths (2bp, 5bp, 8bp, 11bp) between the broken start 
codon and TALE DNA binding motif. The TALE binding site on the GFP reporter is shown in blue; the TALE N-
terminus segment specifies the 5′ thymine base of the binding site.  d. All five TALE-AIDs were tested for targeted 
deaminase activity on all five reporters . Green and grey encode high and low GFP rescue, respectively.  
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We tested DNA sequence specificity of targeted deaminases by measuring GFP rescue 
using reporters with point-mutated ZF/TALE recognition sequences. We first altered three 
individual nucleotides within the nine-nucleotide ZF recognition sequence. Divergence from the 
intended recognition sequence by a nucleotide led to 4-8 fold decrease in ZF–8aa-AID efficiency 
(Figure 4_7 A), indicating that ZFP-8aa-AID is highly specific to the ZF-addressed locus. We 
next investigated the specificity of TALE-AID by individually mutating each nucleotide in the 
TALE recognition site to the second most preferred base for that position (Figure 4_7 B). 
Interestingly, TALE-C3-AID, which was designed to recognize a 14bp sequence, showed strong 
sequence specificity only for the first 8bp proximal to the target site (5’ TTCTTCCC 3’ in the 
TALE recognition site). Thus, both ZF- and TALE-AID demonstrate sequence specificity. 
However, for reasons that remain to be investigated, sequence alterations at more distal positions 
in the TALE binding site led to variable targeting frequency (Figure 4_7 B).  
To detect possible off-target mutations close to the intended deaminase target site, we 
sorted 10,000 GFP+ and 10,000 GFP- cells after 30 hours of ZF-8aa-AID induction, and 
randomly isolated 200 individual colonies from each population. We Sanger sequenced 1kb 
surrounding the gfp deaminase target site and, as a control, the constitutively expressed gapA 
gene, which lies 1.9Mbp away from gfp. In the GFP+ population, all colonies harbored the 
intended CT transition in the gfp start codon. 5.5% of these colonies contained an additional 
CT mutation upstream or within the gfp gene (Figure 4_7 C). In the GFP- population, the only 
mutation detected over 200 colonies was a single GA transition 1bp away from the intended 
target site (ACGACA), present in 2% of the population (Figure 4_7 C). No mutations were 
found in gapA in any colonies from the two populations. AID has been documented to have 
sequence preference, targeting cytidines in its “hotspot” (WRC, W=A/T, R=A/G) more  
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Figure 4_7. Test of the specificity of AID fusions.  
(A) Test of ZF-8aa-AID sequence specificity using a GFP reporter with point-mutated ZF binding sequences. t-
tests compare each mutated site against the unmodified site (top). Pvalue < 0.05 *, Pvalue < 0.01 **, Pvalue < 0.001 
***, n=4. All error bars indicate s.d..  
(B) Test of TALE-C1-AID sequence specificity using a GFP reporter with point-mutated TALE binding sites. 
t-tests compare each mutated site against the unmodified site (top). Pvalue < 0.05 *, Pvalue < 0.01 **, Pvalue < 
0.001 ***, n=4. All error bars indicate s.d.. Note that we altered the first nucleotide, a TALE-N terminus-specified 
thymine, to other three nucleotides individually, while we changed other nucleotides in the TALE recognition 
domain to the nucleotide mostly likely to be recognized5.  
(C)  Mutation location and spectrum in the GFP gene of GFP+ and GFP- cells collected after ZF-8aa-AID 
induction. A schematic structure of the GFP gene is shown above the mutation frequency along the gene’s length 
among 200 Sanger sequenced colonies of each cell population. Gray lines indicate positions of C/G nucleotides; red 
lines indicate occurrences of the AID preferred motif (WRC).  
(D) Mutation spectrum on the GFP gene of GFP+ and GFP- cells collected after TALE-C1-AID induction 
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frequently than other sites (17). It has also been reported that AID exhibits processive 
behavior, tending to deaminate a stretch of cytidines on the same DNA strand (18).   
Interestingly, only 0.7% of non-target WRC sites in the gfp locus were altered in the GFP+ 
population (Figure 4_7 C), and these mutations were not clustered at any single read. This 
suggests that ZF targeting overrides the native sequence preference as well as processive 
behavior of the AID enzyme.  We next repeated our assay using TALE-C3-AID. In the GFP+ 
population, besides the intended CT mutation, an additional CT mutation 4bp upstream of 
the intended site was found in 9/200 colonies (4.5%) (Figure 4_7 D).  No other off-target 
mutations were detected in the GFP coding sequence or in the GFP- cells. Given that no 
mutations were found in the distant gapA sequence and that off-target mutations were enriched 
in the GFP+ versus GFP- cells, we speculate that the observed off-target mutations might be 
caused by residual processivity of AID, the flexibility of the linker and one-dimensional sliding 
of the DNA binding protein along the chromosome (19). Taking ZF- and TALE- deaminase 
together, among cells that were correctly engineered (GFP+), approximately 95% had no off-
target modification in the gfp locus. The only observed off-target modification frequency in 
GFP- cells was 1bp away from the intended site, at a frequency of 2%. These results indicate that 
the deaminase activity was tightly constrained by the ZF and TALE DNA-binding modules in 
the fusion proteins.  
To more completely assess the global off-target activities of the fusion proteins, we 
sequenced with ~50X coverage the genomes of three GFP+ colonies edited by ZF-8aa-AID, and 
three colonies edited by TALE-C1-AID, and compared them each to control GFP- colonies in 
which the expression of deaminases had not been induced. We did not find a significant 
elevation of nucleotide substitutions in the edited clones relative to the uninduced control  
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Figure 4_8.  Unbiased test of specificity of AID fusion via whole genome sequencing of bacteria 
(A) Whole-genome SNV profiles of strains with/without ZF-AID induction. SNVs that may stem from cytosine 
deamination (C/GT/A) are in either green (if C was in the AID-preferred WRC motif) or blue (all other Cs) bars.  
(B) Whole-genome SNVs profiles of strains with/without TALE-AID induction. Color schematic is the same as 3e.  
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 (Wilcoxon test, Pvalue=0.25) (Figure 4_8). C:GT:A transitions, likely due to cytidine 
deamination, were elevated relative to other mutations in both experimental and control groups, 
as expected from Δung ΔmutS knock-outs. ZF-AIDs triggered a subtle enrichment in WRC 
deamination (Figure 4_8 A), and two of the TALE-AID colonies incurred slightly increased 
WRC and non-WRC deaminations in their genomes (Figure 4_8 B). Nevertheless, the overall 
C:GT:A rate under ZF-AID/TALE-AID expression remained close to that of the uninduced 
strains (uninduced: 15±4 deaminations, induced: 23±8 deaminations; Figure 4_8), suggesting 
that global off-target deamination occurred to a small extent, if at all. No enrichment of in-dels 
and no structural rearrangements were detected in any of the, suggesting that ZF/TALE-AID in 
the Δung ΔmutS background did not trigger DSBs or subsequent NHEJ. Of note, there are other 
four sites in the genome containing the exact ZF binding sequence with a WRC motif 9bp 
upstream. All of these cytidines remained un-mutated, but this is statistically consistent with 
expectations given the number of sites and the measured target site editing frequency (Methods). 
However, we cannot exclude the possibility that other factors, like local transcriptional activity 
(Figure 4_9) or genomic position effects, might differentially affect the editing efficiency at 
these five sites.  Taken together, whole-genome sequencing showed that ZF/TALE-AID is 
specific to the target site and does not cause hypermutation or genomic structural changes.  
 
Test of the activity and toxicity of targeted deaminases in human cells 
Given the intense interest in achieving facile genomic editing for human studies, we 
tested if our targeted deaminase system would function in human cells. We constructed a 
reporter for human cells in which an EF1α promoter drives expression of a broken-start-codon  
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Figure 4_9 Active transcription enhances targeted deamination.  
(A)  Schematic representation of the transcription control of the GFP reporter. This GFP was transcribed by T7 RNA 
polymerase which is transcribed by an IPTG inducible promoter pTac.  
(B)  Schematic representation of the transcription control of ZF-AID. ZF-AID was transcribed from the pL-TetO 
promoter which was modulated by the TetR protein (constitutively expressed) and the inducer aTc.  
(C)  Time line depicting the experiment design.  
(D)  Targeted deamination frequency with/without GFP transcription.  The bacterial culture was induced with IPTG, 
aTc and IPTG&aTC for 10 hours, and then diluted 1000-fold into fresh media without any inducer overnight. Cell 
culture was diluted again 100-fold into fresh media with IPTG to check for the expression of GFP. Targeted 
deamination frequency was quantified via percentage of GFP-positive cells in the population. 
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 (ACG) GFP attached to an IRES-mCherry selection marker. We stably inserted this construct 
into HEK293FT cell lines by lentiviral transduction and established a monoclonal cell line by 
FACS sorting (Figure 4_10 A). The optimized ZF-AID construct (ZF-8aa-AID) was then 
delivered into the reporter cell line via transfection (Figure 4_10 A). As expected, 48 hours of 
expression of ZF-8aa-AID led to GFP expression in 0.12% of transfected cells. We next 
constructed ZF-AID
ΔNES
 by truncating the 15aa from the C-terminus of AID, which contains a 
nuclear export signal (20) and regions that interact with mismatch repair proteins (21). This is 
expected to: 1. Correctly localize ZF-AID to the nucleus; 2. Contribute to editing success via 
decoupling AID from mismatch repair; 3. Minimize toxicity caused by repair-associated DSBs
24
. 
As expected, expression of ZF-AID
ΔNES
 significantly increased GFP rescue versus that of full-
length ZF-AID (Figure 4_10 B) (0.56%, t-test, two-tailed, n=4, Pvalue=0.0013). As in E.coli, we 
then tested the effect of suppressing uracil repair by using the UNG inhibitor UGI (22) and 
knocking down MSH2 (the human homolog of bacteria mutS) with shRNA. UNG and MSH6 
suppression together increased ZF-AID
ΔNES–mediated GFP rescue efficiency to 2.5% (Figure 
4_10 B). Expression of ZFGFPINL-AID
ΔNES
, a fusion protein whose zinc finger domain targets a 
site 265bp from the GFP start codon, resulted in minimal GFP rescue (Figure 4_10 A, C), 
suggesting both that genome editing by ZF-AID
ΔNES
 is sequence-specific, and that the ZF-
binding site and the targeted cytidine must be close for measurable activity. Successful 
C:GT:A targeting of the broken start codon was confirmed by Sanger sequencing of the GFP 
locus in 8/8 stable GFP+ colonies.  Therefore, engineered deaminases are capable of efficient 
sequence-specific genome editing in HEK293 cells. We next sought to characterize the toxicity 
of targeted deaminase in human cells. This is  important as AID has been implicated in 
contributing to translocation-associated lymphomas 
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Figure 4_10 Targeted deamination of ZF-AID in human cells  
(A) Schematic representation of the ACG-GFP reporter system in HEK239FT cells (upper) and the ZF-AID (lower) 
tested for targeting deaminase activity. IRES, Internal ribosome entry site; NLS, nuclear localization signal.  
(B) Targeted deamination activity of ZF-AIDs. ACG-GFP reporter cells were transfected with the constructs labeled 
on the X-axis. Targeted deamination frequency was estimated as the proportion of GFP-rescued cells 48h after 
transfection.  ZF-AIDΔNES is identical to ZF-AID except with a deleted AID nuclear export signal (NES); UGI, 
inhibitor of UNG; sr1, shRNA-MSH2.  
(C) ACG-GFP reporter cells imaged under fluorescence (mCherry (left)/GFP (right)) 48hr after transfection with 
ZF-AID ΔNES /UGI/sr1 or ZF GFPINL-AIDΔNES /UGI/sr1 plasmids. Scale bar = 200m 
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(23) by recruiting repair machineries to create staggered DSBs (21). To test whether ZF-AID
ΔNES
 
can be safely used as a genome editing tool without incurring DSBs, we generated a HEK293FT 
reporter cell line carrying a non-functional frame-shifted GFP, which could be rescued by DSB-
induced HR with exogenous donor DNA (5, 6). DSB frequency caused by a particular cell 
treatment can therefore be estimated by the frequency of GFP+ cells generated by the treatment. 
The GFP-In reporter also carried recognition sites for two known DSB-creating proteins, I-SceI 
and ZFGFPINNs (ZFGFPINLN & ZFGFPINRN), for use as positive controls (6). While expression of I-
SceI and ZFGFPINNs generated 1.01% and 0.43% GFP+ cells respectively, the result for ZFGFPIN-
AID
ΔNES
s was just 0.03%, which was reduced to 0.01% if the UNG inhibitor UGI was co-
transfected (Figure 4_11 B), consistent with previous observation (21, 24). Thus, combined 
targeted deaminase and UGI treatment created 40-fold fewer DSBs at the target locus than the 
zinc finger nuclease treatment, close to the level of a negative control where only the DNA donor 
was delivered. The extent to which ZF-AID
ΔNES 
generated DSBs (0.01%) was very low 
compared to its C:GT:A editing activity (2.1%) (Figure 4_10 B). Furthermore, we observed 
higher cell survival in the ZFGFPIN-AID
ΔNES
s/UGI-expressing population (66%) than in the 
ZFGFPINNs-expressing population (41%, Figure 4_11 C), suggesting that targeted deaminases are 
less toxic than ZFNs. Thus, expression of chimeric AID
ΔNES
s with UGI enables efficient 
genomic editing in human cells without generating DSBs and with low cytotoxicity.  
 
Discussion 
Our study demonstrates that fusing cytidine deaminases with DNA binding modules 
enables site-specific deamination of genomic loci in both prokaryotic and eukaryotic cells. We 
designed and optimized the structure of targeted deaminases to effectively convert a specific C:G  
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Figure 4_11  Targeted deamination of ZF-AID in human cells.   
(A )Schematic design of DSBs assay. The genomically integrated GFP-In reporter includes a 35bp frame-shift 
insertion bearing a stop codon and I-SceI recognition site (I-SceI_RS). Of note, ZFGFPINNs and ZFGFPIN-
AIDΔNESs binding sites (ZF GFPINNs/ZFGFPIN-AIDΔNESs_BS) were identical and located 82bp upstream of 
the insertion. We transfected the cells with a DNA donor carrying the wild-type GFP sequence along with I-Sce1/ 
ZFGFPINNs / ZFGFPIN-AIDΔNESs expression plasmids and assessed the DSB-generating rate by measuring HR 
frequency as determined by GFP rescue of the cells.  
(B) GFP rescue results determined by flow cytometry. Negative control was transfected with the DNA donor only.   
(C) Cytotoxicity assay for ZFGFPIN-AID/UGI relative to I-Sce1. Detailed methods are in Methods. A value of <1 
shows decreased cell survival as compared to I-SceI, and demonstrates a toxic effect.  
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base pair to T:A in the E.coli genome, achieving 13% editing frequency, 95% local 
targeting accuracy and a low rate of genome-wide off-target mutations. We then applied the 
optimized chimeric deaminases to a human cell line and found that these novel enzymes could 
create site-specific single-nucleotide transitions in as many as 2.5% of transfected cells. 
Targeting activity rarely creates DSBs and led to increased cell survivability relative to the zinc 
finger nuclease editing method that is currently broadly employed. These results set the stage for 
the future engineering of additional desirable functionalities onto the engineered targeted 
deaminases, including targeted adenosine deaminases (25), hyperactive and processive targeted 
deaminases. Such a ‘molecular toolkit’ for targeted genome editing will find numerous 
biotechnological and therapeutic applications (26, 27).  
Further investigation is needed to address remaining questions: for instance, it is 
currently unknown whether AID acts as a monomer , or a dimer (12).  While we have found that 
binding of two ZF-AIDs flanking the target site does not increase modification rates compared to 
binding of a single ZF-AID (Figure 4_2), it is possible that a single ZF-AID recruits a second 
ZF-AID to the target site through free dimerization of AIDs.  To the extent that dimers are 
required for functionality, targeting of deaminases might be improved by engineering obligate 
heterodimers as has been done for ZFNs (28) .  Additionally, the dependence of ZF/TALE-AID 
activity on the transcriptional state of the targeted gene requires further characterization. If 
transcription at the desired locus is essential for targeted deamination, combining programmable 
transcriptional activators with targeted deaminases may allow effective editing at 
transcriptionally silent sites.  
While targeted deaminases enable only the generation of single base transitions in a 
genome compared to the broader capabilities supported by other methods, this is sufficient for 
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important applications such as creation of nonsense and missense mutations at defined genomic 
loci, and this limitation is offset by several advantages, notably simplicity, self-contentedness, 
low toxicity, and high potential for multiplexing.   Unlike targeted nuclease-based methods, 
targeted deaminases do not depend on complex DNA repair pathways operating in the cells or on 
the differential induction of competing repair pathways such as HR vs. NHEJ.  This not only 
makes them simple to use but also removes a significant barrier to their portability to other cell 
types and organisms, as seen by the ease with which our system was moved from E. coli to 
human.  Indeed, by contrast, oligo-mediated genome engineering has proved difficult to port 
from E. coli to human even though the Lambda-Red co-factors needed for the former are well 
defined and few in number (13).  Moreover, unlike targeted nucleases, targeted deaminases do 
not depend on DSB repair, and so should neither induce error-prone NHEJ nor cause off-target 
DSBs that result in cytotoxicity. This suggests that, compared with targeted nucleases, many 
targeted deaminases could be expressed in a cell to effect multiplexed changes without toxicity, 
and that deaminases could be targeted to edit abundant sequences in the cell such as common 
regulatory sequences or even repetitive elements. Finally, the lack of need for exogenous donor 
DNA potentially makes targeted deaminases attractive for use in multicellular organisms.  We 
envision experiments in which targeted deaminases could be introduced into intact animals via 
safe-harbor knock-ins or viral vectors, and turned on at specific times in specific cell types to 
specifically mutate target genes seamlessly – requiring neither delivery of high copy number 
donor DNA for targeted nucleases, which is challenging, nor emplacement of complex DNA 
constructions including recombinase sites (such as loxP sites) that introduce unwanted DNA 
sequences and leave scars on excision.  Because of these features, we expect that targeted 
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deaminases will prove to be effective tools for genome engineering, and we plan to explore these 
applications in future experiments.  
 
 
Materials and Methods 
Construction of fusion proteins 
To construct ZFP-AID fusion proteins, we first PCR amplified ZFP from pUC57-ZFP12  
and AID from pTrc99A-AID31  and fused these two parts with various linkers using overlap 
PCR. The fusion constructs were cloned into a pTrc-Kan plasmid. We fused AID with TALE by 
cloning AID into  pLenti-EF1a-TALE(0.5 NI)-WPRE15  plasmid and then cloned TALE-AID 
fusions into the pTrc-Kan plasmid.  APOBEC1, 3F, and 3G genes were synthesized (Genescript) 
and cloned into the pTrc-ZFP-Kan plasmid. To generate pCMV-ZF-AID constructs, we 
amplified ZF-AID cassette from pTrc-ZF-AID and cloned that into pCMV-hygo15  plasmid.   
1. Restriction enzymes and Rapid ligase were purchased from New England Biolabs 
and used according to the manufacturer’s instructions. PCRs were conducted by Kapa HiFi PCR 
2X master mixture (Kapa Biosystems).  The primers and oligos were obtained from IDT and 
gene synthesis was provided by Genescript.  All of the primer, construct and backbone sequences 
are listed in Supplementary Sequences.   
2. Construction of pTrc-Kan as the backbone vector  
3. We first constructed a common inducible expression vector by combining the 
elements from pZE-21 and pROEX-HTa vectors. In brief, the fragment containing lacI gene and 
pTrc promoter of pROEX-HTa was amplified by PCR using lacI-XhoI and pTrc-HindIII 
primers. This fragment was digested with Xhol and HindIII and ligated into a similarly digested 
158 
 
pZE-21 to make pTrc-Kan.  A NheI restriction site was also imbedded downstream of the pTrc 
promoter for future cloning.  
4. Construction of pTrc-ZF and pTrc-AID 
The ZF gene 
10
 was amplified from pUC58-ZFP by PCR using ZF-F and ZF-R-HindIII 
primers. ZF fragments were digested with HindIII and NheI and ligated into the pTrc-Kan 
backbone plasmid, which was similarly digested. The AID gene was amplified from pTrc99A-
AID, a gift from Meng Wang
11
, using primers AID-F-NheI and AID-R. AID fragments were 
digested with HindIII and NheI and ligated into the pTrc-Kan backbone plasmid digested with 
the same enzyme.  
 
5. Construction of pTrc-ZF-AIDs 
The ZF was appended to the N-terminus of AID using amino acid linkers of various sizes 
and composition. The ZFP gene was amplified from pZFPerb2 and the linker sequence was 
created by PCR using ZFP-F and ZFP-R (4aa, 4aa2, 8aa, 11aa) primers individually. In parallel, 
the AID gene was amplified from ptrc99A-AID and the linker sequence was created by PCR 
using AID-F (4aa, 4aa2, 8aa, 11aa) and AID-R primers. ZF and AID with corresponding linkers 
were fused by overlap extension PCR using ZF-F and AID-R primers. Each construct was 
digested with NheI and HindIII and ligated into the four similarly digested pTrc-Kan backbone 
plasmids.   
6. Construction of pTrc-ZF-APOBECs 
We constructed pTrc-ZF-APOBECs with various linkers using the isothermal assembly 
protocol12. In brief, the APOBEC1, APOBEC3F, APOBEC3G 2K3A genes were amplified by 
PCR using primers APOBEC-F and APOBEC-R. pTrc-ZFP-aaAID was linearized by SalI and 
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HindIII digestion and the pTrc-ZF fragment was recovered by gel purification. The pTrc-ZF 
fragment was fused to individual APOBEC fragments by isothermal assembly.   
 
7. Construction of pTrc-TALE-AIDs 
AID gene was amplified from pTrc99A-AID plasmids, digested with NheI and BsrG1 
and cloned into the pLenti-EF1a-TALE(0.5 NI)-WPRE 
13
, which was similarly digested. The 
obtained TALE-C1-AID fusion was amplified and digested with SspI and HindIII and inserted 
into the pTrc-Kan backbone vector to obtain the pTrc-TALE-C1-AID construct. TALE 
truncations were created by amplifying the TALE fragment with the appropriate TALE-F and 
TALE-R deletion primers. The truncated TALEs were then ligated into pTrc-TALE-AID 
plasmid using the SspI and NheI sites. 
 
8. Construction of pTrc-TALE-APOBECs 
APOBEC genes were each amplified by PCR using APOBEC-F-NheI and APOBEC-R-
HindIII primers individually, digested with NheI and HindIII, and ligated into the pTrc-TALE-
AID plasmid that was similarly digested.  
9. Construction of pL-tetO-ZF-AIDs 
The pL-tetO promoter was amplified from the pZE-21G plasmid by PCR using primers 
pL-tetO-5 and pL-tetO-3. This fragment was digested with NheI and XhoI and ligated into pTrc-
ZF-AID plasmid that was similarly digested.  
10. Construction of pCMV-ZF-AIDs 
pCMV-ZF-AID/pCMV-ZF-AID
ΔNES 
constructs were built by amplifying ZF-AID/ZF- 
AID
ΔNES
 using BsiWI -ZF and BsrGI-AID/BsrGI-ΔAID primers respectively. The PCR products 
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were digested with BsrGI and BsiWI, and ligated into pCMV-puro backbone that was similarly 
digested. To generate ZFGFPIN- AID
ΔNES 
expression vectors, ZFGFPINL and ZFGFPINR were 
amplified from pST1374-G223L and pST1374-G223R 
14
 vectors using BsiWI-ZFL/R, BamHI-
ZFL/ZFR primers and cloned into pCMV-ZF-ΔAID to swap the ZF domains using BsiWI and 
BamHI. Subsequently, ZFGFPIN- AID
ΔNES 
were amplified and cloned into pST1374 vector by 
NheI and ApaI restriction sits to generate ZF*-AIDs expression vectors with the same backbone 
and DNA binding module as ZFGFPIN-Ns (ZFGFPINL-Ns/ ZFGFPINR-Ns) 
 
11. Construction of pCMV-UGI 
encoding gene optimized for human cell expression was synthesized and cloned into 
pCMV-puro using XhoI and BsiWI restriction sites. The sequences of the fusion proteins are 
listed in Sequence 4.1-4.5.  
 
Construction of E.coli reporter cell lines 
The GFP coding sequence was amplified from pRSET-EmGFP (Invitrogen). We 
modified the reporter by mutating the start codon to ACG and inserting a ZFP/TAL binding site 
upstream of the GFP coding sequence. To establish stable cell lines with a single copy of the 
GFP reporter sequence in the genome, we integrated the GFP cassette into the galK locus in the 
EcNR1 (MG1566 with λ-prophage::bioA/bioB) and EcNR2 (EcNR1 with mutS knocked out) 
strains
14
. To knock out ung, we replaced the ung gene with Zeocin resistance cassette via 
recombineering.  In addition, all the reporter cell lines were transformed with pTac-
T7polymerase to induce the expression of GFP. Subsequent modifications of the reporter were 
conducted using the MAGE system
14
. All sequences can be found in Sequence 4. 6 and 4.7.  
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1. Construction of the GFP reporter strains 
First, we modified the GFP cassette on pREST-EmGFP (Invitrogen) to contain a ZFP 
binding site. A dsDNA fragment was synthesized with the ZFP binding site (5’ GCCGCAGTG 
3’) 9bp downstream of a start codon, and the fragment was flanked by the NdeI and NheI 
restriction sites. This fragment was digested with NdeI and NheI and ligated to a similarly 
digested pREST-EmGFP to construct pREST-ZFP-EmGFP. Modified GFP cassette was 
incorporated into the galK locus in the EcNR1 and EcNR2 strains using the λ-red 
recombineering. In brief, the GFP cassette was amplified by PCR using 5’-galk-gfp and 3’-gfp-
galk primers to create galK homology on both sides of GFP. This fragment was transformed into 
λ-red-induced strains, and successful insertions were selected for based on GalK negative 
selection 
16
. Subsequently, we modified the single-copy GFP reporter through MAGE. To 
control the expression of GFP from the T7 promoter, we introduced the plasmid pTac-T7 RNA 
polymerase, in which T7 RNA polymerase is transcribed from tac promoter of the lactose 
operon.  
2. Construction of the ΔmutS Δung strain 
We used the EcNR1 strain as the mutS+ ung+ background and the EcNR2 strain as the 
ΔmutS background to test the targeted deamination frequency. To obtain the ΔmutS Δung  
background, we disrupted the ung gene in the EcNR2 strain by inserting a Zeocin resistance 
cassette in the middle of the gene. In brief, a Zeocin resistance cassette flanked by ung homology 
regions was PCR amplified from pEM7-Zeo vector (Invitrogen) using the 5’ung-zeo and 3’zeo-
ung primers. This PCR fragment was transformed into the EcNR2 reporter strain.   Successful 
disruption of ung was selected based on Zeocin resistance.  
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3. Protocol of MAGE and dsDNA-mediated homologous recombination 
Single colonies were inoculated into LB-min media and cultured under 34 °C to an 
absorbance (600 nm) of 0.4~0.6. The bacterial culture was then shifted to 42 °C for 15 min to 
induce expression of the λ-Red recombination proteins (Exo, Beta and Gam), and then 
immediately chilled on ice (up to 2 hours). 1 ml of bacterial culture was centrifuged at 16,000x g 
for 30 s and washed twice with 1 ml dH20 at 4 °C. Cell pellets were re-suspend with 50µl DNA-
containing water (100ng dsDNA fragment or 200pmole ssDNA) and transferred to a pre-chilled 
1 mm gap electroporation cuvette (Bio-Rad), and electroporated with a Bio-Rad GenePulser 
electroporation system under the following parameters: 1.8 kV, 200 Ω and 25 μF. 1 ml S.O.C 
(New England Biolabs) was immediately added to the electroporated cells. The cells were 
recovered in S.O.C at 34 °C for 2–2.5h before plating on LB-min agar plates to resolve single 
colonies. The plates were incubated for at least 13h at 34 °C. Colony PCR followed by Sanger 
sequencing was performed to screen for colonies with the right genotypes.  
 
 
E.coli cell culture and targeted deaminase activity assay 
The reporter strains were electro-transformed with the plasmids coding for targeted 
deaminases. Single colonies were inoculated and cultured under 34°C in LB-min- media (5g 
NaCl, 5g yeast extract,10g tryptone in 1L ddH2O) supplemented with 100µg/mL Carbenicillin, 
25µg/mL Chloramphenicol, 100µg/mL Spectinomycin, 100ug/mL Kanamycin.  Targeted 
deaminase activities of the targeted deaminases were tested by inducing the expression the fusion 
protein with IPTG of final concentration 100µM when the O.D of the cell culture reached 
163 
 
0.4~0.6. To maintain the continuous cell proliferation, cell culture was diluted 100-fold into 
fresh media every 10 hours.   
 
Flow cytometry 
Targeted deaminase activity as measured by GFP+ cell fraction in the total population 
was assayed by flow cytometry using a LSRFortessa cell analyzer (BD Biosciences). Bacteria 
culture was diluted 1:100 with PBS and vortexed for 30 seconds before flow cytometry. At least 
100,000 events were analyzed for each sample. Targeted deamination efficiency was calculated 
as the percentage of GFP positive cells in the whole population.  
 
gfp gene  Sanger sequencing  
To genotype the GFP and GAPDH genes in E.coli, we inoculated single colonies in LB 
media and cultured them for 16 h at 34ºC. PCR reactions with Phusion enzyme (NEB) were 
conducted with 1µl 100X diluted bacterial culture and Sanger sequencing were performed. 
Specifically, to genotype the GFP and GAPDH genes, we inoculated single colonies in LB media 
and cultured them for 16 hours at 34 ºC. gfp and gapdh loci were amplified from 1ul of 100 
times diluted bacterial culture using 10ul 2X Phusion High-Fidelity PCR Master Mix (NEB), 7ul 
water, and 1ul of 10uM primer(each) with  thermocycling program of 98°C for 2 min; (98°C for 
30s, 60°C for 30s, 72°C for 2min) x 30 cycles, 72°C for 10 min. Sequence of primers can be 
found in the Sequence 4.8.  
 
Genomic library preparation 
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Corresponding reporter strains were transformed with ZFP-8aa-AID and TALE-C3-AID 
respectively. Single colonies were inoculated and split into the induction and non-induction 
groups. The expression of the deaminases was induced for 10 hours and the cell culture was 
plated on IPTG containing agar plate to isolate single colonies. After approximately 24h, we 
inoculated single colonies into LB-min media and cultured them overnight at 34ºC. In order to 
extract chromosomal DNA and minimize the amount of plasmid DNA, Miniprep was first 
performed (Qiagen) according to manufacturer’s protocol and the sodium acetate/SDS 
precipitate formed was resuspended in the Lysis Buffer Type 2 (Illustra bacteria genomicPrep 
Mini Spin Kit, GE Healthcare) and the genomic DNA was recovered following manufacturer’s  
instructions (Illustra bacteria genomicPrep Mini Spin Kit, GE Healthcare).  Genomic DNA 
libraries were constructed from 1.5–2 µg of genomic DNA. DNA was sheared in TE buffer (10 
mM Tris (pH 8.0) 0.1 mM EDTA) using microTube (Covaris) with recommended protocol. 
Median DNA fragment sizes, estimated by gel-electrophoresis, were 150–250 bp. Sheared 
fragments were processed with the DNA Sample Prep Master Mix Set 1 (NEB). Adaptors 
consisted of the Illumina genomic DNA adaptor oligonucleotide sequences with the addition of 
2-bp barcodes. Eight barcoded genomic libraries were pooled with equal molar amount.  
Specifically, the reporter strain for testing ZF-AID-targeted deamination activity was 
transformed with ZF-8aa-AID and one single colony was inoculated. Cells from the colony were 
cultured in 2mL LB-min media supplemented with 1mM IPTG to induce the expression ZF-8aa-
AID. In parallel, cells from the same colony were cultured in 2mL LB-min media without 
induction. After 10 hours,  the bacterial culture was plated on the IPTG-containing agar plate and 
3 GFP+ colonies (after IPTG induction) and 1 GFP- colony (negative control without IPTG 
induction) were inoculated and cultured in 2mL LB-min media overnight at 34ºC. The same 
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work flow was undertaken for experiments with TALE-C1-AID and its corresponding reporter 
strain.  
In order to extract chromosomal DNA and minimize the amount of plasmid DNA, 
Miniprep was first performed (Qiagen) on the 2mL bacteria culture according to manufacturer’s 
protocol. The sodium acetate/SDS precipitate formed was resuspended in the Lysis Buffer Type 
2 (Illustra bacteria genomicPrep Mini Spin Kit, GE Healthcare) and the genomic DNA was 
recovered following manufacturer’s instructions.  Genomic DNA libraries were constructed from 
1.5–2 µg of genomic DNA. DNA was sheared in TE buffer (10 mM Tris (pH 8.0), 0.1 mM 
EDTA) using microTube (Covaris) with duty cycle as 10%, intensity as 5, cycle per burst as 200 
and time as 780sec per sample. Median DNA fragment sizes as estimated by gel-electrophoresis, 
were 150–250 bp. Sheared fragments were processed with the DNA Sample Prep Master Mix 
Set 1 (NEB). Adaptors consisted of the Illumina genomic DNA adaptor oligonucleotide 
sequences with the addition of 2-bp barcodes. Eight barcoded genomic libraries were pooled 
with an equal molar ratio. The sequences of the adaptors and primers can be found in the 
Supplementary Sequence. 
The sequences of the adaptors and primers can be found in the Sequence 4.9. 
 
Genomic DNA sequencing analysis 
The reference genomic sequence for the reporter strain was generated by manually 
modifying the FASTA sequence of E. coli K-12 strain MG1655 to reflect the removal of mutS 
and ung, the insertion of the lambda prophage genome into the bioAB operon, and the insertion 
of the GFP reporter into the galK cassette. Genomic libraries were single-end sequenced using an 
Illumina Genome Analyzer, generating 100bp reads. The reads were first assigned to samples 
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according to their 2-bp barcodes by exact matching and reads with fewer than 60 bases of high-
quality sequence were discarded. Sorted reads were then aligned to the reference genomes using 
the Breseq package
32
. Match lengths of at least 40 bases were required for alignment. In addition 
to Breseq’s single nucleotide variation (SNV) calling functionality, the SAMtools package32 was 
used on the resulting BAM file to corroborate short indels and single nucleotide variants. To 
validate the result of Breseq, MAQ was used as a second method to align the raw reads to the 
reference genomes and to call SNVs. FastQ files containing the sequencing reads were split 
based on the barcode, and trimmed using the FASTX-toolkit library. The resulting fastQ files 
were mapped to the reference genomes with MAQ
33
. Single nucleotide substitutions were 
considered valid when supported by a minimum read depth of 10 or a Phred-like consensus 
quality higher than 80. Finally, these three sets were merged to generate the final SNV set. SNVs 
called by both MAQ and SAMtools, or SNVs called by one and also called by Breseq, were kept. 
Indels were called by SAMtools alone. Breseq was used to identify new junctions using 
candidates generated by split read alignment. LiftOver
34
 was used to map the SNVs back to the 
original MG1655 genome (NCBI accession: NC_000913) for annotation. SNV effect prediction 
was done using the snpEff package
35
 and BioPerl. The analysis flow map (Figure 4_12) provides 
information about the number of raw sequence reads, aligned reads, genome coverage and 
validated SNVs, and the list of SNVs  can be found in the supplementary information.  
 
Statistical analysis of the whole-genome sequence data 
Wilcoxon test was used to analyze whether the mutation rate was higher in the strains 
with TALE-AID or ZF-AID induction. Intended mutations in TALE-AID, and ZF-AID strains 
were discarded for this analysis. X (SNVs not induced)=31, 21; Y(SNVs induced)=40, 31, 27, 33, 
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20, 32. H0: There is no difference in the mutation rate; H1: induced strains have a higher 
mutation rate. Pvalue=0.25. The null hypothesis cannot be rejected. Therefore, there was no 
significant difference in the number of mutations between induced and uninduced strains. Due to 
the limited sample size, sensitivity simulations were performed to ensure an appropriate type II 
error. 1) Random samples from the observations of size m+n were taken, and divided in two 
groups A (n members) and B (m members). 2) An arbitrary value δ was added to B. 3) Wilcoxon 
one-sided p-value was calculated for comparison of groups A and B. A p-value under 0.05 was 
considered a success and recorded; otherwise a failure was recorded. 4) Steps 1 to 3 were 
repeated 10,000 times. The estimated power of the test was approximated by the proportion of 
successes  
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Figure 4_12 Flow map of the whole-genome sequence data analysis.  
Breseq and MAQ were used independently to assign the raw reads to different strains and align the reads to the 
reference genomes. After alignment, we used Samtools and MAQ to identify single nucleotide substitutions (SNSs), 
Breseq to identify new genomic junctions and Samtools to call indels.  
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Figure 4_13 Sensitivity simulations for the Wilcoxon test of numbers of genome SNV comparison  
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among the 10,000 repetitions. 5) Steps 1 to 4 were repeated for a range of values of m+n and a 
range of δ values. The results are presented in the Figure 4_13. With the current sample size, we 
could detect an increase of 13 SNVs, or higher (Statistical power=0.8). 
 
Poisson based modeling of number of genome edited sites: There are four sites in the 
genome with equivalent features as the targeted site. All of them contain an exact ZF binding 
sequence 11bp away from an upstream WRC motif. Deamination was only detected in the 
targeted site with a maximum frequency of 7%. Assuming that alterations of these sites are 
Poisson distributed with  = .07, the probability of detecting a second mutation in any strain is 
0.03, and the probability P of not detecting an additional mutation in any of the 3 ZF-AID strains 
is 0.90. 
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Human cell culture 
The human embryonic kidney cell line HEK293FT (Invitrogen) and the derivative 
reporter cell lines was maintained under 37 °C, 5% CO2 using Dulbecco's modified Eagle's 
Medium supplemented with 10% FBS, 2 mM GlutaMAX (Invitrogen), 100 U/ml penicillin and 
100 μg/ml streptomycin.  
 
Targeted deaminase activity assay in human cells 
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The GFP-ACG reporter cell lines were generated by lentiviral transduction with low virus 
titration to make sure at most one copy of the reporter can be integrated into the genome. Single 
cells were isolated via FACS based on mCherry signal (Beckman Coulter MoFlo). Deaminase 
activity was tested by transfecting reporter cells with plasmids carrying ZF-AIDs. Briefly, 
HEK293FT cells were seeded into 12-well plates the day before transfection at densities of 4 × 
105 cells/well. Approximately 24 h after initial seeding, cells were transfected using 
Lipofectamine 2000 (Invitrogen) and 1.6ug DNA (400 ng of ZF-AID expression plasmid and/or 
20 ng of UGI expression plasmid, and/or 20ng of ShRNA-MSH6 expression plasmid (Sigma), 
and pUC19(Invitrogen) plasmid to 1.6ug) per well. After 48 h, cells were trypsinized from their 
culturing plates and resuspended in 200 μl of media for flow cytometry analysis. At least 25,000 
events were analyzed for each transfection sample. The flow cytometry data were analyzed using 
BD FACSDiva (BD Biosciences). The reporter and constructs sequences can be found in the 
Sequences 4.10-4.12.  
 
Genotyping of human cell 
To genotype the GFP target locus in HEK293 cells, we picked single GFP+ 
monocolonies and added each to 10ul 1X prepGEM buffer and enzyme (ZyGEM). After cell 
lysis according to the manufacturer’s instructions, the bulk product was added to a PCR reaction 
containing Platinum Taq polymerase (invitrogen). PCR products were cloned in pCR™4-TOPO 
(invitrogen) and capillary sequenced by Genewiz.  
 
DSB generating potential assay 
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The GFP-In reporter
7
 cell lines were generated by lentiviral transduction and successful 
reporter insertions were selected via puromycin selection. GFP-In reporter cells were plated in 
12-well plates the day before transfection at densities of 4 × 105 cells/well transfected using 
Lipofectamine 2000 (Invitrogen) and 1.6ug DNA (400 ng of ZF-AID/ZF-nuclease/I-Sce1 
expression plasmid and/or 20 ng of UGI expression plasmid, and/or 20ng of ShRNA-MSH6 
expression plasmid, 1ug of DNA donor pUC19(Invitrogen) plasmid to 1.6ug) per well. 72 hours 
after the transfection, cell were trypsinized and resuspended in 200 μl of media for flow 
cytometry analysis. At least 25,000 events were analyzed for each transfection sample. The flow 
cytometry data were analyzed using BD FACSDiva (BD Biosciences). The constructs sequence 
can be found in the Sequences 4.13.  
 
Cytotoxicity assay 
The assays were conducted as described before
36
. Briefly, HEK293FT cells were seeded in 12-
well plates (4X10
5 cells/well) and transfected after 24 h with 200 ng of deaminase/ nuclease 
expression plasmids, 10 ng of pmaxGFP (Lonzon), and pUC19 to 2 µg using calcium phosphate-
mediated protocol. After 2 and 5 days, the fractions of GFP-positive cells were determined by 
flow cytometry (BD Biosciences). The survivability was calculated as the percentage of GFP-
positive cell surviving at day 5 divided by the percentage of GFP-positive cells determined at 
day 2 after transfection. This ratio was normalized to the corresponding ratio after I-SceI 
transfection, to yield the percentage survival as compared to I-SceI.  
 
Test of targeted deamination frequency on a reporter with two ZF binding sites 
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Although AID was observed to function as a monomer, it has also been postulated that 
AID forms homodimers and homotetramers based on structural modeling with homologous 
cytidine deaminases (12, 27). Having shown that a single ZF binding site was sufficient for ZF-
AID editing (Figure 4_1), we next sought to test whether we can increase the targeted 
deamination frequency by adding another zinc finger binding site. This would facilitate 
dimerziation of AID, if it functions as a dimer.  To this end, we first sought to modify the 
reporter by adding two ZF binding sites flanking the targeting site (the broken start codon, ACG) 
while ensuring that the modifications would not compromise the expression of the GFP protein. 
Four different modified GFP reporters were investigated (Figure 4_2), however only one reporter 
in which an additional ZF binding sequence (5’GCCGACGTG3’ in the bottom strand) lay 14bp 
upstream of the start codon did not compromise the translation efficiency (Figure 4_2). 
Therefore, we further modified this reporter by mutating its start codon to ACG with MAGE and 
used it to conduct further studies. Interestingly, induction of ZF-AID led to similar GFP rescue 
frequency (0.1%) on the dimer reporter as the one with a single ZF binding site (0.12%) (Figure 
4_2), indicating that the targeting a single copy of ZF-AID at the targeting site is sufficient to 
exert deaminase activity in the cell. Future experiment with symmetrical zinc finger DNA 
binding sites is needed to substantiate this conclusion. Also, test the deamination frequency of 
ZF-AID with a mutated dimerization interface 
1-2
 might help determine the stoichiometry of the 
functional ZF-AIDs.  
 
 
Sequences:   
 
Sequence 4.1. ZF -AID constructs  and the PCR primer sequences 
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ZF coding sequence is capitalized, linker sequence is highlighted in green, AID coding 
sequence is un-capitalized. NheI cutting site is labeled in Red, HindIII cutting site is labeled 
in Blue.  
 
ZF -4aa-AID:  
 
GCTAGCCCCAGAGTGAGAACCGGTTCTAAGACACCTCCCCACGAGAGGCCTTTTCAGTGTAGAATTTGTATGC
GTAATTTTTCTAGGTCCGATGTGCTGGCCAATCACACAAGGACTCACACTGGTGAAAAGCCCTTCCAATGTAG
AATTTGTATGCGCAATTTTTCTCAATCTTCTACTCTGACTAGACATCTGAGGACCCACACAGGCGAAAAGCCTT
TCCAGTGCAGAATTTGTATGAGAAATTTTTCTGAAAGACAGGGTCTGAAAAGACATCTGAAGACACATACAG
GTGAAAAAGGATCCGGTGGTGGTTCTgacagcctcttgatgaaccggaggaagtttctttaccaattcaaaaatgtccgctgggctaagggtcggcgtgaga
cctacctgtgctacgtagtgaagaggcgtgacagtgctacatccttttcactggactttggttatcttcgcaataagaacggctgccacgtggaattgctcttcctccgctacatctcggac
tgggacctagaccctggccgctgctaccgcgtcacctggttcacctcctggagcccctgctacgactgtgcccgacatgtggccgactttctgcgagggaaccccaacctcagtctg
aggatcttcaccgcgcgcctctacttctgtgaggaccgcaaggctgagcccgaggggctgcggcggctgcaccgcgccggggtgcaaatagccatcatgaccttcaaagattatttt
tactgctggaatacttttgtagaaaaccacgaaagaactttcaaagcctgggaagggctgcatgaaaattcagttcgtctctccagacagcttcggcgcatccttttgcccctgtatgagg
ttgatgacttacgagacgcatttcgtactttgggactt 
 
ZF -4aa2-AID:  
 
GCTAGCCCCAGAGTGAGAACCGGTTCTAAGACACCTCCCCACGAGAGGCCTTTTCAGTGTAGAATTTGTATGC
GTAATTTTTCTAGGTCCGATGTGCTGGCCAATCACACAAGGACTCACACTGGTGAAAAGCCCTTCCAATGTAG
AATTTGTATGCGCAATTTTTCTCAATCTTCTACTCTGACTAGACATCTGAGGACCCACACAGGCGAAAAGCCTT
TCCAGTGCAGAATTTGTATGAGAAATTTTTCTGAAAGACAGGGTCTGAAAAGACATCTGAAGACACATACAG
GTGAAAAAGGATCCCTGCGTGGTTCTgacagcctcttgatgaaccggaggaagtttctttaccaattcaaaaatgtccgctgggctaagggtcggcgtgaga
cctacctgtgctacgtagtgaagaggcgtgacagtgctacatccttttcactggactttggttatcttcgcaataagaacggctgccacgtggaattgctcttcctccgctacatctcggac
tgggacctagaccctggccgctgctaccgcgtcacctggttcacctcctggagcccctgctacgactgtgcccgacatgtggccgactttctgcgagggaaccccaacctcagtctg
aggatcttcaccgcgcgcctctacttctgtgaggaccgcaaggctgagcccgaggggctgcggcggctgcaccgcgccggggtgcaaatagccatcatgaccttcaaagattatttt
tactgctggaatacttttgtagaaaaccacgaaagaactttcaaagcctgggaagggctgcatgaaaattcagttcgtctctccagacagcttcggcgcatccttttgcccctgtatgagg
ttgatgacttacgagacgcatttcgtactttgggactt 
 
ZF-8AA-AID  
 
GCTAGCCCCAGAGTGAGAACCGGTTCTAAGACACCTCCCCACGAGAGGCCTTTTCAGTGTAGAATTTGTATGC
GTAATTTTTCTAGGTCCGATGTGCTGGCCAATCACACAAGGACTCACACTGGTGAAAAGCCCTTCCAATGTAG
AATTTGTATGCGCAATTTTTCTCAATCTTCTACTCTGACTAGACATCTGAGGACCCACACAGGCGAAAAGCCTT
TCCAGTGCAGAATTTGTATGAGAAATTTTTCTGAAAGACAGGGTCTGAAAAGACATCTGAAGACACATACAG
GTGAAAAAGGATCCTCTGGTGGTGGTCTGGGGTCGACTgacagcctcttgatgaaccggaggaagtttctttaccaattcaaaaatgtccgctgg
gctaagggtcggcgtgagacctacctgtgctacgtagtgaagaggcgtgacagtgctacatccttttcactggactttggttatcttcgcaataagaacggctgccacgtggaattgctc
ttcctccgctacatctcggactgggacctagaccctggccgctgctaccgcgtcacctggttcacctcctggagcccctgctacgactgtgcccgacatgtggccgactttctgcgag
ggaaccccaacctcagtctgaggatcttcaccgcgcgcctctacttctgtgaggaccgcaaggctgagcccgaggggctgcggcggctgcaccgcgccggggtgcaaatagcca
tcatgaccttcaaagattatttttactgctggaatacttttgtagaaaaccacgaaagaactttcaaagcctgggaagggctgcatgaaaattcagttcgtctctccagacagcttcggcgc
atccttttgcccctgtatgaggttgatgacttacgagacgcatttcgtactttgggactt 
 
ZF-11AA-AID:  
 
GGTTCTGGTGGTGGTGGTTCTGGTGGTGGTGGTGCTAGCCCCAGAGTGAGAACCGGTTCTAAGACACCTCCCC
ACGAGAGGCCTTTTCAGTGTAGAATTTGTATGCGTAATTTTTCTAGGTCCGATGTGCTGGCCAATCACACAAG
GACTCACACTGGTGAAAAGCCCTTCCAATGTAGAATTTGTATGCGCAATTTTTCTCAATCTTCTACTCTGACTA
GACATCTGAGGACCCACACAGGCGAAAAGCCTTTCCAGTGCAGAATTTGTATGAGAAATTTTTCTGAAAGACA
GGGTCTGAAAAGACATCTGAAGACACATACAGGTGAAAAAGGATCCGGTTCTGGTGGTGGTGGTTCTGGTGG
TGGTGGTgacagcctcttgatgaaccggaggaagtttctttaccaattcaaaaatgtccgctgggctaagggtcggcgtgagacctacctgtgctacgtagtgaagaggcgtga
cagtgctacatccttttcactggactttggttatcttcgcaataagaacggctgccacgtggaattgctcttcctccgctacatctcggactgggacctagaccctggccgctgctaccgc
gtcacctggttcacctcctggagcccctgctacgactgtgcccgacatgtggccgactttctgcgagggaaccccaacctcagtctgaggatcttcaccgcgcgcctctacttctgtga
ggaccgcaaggctgagcccgaggggctgcggcggctgcaccgcgccggggtgcaaatagccatcatgaccttcaaagattatttttactgctggaatacttttgtagaaaaccacga
aagaactttcaaagcctgggaagggctgcatgaaaattcagttcgtctctccagacagcttcggcgcatccttttgcccctgtatgaggttgatgacttacgagacgcatttcgtactttg
ggactt 
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Primers for ZF-AID constructs 
ZFP-F ATCGGCTAGCCCCAGAGTGAGAACCGGT 
ZFP-R-4AA ccggttcatcaagaggctgtcAGAACCACCACCGGATCCTTTTTCACCTGTATG 
ZFP-R-4AA2 ccggttcatcaagaggctgtcAGAACCACGCAGGGATCCTTTTTCACCTGTATG 
ZFP-R-8AA ctgtcAGTCGACCCCAGACCACCACCAGAGGATCCTTTTTCACCTGTATG 
ZFP-R-11AA 
gtcACCACCACCACCAGAACCACCACCACCAGAACCGGATCCTTTTTCACCTGTAT
G 
ZFP-R-Hind3 atcgaagcttGGATCCTTTTTCACCTGTATG 
AID-F-Nhe1 ATCGGCTAGCgacagcctcttgatgaaccg 
AID-F-4AA TACAGGTGAAAAAGGATCCGGTGGTGGTTCTgacagcctcttgatgaaccg 
AID-F-4AA2 TACAGGTGAAAAAGGATCCCTGCGTGGTTCTgacagcctcttgatgaaccg 
AID-F-8AA AGGATCCTCTGGTGGTGGTCTGGGGTCGACTgacagcctcttgatgaaccg 
AID-F-11AA GATCCGGTTCTGGTGGTGGTGGTTCTGGTGGTGGTGGTgacagcctcttgatgaaccg 
AID-R atcgaagcttaaagtcccaaagtacgaaatgcg 
 
Sequence 4.2 TALE-AID constructs and the PCR primer sequences 
 
TALE-AID full sequence: TALE N-terminus is in Blue , TALE central repeating domain is in Red, 
TALE-C terminus is in Green. Linker sequence is in Brown. AID coding sequence is un-capitalized 
in Black.  
 
ATGTCGCGGACCCGGCTCCCTTCCCCACCCGCACCCAGCCCAGCGTTTTCGGCCGACTCGTTCTCAGACCTGCT
TAGGCAGTTCGACCCCTCACTGTTTAACACATCGTTGTTCGACTCCCTTCCTCCGTTTGGGGCGCACCATACGG
AGGCGGCCACCGGGGAGTGGGATGAGGTGCAGTCGGGATTGAGAGCTGCGGATGCACCACCCCCAACCATGC
GGGTGGCCGTCACCGCTGCCCGACCGCCGAGGGCGAAGCCCGCACCAAGGCGGAGGGCAGCGCAACCGTCC
GACGCAAGCCCCGCAGCGCAAGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAAG
CCCAAAGTGAGGTCGACAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACATGCCCACATC
GTAGCCTTGTCGCAGCACCCTGCAGCCCTTGGCACGGTCGCCGTCAAGTACCAGGACATGATTGCGGCGTTGC
CGGAAGCCACACATGAGGCGATCGTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGT
TGACGGTCGCGGGAGAGCTGAGAGGGCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTGAAGATCGCGAAGC
GGGGAGGAGTCACGGCGGTCGAGGCGGTGCACGCGTGGCGCAATGCGCTCACGGGAGCACCCCTCAACCTGA
CCCCAGAGCAGGTCGTGGCAATCGCCTCCAACATTGGCGGGAAACAGGCACTCGAGACTGTCCAGCGCCTGC
TTCCCGTGCTGTGCCAAGCGCACGGACTCACCCCAGAGCAGGTCGTGGCGATCGCAAGCCACGACGGAGGAA
AGCAAGCCTTGGAAACAGTACAGAGGCTGTTGCCTGTGCTGTGCCAAGCGCACGGCCTCACCCCAGAGCAGG
TCGTGGCAATCGCGAGCAATAACGGCGGAAAACAGGCTTTGGAAACGGTGCAGAGGCTCCTTCCAGTGCTGT
GCCAAGCGCACGGATTAACCCCAGAGCAGGTCGTGGCAATCGCCTCCAACATTGGCGGGAAACAGGCACTCG
AGACTGTCCAGCGCCTGCTTCCCGTGCTGTGCCAAGCGCACGGCTTAACCCCAGAGCAGGTCGTGGCGATCGC
AAGCCACGACGGAGGAAAGCAAGCCTTGGAAACAGTACAGAGGCTGTTGCCTGTGCTGTGCCAAGCGCACGG
ACTTACCCCAGAGCAGGTCGTGGCCATTGCCTCGAATGGAGGGGGCAAACAGGCGTTGGAAACCGTACAACG
ATTGCTGCCGGTGCTGTGCCAAGCGCACGGCCTTACCCCAGAGCAGGTCGTGGCGATCGCAAGCCACGACGG
AGGAAAGCAAGCCTTGGAAACAGTACAGAGGCTGTTGCCTGTGCTGTGCCAAGCGCACGGACTAACCCCAGA
GCAGGTCGTGGCAATCGCCTCCAACATTGGCGGGAAACAGGCACTCGAGACTGTCCAGCGCCTGCTTCCCGTG
CTGTGCCAAGCGCACGGGCTCACCCCAGAGCAGGTCGTGGCGATCGCAAGCCACGACGGAGGAAAGCAAGC
CTTGGAAACAGTACAGAGGCTGTTGCCTGTGCTGTGCCAAGCGCACGGGCTAACCCCAGAGCAGGTCGTGGC
CATTGCCTCGAATGGAGGGGGCAAACAGGCGTTGGAAACCGTACAACGATTGCTGCCGGTGCTGTGCCAAGC
GCACGGCCTAACCCCAGAGCAGGTCGTGGCAATCGCCTCCAACATTGGCGGGAAACAGGCACTCGAGACTGT
CCAGCGCCTGCTTCCCGTGCTGTGCCAAGCGCACGGGTTAACCCCAGAGCAGGTCGTGGCCATTGCCTCGAAT
GGAGGGGGCAAACAGGCGTTGGAAACCGTACAACGATTGCTGCCGGTGCTGTGCCAAGCGCACGGACTCACG
CCTGAGCAGGTAGTGGCTATTGCATCCAATATCGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCCAGCTTT
CGAGGCCGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGCGGACGACC
CGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAGCGGACCAACAGAAGGATTCC
CGAGAGGACATCACATCGAGTGGCAGATCACGCGCAAGTGGTCCGCGTGCTCGGATTCTTCCAGTGTCACTCC
CACCCCGCACAAGCGTTCGATGACGCCATGACTCAATTTGGTATGTCGAGACACGGACTGCTGCAGCTCTTTC
GTAGAGTCGGTGTCACAGAACTCGAGGCCCGCTCGGGCACACTGCCTCCCGCCTCCCAGCGGTGGGACAGGA
TTCTCCAAGCGAGCGGTATGAAACGCGCGAAGCCTTCACCTACGTCAACTCAGACACCTGACCAGGCGAGCC
TTCATGCGTTCGCAGACTCGCTGGAGAGGGATTTGGACGCGCCCTCGCCCATGCATGAAGGGGACCAAACTC
GCGCGTCAGCTAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCgacagcctcttgatgaaccggaggaagtttctttaccaattcaaaa
atgtccgctgggctaagggtcggcgtgagacctacctgtgctacgtagtgaagaggcgtgacagtgctacatccttttcactggactttggttatcttcgcaataagaacggctgccac
gtggaattgctcttcctccgctacatctcggactgggacctagaccctggccgctgctaccgcgtcacctggttcacctcctggagcccctgctacgactgtgcccgacatgtggccg
actttctgcgagggaaccccaacctcagtctgaggatcttcaccgcgcgcctctacttctgtgaggaccgcaaggctgagcccgaggggctgcggcggctgcaccgcgccggggt
176 
 
gcaaatagccatcatgaccttcaaagattatttttactgctggaatacttttgtagaaaaccacgaaagaactttcaaagcctgggaagggctgcatgaaaattcagttcgtctctccagac
agcttcggcgcatccttttgcccctgtatgaggttgatgacttacgagacgcatttcgtactttgggactttga 
 
 
     Primer sequences 
TAL-F-ssp1 
TGGCAAATATTCTGAAATGAGCTGTTGACAATTAATCATCCGGTCCGTATAATCT
GTGGAATTGTGAGCGGATAACAATTTCACACAAAGAGGAGAAAGGTACCATGT
CGCGGACCCGGCTCCC 
TAL-C1-Nhe1 TGGGGCTAGCTGACGCGCGAGTTTGGTCCC 
TAL-C2-Nhe1 TCTTGGGGCTAGCGCGGGAGGCAGTGTGCCCGA 
TAL-C3-Nhe1 TCTTGGGGCTAGCTGCCACTCGATGTGATGTCCTCTCGGGAATCCT 
TAL-C4-Nhe1 TCTTGGGGCTAGCGCGGCCAGCGCGGGGTCCG 
TAL-C5-Nhe1 TCTTGGGGCTAGCCTCCAGTGCGGGTCTGCC 
AID-R atcgaagcttaaagtcccaaagtacgaaatgcg 
 
 
Sequence 4.3 APOBECs and PCR primer sequences 
 
APOBEC1 sequence:  
ACTTCTGAAAAAGGTCCATCTACTGGTGATCCTACTCTGCGTCGTCGTATTGAACCGTGGGAATTTGACGTGTT
CTACGACCCACGCGAACTGCGTAAAGAGGCTTGCCTGCTGTACGAAATCAAATGGGGTATGTCTCGCAAAATT
TGGCGCTCCAGCGGTAAAAACACCACTAACCACGTTGAAGTCAACTTCATCAAAAAGTTCACCTCTGAACGCG
ACTTCCACCCGTCCATGTCTTGTTCTATCACCTGGTTCCTGTCTTGGAGCCCGTGCTGGGAGTGCTCCCAAGCC
ATCCGCGAATTCCTGTCTCGTCACCCGGGTGTAACGCTGGTGATCTATGTCGCCCGTCTGTTCTGGCATATGGA
TCAGCAAAACCGTCAGGGTCTGCGTGATCTGGTGAACAGCGGCGTCACGATCCAGATCATGCGTGCATCCGA
ATATTACCATTGCTGGCGTAACTTCGTAAACTACCCTCCGGGTGATGAAGCGCACTGGCCGCAATACCCGCCG
CTGTGGATGATGCTGTACGCTCTGGAGCTGCATTGCATCATCCTGTCTCTGCCACCGTGCCTGAAAATTTCCCG
CCGTTGGCAGAACCATCTGACCTTCTTCCGTCTGCATCTGCAGAACTGTCACTACCAGACTATCCCGCCTCACA
TCCTGCTGGCTACTGGCCTGATCCATCCGTCTGTTGCGTGGCGC 
 
APOBEC3F sequence 
AAACCGCATTTTCGTAACACCGTTGAGCGTATGTATCGTGACACTTTCTCTTACAACTTCTACAACCGTCCGAT
CCTGTCTCGCCGCAACACCGTGTGGCTGTGTTATGAAGTTAAAACCAAAGGCCCGTCTCGTCCGCGTCTGGAC
GCGAAGATCTTCCGTGGCCAGGTACCGCGTTCCTTTATTCGTGCGCCGTTTCAGGTGCTGTCTAGCCCGTTCGG
CCAGTGTGCACCGCCGCACGGTACGGCGCAGGTTCAATGGCCTCCGCAGCTGACTGCCGGTCGCGAGCAGGG
TCGTCCG 
 
APOBEC3G 2K3A sequence  
GAAATTCTGCGTCACTCTATGGACCCGCCAACTTTTACTTTCAACTTCAACAATGAACCGTGGGTCCGTGGCCG
TCACGAGACTTACCTGTGCTACGAGGTGGAGCGTATGCACAATGATACCTGGGTGAAACTGAACCAGCGTCG
CGGTTTCCTGGCTAACCAGGCTCCGCACAAACACGGCTTCCTGGAGGGCCGTCACGCTGAACTGTGCTTCCTG
GATGTTATTCCTTTCTGGAAACTGGACCTGGACCAAGATTATCGTGTAACTTGCTTCACTAGCTGGAGCCCATG
CTTCAGCTGCGCACAGGAAATGGCCAAGTTCATTTCTAAAAACAAACATGTTTCTCTGTGTATCAAGACTGCT
CGCATCTATGATGACCAGGGCCGTGCTCAGGAAGGCCTGCGTACTCTGGCGGAAGCAGGTGCTAAAATTAGC
ATCATGACTTACAGCGAATTCAAACACTGCTGGGACACCTTCGTGGACCACCAGGGTGCGCCTTTCCAGCCTT
GGGATGGTCTGGATGAACACTCTCAGGACCTGTCTGGTCGTCTGCGTGCGATCCTGCAGAACCAGGAAAAT 
 
Primers for ZF-APOBECs constructs 
Homology to the vectors is in Black; linker sequence is highlighted in Green and the homology to the 
APOBECs sequences is in Red.  
 
APOBEC1-F-4AA1 GAAAAGACATCTGAAGACACATACAGGTGAAAAAGGATCCGGTGGTGGTTCTA
CTTCTGAAAAAGGTCCATCTAC 
APOBEC1-reverse CCATGGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTTCAGCGCCACGCA
ACAGAC 
APOBEC3F-F-4AA1 GAAAAGACATCTGAAGACACATACAGGTGAAAAAGGATCCGGTGGTGGTTCT 
AAACCGCATTTTCGTAACACCGTTGAGCG 
177 
 
APOBEC3F-reverse CCATGGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTCACGGACGACCCT
GCTCGC 
APOBEC3G-F-4AA1 GAAAAGACATCTGAAGACACATACAGGTGAAAAAGGATCCGGTGGTGGTTCT 
GAAATTCTGCGTCACTCTATGGAC 
APOBEC3G-reverse CCATGGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTTCAATTTTCCTGGT
TCTGC 
 
Primers for TALE-APOBECs construct 
 NheI cutting site is in Red and HindIII cutting site is in the Blue.  
 
APOBEC1-F ATCGGCTAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCACTTCTGAAAAAG
GTCCATCTACTGGTG 
APOBEC1-R ATCGAAGCTTTCAGCGCCACGCAACAGACGGATGG 
APOBEC3F-F ATCGGCTAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCAAACCGCATTTTC
GTAACACCGTTGAG 
APOBEC3F-R ATCGAAGCTTTCACGGACGACCCTGCTCGCGACCG 
APOBEC-3G-F ATCGGCTAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCGAAATTCTGCGTC
ACTCTATG 
APOBEC-3G-R ATCGAAGCTTTCAATTTTCCTGGTTCTGCAGGATCG 
 
Sequence 4.4 pTrc-Kan backbone sequence 
CTCGAGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATCAGACCG
TTTCCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCGGGAAAAAGTGGAAGCGGCGATGGCGG
AGCTGAATTACATTCCCAACCGCGTGGCACAACAACTGGCGGGCAAACAGTCGTTGCTGATTGGCGTTGCCAC
CTCCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTCGCGGCGATTAAATCTCGCGCCGATCAACTGGGTGCC
AGCGTGGTGGTGTCGATGGTAGAACGAAGCGGCGTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCG
CAACGCGTCAGTGGGCTGATCATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCA
CTAATGTTCCGGCGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTTCTCCCATGAAGAC
GGTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCGGGCCCATTAA
GTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATATCTCACTCGCAATCAAATTCAGCCGATAGC
GGAACGGGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAACAAACCATGCAAATGCTGAATGAGGGCATCGT
TCCCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTG
CGCGTTGGTGCGGATATCTCGGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAA
CCACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGGGCCA
GGCGGTGAAGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCACCCAATACGCA
AACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGG
CAGTGAGCGCAACGCAATTAATGTGAGTTAGCGCGAATTGATCTGGTTTGACAGCTTATCATCGACTGCACGG
TGCACCAATGCTTCTGGCGTCAGGCAGCCATCGGAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCAT
AATTCGTGTCGCTCAAGGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAAA
TATTCTGAAATGAGCTGTTGACAATTAATCATCCGGTCCGTATAATCTGTGGAATTGTGAGCGGATAACAATT
TCACACAGGAAACAGACCATGTCGTACTACCATCACCATCACCATCACGATTACGATATCCCAACGACCGAA
AACCTGTATTTTCAGGGCGCCGCTAGCCCCAGCGACTAAGCTTGATATCGAATTCCTGCAGCCCGGGGGATCC
CATGGTACGCGTGCTAGAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTG
TTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGCCCTAGACCTAGGGCGTTCGGCTGCGGCGA
GCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATG
TGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGC
CCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATAC
CAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGC
CTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTC
GCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCT
TGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAG
GTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGT
ATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCG
CTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTT
GATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGACTAGTGCT
TGGATTCTCACCAATAAAAAACGCCCGGCGGCAACCGAGCGTTCTGAACAAATCCAGATGGAGTTCTGAGGT
CATTACTGGATCTATCAACAGGAGTCCAAGCGAGCTCTCGAACCCCAGAGTCCCGCTCAGAAGAACTCGTCA
AGAAGGCGATAGAAGGCGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTCAGC
CCATTCGCCGCCAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGGTCCGCCACACCC
AGCCGGCCACAGTCGATGAATCCAGAAAAGCGGCCATTTTCCACCATGATATTCGGCAAGCAGGCATCGCCA
178 
 
TGGGTCACGACGAGATCCTCGCCGTCGGGCATGCGCGCCTTGAGCCTGGCGAACAGTTCGGCTGGCGCGAGC
CCCTGATGCTCTTCGTCCAGATCATCCTGATCGACAAGACCGGCTTCCATCCGAGTACGTGCTCGCTCGATGC
GATGTTTCGCTTGGTGGTCGAATGGGCAGGTAGCCGGATCAAGCGTATGCAGCCGCCGCATTGCATCAGCCAT
GATGGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCCGGCACTTCGCCCAATAGCAG
CCAGTCCCTTCCCGCTTCAGTGACAACGTCGAGCACAGCTGCGCAAGGAACGCCCGTCGTGGCCAGCCACGAT
AGCCGCGCTGCCTCGTCCTGCAGTTCATTCAGGGCACCGGACAGGTCGGTCTTGACAAAAAGAACCGGGCGC
CCCTGCGCTGACAGCCGGAACACGGCGGCATCAGAGCAGCCGATTGTCTGTTGTGCCCAGTCATAGCCGAAT
AGCCTCTCCACCCAAGCGGCCGGAGAACCTGCGTGCAATCCATCTTGTTCAATCATGCGAAACGATCCTCATC
CTGTCTCTTGATCAGATCTTGAT 
 
Sequence 4.5 pL-tetO promoter and PCR primers 
 
CTCGAGTCCCTATCAGTGATAGAGATTGACATCCCTATCAGTGATAGAGATACTGAGCACATCAGCAGGACGC
ACTGACCGAA TTCATTAAAGAGGAGAAAGGTACC 
pL-tetO-5 ATCGCTCGAGTCCCTATCAGTGATAGAGATTGACATCC 
pL-tetO-3 ACTCTGGGGCTAgcCATGGTACCTTTCTCCTCTTTAATG 
 
 
 
Sequence 4.6 GFP reporter cassette, PCR primer sequences and recombineering oligos  
 
GFP reporter cassette 
Start codon is in Blue and the ZFP binding site is highlighted in Yellow, GFP coding sequence is in 
Green.  
 
CGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAA
GAAGGAGATATACATATGCGGGGTTCTGCCGCAGTGGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGT
CGGGATCTGTACGACGATGACGATAAGGATCGATGGGGATCCGAATTCGCCACCATGGTGAGCAAGGGCGAG
GAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTG
TCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTG
CCCGTGCCCTGGCCCACCCTCGTGACCACCTTGACCTACGGCGTGCAGTGCTTCGCCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGA
CGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAA
GGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAGGT
CTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGACCCGCCACAACATCGAGGACGG
CAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAA
CCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGA
GTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAACTCGAGAAGCTTGATCCGGCT
GCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGG
GCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATCTGGCGT 
 
Primers for reporter integration  
 
5’-galk-gfp  atcaaaccgtgatcagttgtgcaccacgcgatgaccgtaaCGCGAAATTAATACGACTCAC 
3’-gfp-galk gtcgagctgattttcataatcggctgccatcacgcgaactACGCCAGATCCGGATATAGTTC 
 
Oligo designed for reporter modification  
The start codon position (ACG/ATG) is in Red, and the ZF/TALE binding site is highlighted in 
yellow and blue respectively. * is the phosphothioester bond.  
 
ZFP-ACG C*T*CTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACAAACGCGGGG
TTCTGCCGCAGTGGGTATGGCTAGCATGACTGGTGGA*C*A 
TAL-ACG-3bp-spacer TAATTTTGTTTAACTTTAAGAAGGAGATATACATACGAcGGGAAGAATCGTGA
GTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCG 
TAL-ACG-6bp-spacer TTTGTTTAACTTTAAGAAGGAGATATACATACGATTAGGGGAAGAATCGTGAG
TATGGCTAGCATGACTGGTGGACAGCAAATGGGT 
TAL-ACG-9bp-spacer TTTGTTTAACTTTAAGAAGGAGATATACATACGATTAGTCTGGGAAGAATCGT
GAGTATGGCTAGCATGACTGGTGGACAGCAAATGGGT 
179 
 
TAL-ACG-12bp-spacer ACTTTAAGAAGGAGATATACATACGATTAGTCTGTTGGGAAGAATCGTGAGT
ATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGA 
TAL-ACG-15bp-spacer TTGTTTAACTTTAAGAAGGAGATATACATACGATTAGTCTGTTTACGGGAAGA
ATCGTGAGTATGGCTAGCATGACTGGTGGACAGCAAA 
APOBEC1-ACG-ZFP C*T*C*TAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACAAACGAAAC
AACAAGCCGCAGTGGGTATGGCTAGCATGACTGGTG*G*A*C 
 
APOBEC3F-ACG-ZFP C*T*C*TAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATACGAAACA
ACAAGCCGCAGTGGGTATGGCTAGCATGACTGGTG*G*A*C 
 
APOBEC3G-ACG-ZFP C*T*C*TAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACACACGCAACA
ACAAGCCGCAGTGGGTATGGCTAGCATGACTGGTG*G*A*C 
 
APOBEC1-ACG-TAL C*C*TCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACAAACGATTA
GTCTGGGAAGAATCGTGAGTATGGCTAGCATGACTGG*T*G 
 
APOBEC3F-ACG-TAL C*C*TCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATACGATTAG
TCTGGGAAGAATCGTGAGTATGGCTAGCATGACTGG*T*G 
APOBEC3G-ACG-TAL C*T*CTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACACACGCTTAGT
CTGGGAAGAATCGTGAGTATGGCTAGCATGACTGG*T*G 
 
ATG-NNCCAA-ZFP A*A*TTTTGTTTAACTTTAAGAAGGAGATATACAAATGANNCAATTATTACTGC
CGCAGTGTGGTATGGCTAGCATGACTGGTGGACAGC*A*A 
 
Sequence 4.7 Zeocin resistance cassette and PCR primer sequences 
 
TTTGCTGGCCTTTTGCTCACATGTGTGCTGGGCCCAGCCGGCCAGATCTGAGCTCGCGGCCGCGATATCGCTA
GCTCGAGCACGTGTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACAAGGTGAGGAACT
AAACCATGGCCAAGTTGACCAGTGCCGTTCCGGTGCTCACCGCGCGCGACGTCGCCGGAGCGGTCGAGTTCTG
GACCGACCGGCTCGGGTTCTCCCGGGACTTCGTGGAGGACGACTTCGCCGGTGTGGTCCGGGACGACGTGAC
CCTGTTCATCAGCGCGGTCCAGGACCAGGTGGTGCCGGACAACACCCTGGCCTGGGTGTGGGTGCGCGGCCT
GGACGAGCTGTACGCCGAGTGGTCGGAGGTCGTGTCCACGAACTTCCGGGACGCCTCCGGGCCGGCCATGAC
CGAGATCGGCGAGCAGCCGTGGGGGCGGGAGTTCGCCCTGCGCGACCCGGCCGGCAACTGCGTGCACTTCGT
GGCCGAGGAGCAGGACTGAGAATTCCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCACTG
GCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCC
CTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG
CGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATATGGTGCACTCT
CAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGC 
 
5’ung-zeo  ATGGCTAACGAATTAACCTGGCATGACGTGCTGGCTGAAGCTTTTGCTGGCCTTT
TGCTC 
 
3’zeo-ung TTACTCACTCTCTGCCGGTAATACTGGCATCCAGTCAATCGTCAGCGGGTGTTGG
CGGGT 
 
 
Sequence 4.8 GFP and GAPDH amplification and sequence primer sequences  
 
Amplification-GFP-5 Cgtttgcgcgcagtcagcgatatccattttcgcgaatccg 
Ampliciation-GFP-3 CGCAGTTACAGCCTACAAACTGGTTTTCTGCTTC 
Sequencing-GFP-f Atgagtctgaaagaaaaaacacaatc 
Sequencing-GFP-r TGACCGTTAAGCGCGATTTG 
Amplification-GAPDH-5 Tatttacagtcttaatgagtgaaagaggcggagg 
Amplification-GAPDH-3 Gccatcctggtctaagcttggaaagg 
Sequencing-GAPDH-f Aggcggaggttttttcctccgcctgtgcgcg 
Sequencing-GAPDH-r Atcaattttcatccgaacgttcc 
 
 
Sequence 4.9 Next generation adaptor and PCR primer sequences 
180 
 
 
Adaptor1 PE-A1-F TACACTCTTTCCCTACACGACGCTCTTCCGATCTac*T 
PE-A1-R /5Phos/gtAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
Adaptor2 PE-A2-F TACACTCTTTCCCTACACGACGCTCTTCCGATCTtg*T 
PE-A2-R /5Phos/caAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
Adaptor3 PE-A3-F TACACTCTTTCCCTACACGACGCTCTTCCGATCT tc*T 
PE-A3-R /5Phos/gaAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
Adaptor4 PE-A4-F TACACTCTTTCCCTACACGACGCTCTTCCGATCT ga*T 
PE-A4-R /5Phos/tcAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
Adaptor5 PE-A5-F TACACTCTTTCCCTACACGACGCTCTTCCGATCTag*T 
PE-A5-R /5Phos/ctAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
Adaptor6 PE-A6-F TACACTCTTTCCCTACACGACGCTCTTCCGATCTgt*T 
PE-A6-R /5Phos/acAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
Adaptor7 PE-A7-F TACACTCTTTCCCTACACGACGCTCTTCCGATCT ct*T 
PE-A7-R /5Phos/agAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
Adaptor8 PE-A8-F TACACTCTTTCCCTACACGACGCTCTTCCGATCT ca*T 
PE-A8-R /5Phos/tgAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG 
PCR primers PE-PCR-1 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACG
AC 
PE-PCR-2 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCT
GAACC 
 
4. Sequence 4.10 Human GFP-ACG reporter sequence and genotyping primers  
The pEF-1α promoter sequence is in Blue, the GFP ORF is in Green and the IRES is 
highlighted in Gray and the mcherry ORF is in Red. Of note, the barcode sequence is 
highlighted in Yellow.  
 
TGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTAGGTCTTGAAAGGAGT
GGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGG
GGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCT
CCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAAC
GGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCC
CTTGCGTGCCTTGAATTACTTCCACTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGT
GGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTG
GGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAA
ATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACT
GGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGG
GGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGC
CTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAA
AGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGT
GAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGG
181 
 
CGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTAT
GCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCT
TGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTC
CATTTCAGGTGTCGTGACGTACGHHHHHHHHTCCAGTAGCAGACCTACGGCCACCACGCGGGGTTCTGCCGC
AGTGGATCGATGGGGATCCGAATTCGCCACCGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCAT
CCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCAC
CTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACC
ACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCG
CCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG
AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCA
ACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGA
ACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCT
GAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCT
CGGCATGGACGAGCTGTACAAGTAAGGCGCGCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGG
CCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTG
GCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTC
GTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGG
AACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCA
CAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACA
AGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTAC
ATGTGTTTAGTCGAGGTTAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACAC
GATGATAATATGGCCACAACCATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATG
CGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGC
CCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGACATC
CTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGC
TGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCC
AGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGG
CCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCT
GAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGGTCAAGACCACCT
ACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAACATCAAGTTGGACATCACCTCCCACA
ACGAGGACTACACCATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATGGACGAGC
TGTACAAGTAA 
 
 
5. Sequence 4.11 UGI encoding sequence and primers  
UGI encoding sequence: NLS is highlighted in Yellow.  
ATGACAAATCTGAGCGATATTATAGAAAAAGAGACTGGTAAACAGCTCGTGATTCAAGAGAGTATCCTTATG
CTGCCTGAGGAAGTGGAAGAAGTTATCGGCAATAAACCCGAGTCCGACATTCTGGTGCACACGGCGTATGAT
GAAAGCACCGACGAAAATGTGATGCTGCTTACTAGCGACGCTCCAGAGTACAAGCCATGGGCCCTGGTGATT
CAAGACAGTAACGGAGAGAATAAGATCAAAATGCTCTCCGGACTCAGATCTCGAGCTGATCCAAAAAAGAAG
AGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTA 
 
BsiWI-UGI TAGGGGCGTACGGCCACCATGACAAATCTGAGCGATATTATA 
XhoI-UGI TCAGCTCGAGATCTGAGTCCGGAGAGCATTTTGATCTTATTCTC 
 
 
 
6. Sequence 4.12 ZF-AID-NLS/ZFP-AIDΔNES sequences and primers 
ZF-AID sequence: The NLS is highlighted in Yellow. ZF is in Red, the linker is in Green and 
the deaminase is in Blue. Of note, the nucleus export signal (NES) highlighted in Gray at the 
C-terminus of the deaminase was missing in ZF- AIDΔNES.  
 
 
ATGGCTAGCCCCAGAGTGAGAACCGGTTCTAAGACACCTCCCCACGAGAGGCCTTTTCAGTGTAGAATTTGTA
TGCGTAATTTTTCTAGGTCCGATGTGCTGGCCAATCACACAAGGACTCACACTGGTGAAAAGCCCTTCCAATG
TAGAATTTGTATGCGCAATTTTTCTCAATCTTCTACTCTGACTAGACATCTGAGGACCCACACAGGCGAAAAG
CCTTTCCAGTGCAGAATTTGTATGAGAAATTTTTCTGAAAGACAGGGTCTGAAAAGACATCTGAAGACACATA
182 
 
CAGGTGAAAAAGGATCCTCTGGTGGTGGTCTGGGTTCTACTGACAGCCTCTTGATGAACCGGAGGAAGTTTCT
TTACCAATTCAAAAATGTCCGCTGGGCTAAGGGTCGGCGTGAGACCTACCTGTGCTACGTAGTGAAGAGGCGT
GACAGTGCTACATCCTTTTCACTGGACTTTGGTTATCTTCGCAATAAGAACGGCTGCCACGTGGAATTGCTCTT
CCTCCGCTACATCTCGGACTGGGACCTAGACCCTGGCCGCTGCTACCGCGTCACCTGGTTCACCTCCTGGAGC
CCCTGCTACGACTGTGCCCGACATGTGGCCGACTTTCTGCGAGGGAACCCCAACCTCAGTCTGAGGATCTTCA
CCGCGCGCCTCTACTTCTGTGAGGACCGCAAGGCTGAGCCCGAGGGGCTGCGGCGGCTGCACCGCGCCGGGG
TGCAAATAGCCATCATGACCTTCAAAGATTATTTTTACTGCTGGAATACTTTTGTAGAAAACCACGAAAGAAC
TTTCAAAGCCTGGGAAGGGCTGCATGAAAATTCAGTTCGTCTCTCCAGACAGCTTCGGCGCATCCTTTTGCCCC
TGTATGAGGTTGATGACTTACGAGACGCATTTCGTACTTTGGGACTTTCCGGACTCAGATCTCGAGCTGATCCA
AAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTA 
 
 
BsiWI-ZF ATAGGGGCGTACGGCCACCATGGCTAGCCCCAGAGTGAGAACCGGT 
BsrGI-AID 
TACTTGTACATTATACCTTTCTCTTCTTTTTTGGATCTACCTTTCTCTTCTTTTTTG
GATCTACCTTTCTCTTCTTTTTTGGATCAGCTCGAGATCTGAGTCCGGAAAGTCC
CAAAGTACGAAATGCGTCTCGTAA 
BsrG1-ΔAID 
CTTACTTGTACATTATACCTTTCTCTTCTTTTTTGGATCTACCTTTCTCTTCTTTTT
TGGATCTACCTTTCTCTTCTTTTTTGGATCAGCTCGAGATCTGAGTCCGGACAGG
GGCAAAAGGATGCGCCGAAG 
 
 
 
7. Sequence 4.13 ZFGFPIN- AID
ΔNES s/ZFGFPINNs sequence and primers 
The SV40 NLS is highlighted in Yellow. ZFGFPIN (ZFGFPINL/ZFGFPINR) modules are in Red, 
nuclease/deaminase with the linkers is in Blue.  
 
ZFGFPINL- AID
ΔNES 
ATGGGACCTAAGAAAAAGAGGAAGGTGGCGGCCGCTGACTACAAGGATGACGACGATAAATCTAGACCCGG
GGAGCGCCCCTTCCAGTGTCGCATTTGCATGCGGAACTTTTCGCAGGACTCCTCCCTGCGGCGGCATACCCGT
ACTCATACCGGTGAAAAACCGTTTCAGTGTCGGATCTGTATGCGAAATTTCTCCCGGCAGGAGCACCTGGTGC
GGCATCTACGTACGCACACCGGCGAGAAGCCATTCCAATGCCGAATATGCATGCGCAACTTCAGTGACCCCA
CCTCCCTGAACCGGCATCTGAAGACACATACAGGTGAAAAAGGATCCTCTGGTGGTGGACTGGGGTCGACTG
ACAGCCTCTTGATGAACCGGAGGAAGTTTCTTTACCAATTCAAAAATGTCCGCTGGGCTAAGGGTCGGCGTGA
GACCTACCTGTGCTACGTAGTGAAGAGGCGTGACAGTGCTACATCCTTTTCACTGGACTTTGGTTATCTTCGCA
ATAAGAACGGCTGCCACGTGGAATTGCTCTTCCTCCGCTACATCTCGGACTGGGACCTAGACCCTGGCCGCTG
CTACCGCGTCACCTGGTTCACCTCCTGGAGCCCCTGCTACGACTGTGCCCGACATGTGGCCGACTTTCTGCGA
GGGAACCCCAACCTCAGTCTGAGGATCTTCACCGCGCGCCTCTACTTCTGTGAGGACCGCAAGGCTGAGCCCG
AGGGGCTGCGGCGGCTGCACCGCGCCGGGGTGCAAATAGCCATCATGACCTTCAAAGATTATTTTTACTGCTG
GAATACTTTTGTAGAAAACCACGAAAGAACTTTCAAAGCCTGGGAAGGGCTGCATGAAAATTCAGTTCGTCTC
TCCAGACAGCTTCGGCGCATCCTTTTGCCCCTGTATGAGGTTGAT 
 
ZFGFPINR- AID
ΔNES 
ATGGGACCTAAGAAAAAGAGGAAGGTGGCGGCCGCTGACTACAAGGATGACGACGATAAATCTAGACCCGG
GGAGCGCCCCTTCCAGTGTCGCATTTGCATGCGGAACTTTTCGTCCCAGACCCAGCTGGTGCGGCATACCCGT
ACTCATACCGGTGAAAAACCGTTTCAGTGTCGGATCTGTATGCGAAATTTCTCCCAGTCCACCACCCTGAAGC
GGCATCTACGTACGCACACCGGCGAGAAGCCATTCCAATGCCGAATATGCATGCGCAACTTCAGTCAGCGGA
ACAACCTGGGCCGGCATCTGAAGACACATACAGGTGAAAAAGGATCCTCTGGTGGTGGACTGGGGTCGACTG
ACAGCCTCTTGATGAACCGGAGGAAGTTTCTTTACCAATTCAAAAATGTCCGCTGGGCTAAGGGTCGGCGTGA
GACCTACCTGTGCTACGTAGTGAAGAGGCGTGACAGTGCTACATCCTTTTCACTGGACTTTGGTTATCTTCGCA
ATAAGAACGGCTGCCACGTGGAATTGCTCTTCCTCCGCTACATCTCGGACTGGGACCTAGACCCTGGCCGCTG
CTACCGCGTCACCTGGTTCACCTCCTGGAGCCCCTGCTACGACTGTGCCCGACATGTGGCCGACTTTCTGCGA
GGGAACCCCAACCTCAGTCTGAGGATCTTCACCGCGCGCCTCTACTTCTGTGAGGACCGCAAGGCTGAGCCCG
AGGGGCTGCGGCGGCTGCACCGCGCCGGGGTGCAAATAGCCATCATGACCTTCAAAGATTATTTTTACTGCTG
GAATACTTTTGTAGAAAACCACGAAAGAACTTTCAAAGCCTGGGAAGGGCTGCATGAAAATTCAGTTCGTCTC
TCCAGACAGCTTCGGCGCATCCTTTTGCCCCTGTATGAGGTTGAT 
 
 
183 
 
ZFGFPINL-N 
ATGGGACCTAAGAAAAAGAGGAAGGTGGCGGCCGCTGACTACAAGGATGACGACGATAAATCTAGACCCGG
GGAGCGCCCCTTCCAGTGTCGCATTTGCATGCGGAACTTTTCGCAGGACTCCTCCCTGCGGCGGCATACCCGT
ACTCATACCGGTGAAAAACCGTTTCAGTGTCGGATCTGTATGCGAAATTTCTCCCGGCAGGAGCACCTGGTGC
GGCATCTACGTACGCACACCGGCGAGAAGCCATTCCAATGCCGAATATGCATGCGCAACTTCAGTGACCCCA
CCTCCCTGAACCGGCACCTAAAAACCCACCTGAGGGGATCCCAACTAGTCAAAAGTGAACTGGAGGAGAAGA
AATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTGAATTAATTGAAATTGCCAGAAATTC
CACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAATTTTTTATGAAAGTTTATGGATATAGAGGTAAACAT
TTGGGTGGATCAAGGAAACCGGACGGAGCAATTTATACTGTCGGATCTCCTATTGATTACGGTGTGATCGTGG
ATACTAAAGCTTATAGCGGAGGTTATAATCTGCCAATTGGCCAAGCAGATGAAATGCAACGATATGTCGAAG
AAAATCAAACACGAAACAAACATATCAACCCTAATGAATGGTGGAAAGTCTATCCATCTTCTGTAACGGAATT
TAAGTTTTTATTTGTGAGTGGTCACTTTAAAGGAAACTACAAAGCTCAGCTTACACGATTAAATCATATCACTA
ATTGTAATGGAGCTGTTCTTAGTGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACATTAAC
CTTAGAGGAAGTGAGACGGAAATTTAATAACGGCGAGATAAACTTT 
 
ZFGFPINR-N 
ATGGGACCTAAGAAAAAGAGGAAGGTGGCGGCCGCTGACTACAAGGATGACGACGATAAATCTAGACCCGG
GGAGCGCCCCTTCCAGTGTCGCATTTGCATGCGGAACTTTTCGTCCCAGACCCAGCTGGTGCGGCATACCCGT
ACTCATACCGGTGAAAAACCGTTTCAGTGTCGGATCTGTATGCGAAATTTCTCCCAGTCCACCACCCTGAAGC
GGCATCTACGTACGCACACCGGCGAGAAGCCATTCCAATGCCGAATATGCATGCGCAACTTCAGTCAGCGGA
ACAACCTGGGCCGGCACCTAAAAACCCACCTGAGGGGATCCCAACTAGTCAAAAGTGAACTGGAGGAGAAG
AAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTGAATTAATTGAAATTGCCAGAAATT
CCACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAATTTTTTATGAAAGTTTATGGATATAGAGGTAAACA
TTTGGGTGGATCAAGGAAACCGGACGGAGCAATTTATACTGTCGGATCTCCTATTGATTACGGTGTGATCGTG
GATACTAAAGCTTATAGCGGAGGTTATAATCTGCCAATTGGCCAAGCAGATGAAATGCAACGATATGTCGAA
GAAAATCAAACACGAAACAAACATATCAACCCTAATGAATGGTGGAAAGTCTATCCATCTTCTGTAACGGAA
TTTAAGTTTTTATTTGTGAGTGGTCACTTTAAAGGAAACTACAAAGCTCAGCTTACACGATTAAATCATATCAC
TAATTGTAATGGAGCTGTTCTTAGTGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACATTA
ACCTTAGAGGAAGTGAGACGGAAATTTAATAACGGCGAGATAAACTTT 
 
BsiWI-ZFL/R 
TGGCAAATATTCTGAAATGAGCTGTTGACAATTAATCATCCGGTCCGTATAATCTGTG
GAATTGTGAGCGGATAACAATTTCACACAAAGAGGAGAAAGGTACCATGTCGCGGA
CCCGGCTCCC 
BamHI-ZFL/R 
AGAGGATCCTTTTTCACCTGTATGTGTCTTCAGATGCCGGCCCAGGTTGTTCCGCTGA
C 
NheI-ZFL/R 
TGGCTAGCACCATGGGACCTAAGAAAAAGAGGAAGGTGGCGGCCGCTGACTACAAG
GATGACGACGATAAATCTAGACCCGGGGAGCGCCCCTTCCAGTGTCG 
ApaI-ZFL/R CTTACCTTCGAAGGGCCCTTAATCAACCTCATAC 
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Summary 
Patient specific iPSCs promise to offer new insights into human disease pathogenesis. 
However, significant hurdles remain in developing disease models that replicate disease 
pathophysiology. Here, we demonstrated that we can use the combination of patient derived 
hiPSCs  and genetically engineered iPSCs to model the mitochondrial cardiomyopathy of Barth 
syndrome (BTHS). Using Cas9, we generated isogenic iPSCs carrying the mutation identified in 
BTHS patients. CM derived from patients’  and engineered hiPSC recapitulated characteristic 
disease metabolic abnormalities. BTHS iPSC-CMs did not assemble myofibers normally, and 
engineered BTHS “heart on chip” tissues contracted poorly. Replacement of the defective gene 
product, or supplementation with a precursor to a depleted metabolite, corrected metabolic 
abnormalities, myofibrillogenesis, and contractile activity of BTHS iPSC-CMs. These data 
indicate that the combination of patient-specific iPSCs and genetically engineered iPSCs with 
organ-on-chip models form an effective platform to reveal the cellular etiology of disease and to 
identify potential therapeutic strategies. 
 
Introduction 
Research into the pathogenesis of cardiomyopathy has historically been hindered by the 
lack of suitable model systems. Cardiomyocyte differentiation of patient-derived induced 
pluripotent stem cells (iPSCs) offers one promising avenue to surmount this barrier, and reports 
of iPSC modeling of cardiomyopathy have begun to emerge (1–3). However, realization of this 
promise will require approaches to overcome genetic heterogeneity of patient-derived iPSC lines 
and to assay contractile function of tissue constructs assembled from iPSC-derived 
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cardiomyocytes (iPSC-CMs). Here, we combined genome-edited iPSCs, modified RNA 
(modRNA) (4), and “heart on a chip” (5) technologies to replicate the pathophysiology of Barth 
syndrome cardiomyopathy in tissue constructs. Furthermore, we use the bioengineered tissue 
constructs to model the genetic and metabolite-induced correction of the Barth disease 
phenotype. 
 
Results 
An iPSC-CM model of Barth syndrome 
Barth syndrome is an X-linked cardiac and skeletal mitochondrial myopathy caused by 
mutation of the gene Tafazzin (TAZ) (6), an acyltransferase responsible for normal acylation of 
cardiolipin (CL), the major phospholipid of the mitochondrial inner membrane (7). The 
pathogenesis of cardiomyopathy in Barth syndrome is poorly understood. We generated iPSCs 
from two unrelated individuals with Barth Syndrome under institutionally approved protocols 
(Supplemental Materials). Two lines, BTH-H and BTH-C, reprogrammed using retroviral or 
modified RNA approaches (8), respectively. As controls, we used three normal iPSC lines, 
generated by retroviral (2) or modified RNA (1) reprogramming. We next differentiated the 
iPSCs into iPSC-derived cardiomyocytes (iPSC-CMs) using an established protocol (9)  
Having established the cell lines, we investigated the phenotype of BTHS iPSC-CMs. 
BTHS is characterized by depletion of mature CL and accumulation of an immature form, 
monolysocardiolipin (MLCL) (10, 11). This hallmark of BTHS was recapitulated in the patient-
derived iPSC-CMs, in which phospholipid mass spectrometry showed that the ratio of MLCL to 
CL in BTHS iPSC-CMs exceeded 0.3, the clinically used diagnostic threshold
 
(11) (Figure 5_1 
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A-B). To determine if energy metabolism was perturbed in BTHS iPSC-CMs, we measured 
cellular ATP levels in iPSC-CMs cultured in galactose, which does not support glycolysis. 
BTHS iPSC-CM ATP levels were significantly lower than controls (Figure 5_1 C). Consistent 
with cellular energy deprivation, AMP-dependent kinase (AMPK) was markedly activated in 
BTHS iPSC-CMs, as demonstrated by immunoblotting with activation-state-specific antibodies 
(Figure 5_1 D).  
We went further to investigate BTHS iPSC-CM metabolic activity. Despite lower basal 
ATP levels, BTHS iPSC-CMs had a higher basal and F1F0 ATP synthase-dependent oxygen 
consumption rate (OCR) than control iPSC-CMs (Figure 5_1 E-G), indicative of inefficient 
mitochondrial ATP generation. Oligomycin-independent oxygen consumption (“H+ leak”) was 
also increased in BTHS iPSC-CMs (Figure 5_1H), while maximal electron transport chain 
activity (“Respiratory Capacity”) was severely impaired (Figure 5_1I). As a result of increased 
basal and depressed maximal OCR, BTHS iPSC-CMs had markedly decreased respiratory 
reserve (Figure 5_1 J).  
Decreased ATP levels in the setting of increased F1F0 ATP synthase-dependent oxygen 
consumption suggested that CL abnormalities impaired F1F0 ATP synthase activity. We tested 
this hypothesis by measuring F1F0 ATP synthase specific activity by selective complex 
immunocapture followed by assays of complex quantity and activity. While expression was 
comparable between BTHS and control iPSC-CMs, activity was lower in BTHS iPSC-CMs 
(Figure 5_1K). Collectively, the data demonstrate that TAZ deficiency and consequent CL 
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Figure 5_1. Mitochondrial abnormalities in BTHS iCMs.  
(A) Mass spectrum of control and BTH-H CL, showing depletion of mature CL and accumulation of its immature 
form (MLCL) in BTHS iPSC-CMs. 
(B) Comparison of MLCL/CL ratio in BTH-H, BTH-C, and control iPSC-CMs. The dashed line indicates the 
clinical 
diagnostic threshold for BTHS. 
(C) ATP levels in BTHS and control iPSCCMs cultured in galactose. n=3. 
(D) AMPK activation in BTHS iPSC-CMs cultured in galactose. Activated and total AMPK were measured by 
quantitative western blotting. 
(E-G) Abnormal BTH-H iPSC-CM mitochondrial function. Function was measured using cellular oxygen 
consumption rate (OCR), normalized to total protein. Oligo, oligomycin. FCCP, carbonyl cyanide-4- 
(trifluoromethoxy)phenylhydrazone. A/R, antimycin plus rotenone. Measures of mitochondrial function (defined in 
Fig. S4) were quantitatively compared between control and BTH-H iCMs. n=3. *, P<0.05. 
(K) Measurement of F1F0 ATP synthase specific activity. Total activity was normalized to the amount of F1F0 ATP 
synthase, measured by ELISA. n=3. 
(L) BTHS iPSC-CM and control ATP levels were comparable when cultured in glucose. n=3.  
A B C 
D E 
F 
G H I J 
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abnormalities decrease basal mitochondrial ATP generating efficiency by impairing F1F0 ATP 
synthase activity and by reducing peak mitochondrial electron transport chain function. 
Measurement of cardiac energy stores by nuclear magnetic resonance spectroscopy in a 
Barth syndrome patient with cardiomyopathy indicated that myopathy can occur without 
measurable energy depletion in at least some BTHS patients, suggesting that recruitment of 
compensatory metabolic pathways can normalize cardiac energy levels. We tested this 
hypothesis by culturing BTHS iPSC-CMs in glucose, which supports both glycolysis and 
oxidative phosphorylation. Interestingly, glucose normalized BTHS iCM ATP levels and 
reversed the elevated basal oxygen consumption rate (Figure 5_1L). These observations indicate 
that glucose restores ATP levels through alternative metabolic pathways, thereby reducing basal 
F1F0 ATPase activity, but does not correct underlying mitochondrial defects in the electron 
transport chain. 
 
Using engineered isogenic CM to test whether TAZ mutation causes BTHS phenotypes 
Because BTHS patient-derived and control iPSCs had numerous genetic differences other 
than TAZ mutation, we took two independent approaches to further establish the causative role 
of TAZ mutation in abnormal CL biogenesis and mitochondrial function.  
First, we sought to test whether TAZ mutation is sufficient for the phenotype by re-
introducing WT TAZ into BTHS iPSC-CMs. To this end, we synthesized TAZ mRNA, 
substituting 5-methylcytidine for cytidine, and pseudouridine for uridine. This modified RNA 
(“modRNA”) has minimal toxicity (4, 8) and efficiently transfects cardiomyocytes (Figure 
5_2A). TAZ modRNA likewise transfected iPSC-CMs and TAZ protein localized to 
mitochondrial function in BTHS iPSC-CMs, although maximal respiratory capacity was rescued 
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incompletely (Figure 5_2 B-E). These results indicate that TAZ restoration rapidly corrects the 
BTHS mitochondrial phenotype. 
Second, we used Cas9-mediated scarless genome editing (12) to mutate TAZ in the 
control human line PGP1-iPSC, yielding three iPSC lines that are isogenic except for the 
sequence at TAZ exon 6 (Figure 5_3 A-D). PGP1-BTHH contains the TAZ frameshift mutation 
from the BTH-H line (1 nt deletion), while PGP1-NHEJ contains a distinct frameshift mutation 
at the same site (14 nt insertion). PGP1-NT is a control line handled in parallel to PGP1-BTHH 
and PGP1-NHEJ, but without a TAZ mutation. We verified the pluripotency of the cell line ( 
Figure 5_3 E-G) and differentiated into iPSC-CMs.  iPSC-CMs derived from these isogenic TAZ 
mutant lines fully recapitulated the cardiolipin, mitochondrial, and ATP deficits that we observed 
in patient-derived iPSCs and in the neonatal rat TAZ knockdown model (Figure 5_4 A-D). 
Together, these data indicate that TAZ mutation alone is sufficient to cause these phenotypes in a 
control genetic background. 
 
Abnormal sarcomerogenesis in BTHS iPSC-CMs 
Mitochondria regulate cardiomyocyte maturation (13), a hallmark of which is assembly 
of organized arrays of sarcomeres. To test whether TAZ deficiency causes defective sarcomeres 
arrangmetn, we engineered iPSC-CM shape by seeding the cells on micropatterned fibronectin 
rectangles designed to mimic the dimensions of human adult cardiomyocytes (14), with 
length:width ratios of approximately 7:1 (95 µm X 13 µm). While sarcomeres in control iPSC-
CMs extended serially across the entire length of the cell, sarcomeres in patient-derived BTH-H 
iPSC-CMs were intermittent and sparse (Figure 5_5 A). In BTH-H iPSC-CMs, sarcomeric 
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 Figure 5_2. TAZ deficiency is necessary and sufficient to cause the iPSC-CM metabolic phenotype. 
(A) ModRNA encoding FLAG-tagged TAZ was transfected into iCMs. Mitochondria were labeled with virally 
delivered RFP with a mitochondrial localization sequence. FLAG co-localized with RFP. Bar = 10 μm.  
(B) TAZ modRNA restored cardiolipin biogenesis. BTH-H or control iCMs were transfected with the indicated 
modRNA and cardiolipin composition was measured by mass spectroscopy. 
(C) Mitochondrial function testing showed that TAZ modRNA normalized mitochondrial function in BTHS iCMs.  
(D)Quantitation of mitochondrial functional parameters from c. n=3.  
(E) F1F0 ATP Synthase specific activity. n=6. *, P<0.05 compared to each other group 
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Figure 5_3 Generation and characterization of isogentic iPSCs through Cas9-mediated genome editing 
(A) Schematic of modified genome editing approach 
(B) Targeting strategy 
(C) Sequences of targeted region of exon 6 in clones used in the study 
(D) PiggyBac-mediated removal of Cas9 expression cassette. Clones were genotyped using Cas9 primers 
(E) Expression of the pluripotency marker in genome-edited clones 
(F) Expression of the pluripotency marker Nanog in genome-edited clones 
(G) Formation of tissues from all three germ layers in teratoma assays from two of the clones used in this study 
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Figure 5_4 Functional analysis of isogentic iPSCs 
(A) Cardiolipin  maturation abnormalities in CM dereived from PGP1 carrrying TAZ mutation but not isogenic 
control iPSC-CMs 
(B)  Decreased basal ATP level of TAZ mutant compared to isogenic control iPSC-CM culture in galactose media 
(C)  Decrased F1F0 ATPase specificity activity in TAZ mutant compared to isogenic control iPSC-CMs 
(D) Abnormalities of mitochondrial function in TAZ mutant iPSC-CMs. Abnormalities were rescued by TAZ 
modRNA transfection.  
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Figure 5_5 Reduced sarcomere organization and contractile function in BTHS iPSC-CMs 
(A) Representative images of a-actinin-stained iPSC-CMs cultured on micropatterned fibronectin rectangles with 
length:width ratios of 7:1. an unbiased metric of sacromeric organization, showed significantly impared myofibrillar 
assembly in BTHS iCMs, which was rescued by TAZ modRNA but not glucose culture. Bar= 10 m 
(B) Representative images of a-actinin-stained isogenetic hiPSCs cultured on micropatterned fibronectin rectangles 
with length:width ratios of 7:1. an unbiased metric of sacromeric organization, showed significantly impared 
myofibrillar assembly in BTHS iCMs, which was rescued by TAZ modRNA but not glucose culture. Bar= 10 m 
(C) iPSC-CM engineered tissue was cultured on micropatterned muscular thin film (MTF) substrate. Cardiomyocyte 
force generation reduces the radius of curvature of the construct while contracting from diastole to peak systole.  
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organization was lower compared to control and was recovered to by TAZ modRNA treatment 
(Figure 5_5 A). Although glucose culture normalized ATP levels to a comparable degree 
compared to TAZ modRNA, glucose culture did not normalize sarcomere formation (Figure 5_5 
A). The defects in sarcomere assembly were recapitulated in genome edited PGP1-BTHH and 
PGP1-NHEJ iPSC-CMs compared to isogenic PGP1-NT controls (Figure 5_5B), confirming the 
causative role of the BTH-H exon 6 frameshift TAZ mutation. These data suggest that 
myofibrillogenesis and cell size are sensitive to mitochondrial function independent of whole cell 
ATP levels. Interestingly, BTH-C iPSC-CMs exhibited sarcomere organization that was not 
significantly different from controls (Figure 5_5 C). This phenotypic heterogeneity may be due 
to the specific BTH-C missense mutation, or it may be due other variables between cell lines. 
Further use of genome-edited cell lines will be necessary to better understand genotype-
phenotype relationships in this disease. 
 
Myocardial constructs model BTHS and its genetic rescue 
We asked if we could replicate the pathophysiology of Barth Syndrome in an in vitro 
model of engineered myocardium and demonstrate the efficacy of the TAZ modRNA treatment 
on the disease. We used our “heart on a chip” assay (5) to quantitatively measure contractility of 
myocardial tissue assembled from BTHS or control iPSC-CMs. MACS-selected iPSC-CMs were 
seeded onto thin elastomers supported by glass coverslips (15, 16). Over a five day culture 
period, the iPSC-CMs self-organized into laminar, anisotropic myocardium. Pre-cut muscular 
thin films (MTF) were then peeled from the glass substrate, allowing them to contract away from 
the plane of the coverslip (Figure 5_6 A). From the radius of curvature of each MTF measured  
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Figure 5_6 Depressed force generation by BTHS myocardial tissue constructs  
(A) iPSC-CMs seeded onto thin elastomers with linearly patterned fibronectin formed selforganizing anisotropic 
myocardial tissues. Cardiomyocyte force generation reduces the radius of curvature of the construct while 
contracting from diastole to peak systole. Red lines indicate automated tracking of muscular thin film (MTF) 
projected onto the horizontal plane.  
(B) and (C) Twitch stress and peak systolic stress generated by MTFs from patient-derived BTH-H and control 
iPSC-CMs (b), genome-edited TAZ frameshift and control iPSC-CMs (c), Statistical comparisons by Kruskal-
Wallis One Way ANOVA on ranks and Dunn’s post-hoc test. Sample size is indicated by number inside each bar.   
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throughout the myocardial tissue contraction cycle, we calculated the diastolic and peak systolic 
stresses using a modification of Stoney’s equation (5, 15, 17). Patient-derived BTH-H iPSC-CM 
tissues in galactose were significantly weaker (Figure 5_6 B) over the same stimulation 
frequency range, indicating that BTHS engineered myocardial tissue recapitulates the BTHS 
myopathic phenotype.  
Next we asked if the engineered myocardial tissue constructs effectively model diseae 
correction. We reintroduced TAZ by treating with modRNA for 5 days, then measured 
myocardial tissue construct function. Treatment of BTH-H iPSC-CMs (Figure 5_6 B) with TAZ 
modRNA restored contractile function to levels comparable to controls, further confirming that 
this phenotype was revsible and due to TAZ mutation. 
We assessed the contribution of whole cell ATP to contractile dysfunction by culturing 
engineered iPSC-CM tissues on MTF substrates in glucose, which increased cellular ATP levels 
to a level comparable to TAZ modRNA. In contrast to TAZ modRNA rescue, glucose culture 
alone did not restore BTH-H iPSC-CM force generation at any tested stimulation frequency 
(Figure 5_6 B). Together, these data show that BTH-H iPSC-CMs have a severe defect in 
contractility that occurred regardless of the energetic substrate. 
To further confirm these results, we generated BTHS and isogenic control myocardial 
tissue constructs using the genome-edited iPSCs. Contractile function of the mock-manipulated 
PGP1-NT iPSC-CM myocardial constructs was equivalent to the parental PGP1 cell line, while 
TAZ disruption in both PGP1-BTHH and PGP1-NHEJ caused severe loss of force generation 
(Figure 5_6 C). Reintroduction of TAZ by modRNA restored contractile force production 
(Figure 5_6C).  
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Together, these results indicate that TAZ mutation is sufficient to cause a myopathic 
phenotype in myocardial tissue constructs, and that this phenotype is readily reversible upon 
TAZ replacement. 
 
Discussion 
One obstacle to wider use of iPSC disease models has been the genetic and epigenetic 
variation between cell lines, which introduces confounding variables that can be difficult to 
control. We show that Cas9-mediated genome editing is an excellent strategy to isolate a 
mutation of interest and show that it is sufficent to cause a disease phenotype. Gene replacement 
using modified RNA technology is another highly portable approach that demonstrates the acute 
requirement of a gene mutation for a disease phenotype within a given cell line.  
Our metabolic and functional analysis of human Barth syndrome cardiomyocytes 
elucidated mitochondrial functional impairment caused by mature CL depletion. Our data show 
that the contracile deficit of BTHS cardiomyocytes is not a result of global cellular energy 
depletion. Although subtle defects in local ATP concentrations cannot be excluded, these data 
support the notion that cardiomyopathy in BTHS results from an ATP-independent role of 
mitochondria in sarcomere assembly and contractile activity. The TAZ frameshift mutation 
hindered both sarcomere assembly, and likely this contributed to impaired systolic and twitch 
stress in tissue constructs assembled from these iPSC-CMs. On the other hand, the TAZ point 
mutation that we studied severely impaired twitch stress but not sarcomere assembly or systolic 
stress, indicating additional mechanisms linking TAZ mutation to impaired contracile force 
generation. These observations have implications for more common diseases such as ischemic 
and diabetic cardiomyopathy, since mature cardiolipin depletion also occurs in these conditions.  
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In conclusion, we show that the combination of tissue engineering, induced pluripotency, 
and genome editing models human heart disease and its genetic and pharmacological correction. 
Prior studies on diseased human iPSC-CMs characterized the properties of individual cells, but 
cardiomyocytes function as components of a highly integrated tissue. In addition, single cell 
contraction assays are complicated by substantial cell-to-cell variation. Using tissue engineering 
approaches, we built control and diseased muscular thin film myocardial tissue constructs and 
showed that these tissues model the cardiomyopathic phenotype seen in patients. Furthermore, 
we envision that the disease-specific “heart-on-chip” assay would be useful for preclinical 
assessment of candidate therapies. 
 
Materials and Methods 
Cell culture 
Cell lines used in this study are summarized in Table 5_1. Low passage skin fibroblasts 
were obtained from skin biopsies from two unrelated BTHS patients with informed consent 
under a Boston Children’s Hospital IRB approved protocol. Control cells were derived from BJ 
cells (Stemgent). The BTH-H iPSC line was established by retroviral delivery of three 
reprogramming factors (SOX2, KLF4 and  OCT4), followed by application of the histone 
deacetylase inhibitor valproic acid (VPA) as described
1. 
The BTH-C iPSC line was established 
by modRNA reprogramming as described
2
. Several iPSC clones with ES cell morphology and 
with positive vital staining for TRA-1-81 or TRA-1-60 staining
3
, were further characterized to 
yield the final two lines studied. Karyotyping was performed by Cell Line Genetics, Inc. 
Teratomas were formed by injection of 10
6
 iPSCs intramuscularly into the flanks of adult SCID 
mice. Teratomas were examined by H&E staining. 
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Table 5. 1. Human iPSCs used in this study 
Name  Starting 
Cells 
Derivation 
method 
Lab source TAZ 
mutation  
Genome 
editing 
Reference 
WT1iPS Male normal 
newborn 
Fibroblasts 
Retrovirus OSKM Pu lab     
WT2iPS Male normal 
adult 
fibroblasts 
Retrovirus OSKM Daley lab   PMID: 18691744 
WT3iPS Male normal 
adult 
fibroblasts 
Modified mRNA 
OSKML 
Allele Biotech   PMID: 22984641 
BTHHiPS Male adult 
patient 
fibroblasts 
Retrovirus OSKM Pu Lab Exon6 
GAC>ACT 
delete G 
  
BTHCiPS Male adult 
patient 
fibroblasts 
Modified mRNA 
OSKML 
Pulab Exon4 
TCC>CCC 
  
PGP1iPS 
 
Male normal 
adult 
fibroblasts 
Retrovirus OSKM Church lab/Coreill 
Institute GM23338 
 Dox inducible 
Cas9 expression 
 
PGP1iPS 
NT (No 
targeting) 
Male adult 
fibroblasts 
Retrovirus OSKM Church lab/Pulab  Cas9 induced 
without TAZ 
mutation 
 
PGP1iPS 
BTHH 
 
Male adult 
fibroblasts 
Retrovirus OSKM Church lab/PuLab Exon6 
GAC>ACT 
delete G 
Homologous 
recombination 
introduction of 
BTHH mutation 
 
PGP1iPS 
NHEJ 
Male adult 
fibroblasts 
Retrovirus OSKM Church lab/Pulab TAZ exon 6 
insertion 
NHEJ-induced 
TAZ mutation 
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Cardiomyocyte differentiation was induced as previously reported
4
, with minor 
modifications. Cells were detached by 3-5 min incubation with Versene (Invitrogen) and seeded 
onto Matrigel-coated plates at a density of 10,000 cells/cm
2
 in murine embryonic fibroblast 
conditioned medium (MEF-CM) plus 4 ng/mL bFGF for 2-3 days before induction. Cells were  
covered with matrigel (1:60 dilution) on the day before induction.  To induce cardiac 
differentiation, we replaced MEF-CM with RPMI+B27 medium (RPMI-1640, 2 mM L-
glutamine, x1 B27 supplement without insulin) supplemented with 100 ng/mL of  Activin A 
(R&D Systems) for 24 hours, followed by 10 ng/mL human bone morphogenetic protein 4 
(R&D) and 10 ng/mL human basic fibroblast growth factor for 4 days without culture medium 
changes.  The culture medium was subsequently replaced with  RPMI+B27 supplemented with 
100 ng/mL of DKK1 (R&D) for 2 days.  At day 7, the culture medium was changed to 
RPMI+B27 without  supplementary cytokines; culture medium was refreshed every 1-2  days. 
Leibovitz L-15 medium was substituted for RPMI for galactose containing culture media. 
NRVMs were isolated from neonatal rat heart ventricles by collagenase digestion using 
the Neomyts isolation kit (Cellutron). Procedures involving animals were performed under 
protocols approved by the Institutional Animal Care and Use Committee. 
Mitochondria were labeled using BacMam 2.0 mitochondria-RFP (Invitrogen), in which 
baculovirus delivers RFP tagged with the mitochondrial localization sequence of E1 alpha 
pyruvate dehydrogenase. 
 
Cas9 Genome Editing 
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In brief, we constructed a piggyBac transposon that expresses the reverse tet activator and 
a human codon optimized Cas9 under the control of a tet response element. Transient 
transfection of PGP1-iPSCs (Coriell) with piggyBac and this engineered transposon yielded 
PGP1iPSC-hCas9. We subsequently designed guide RNA and donor oligonucleotides to 
introduce the BTHH TAZ mutation into exon 6. After transient dox administration and 
transfection with gRNA and donor oligonucleotides, we screened individual clones by Sanger 
sequencing. We selected an unmodified clone, a clone containing the BTHH mutation 
(homologous recombination), and a clone containing a novel insertion due to non-homologous 
end joining. Transient piggyBac transfection subsequently led to removal of the Cas9-containing 
transposon. 
 
Cardiac 
31
P-NMR 
Cardiac 
31
P-NMR was performed under institutionally approved protocols as described
5
. 
High energy phosphate stores were estimated from the phosphocreatine peak area, normalized to 
the peak area from the β-phosphate of ATP5. 
 
iPSC-CM characterization 
For characterization, iPSC-CMs were dissociated with Accumax (Innovative Cell 
Technologies) on day 11-12 of differentiation. Dissociated cells were stained with anti-VCAM1 
antibody (refer to Table 5_1 for antibody information) conjugated with allophycocyanin (APC) 
and magnetically sorted using anti-APC microbeads (Miltenyi Biotec).  For validation of MACS, 
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sorted cells were fixed and stained with TNNT2-Alexa-488.  Data were analyzed with DIVA 
(BD) and FlowJo (Treestar) software. 
For mitochondrial function assays, 60,000 sorted cells were seeded in 0.1% gelatin-
coated seahorse assay wells in alpha MEM (Invitrogen) with 10% FBS. They were then changed 
to L-15 media supplemented with 1x B27 supplement without insulin for 5-7 days. After 
measurement of oxygen consumption rate, total protein levels of iPSC-CMs was determined 
using the BCA protein assay (Thermo Scientific). OCR was measured using a Seahorses 
Biosciences XF24 extracellular flux analyzes and normalized to total protein. For ATP assays, 
cells were grown in indicated media and supplements for 5 days. ATP assay reagent (Promega) 
was added directly to wells and light output was measured with a plate luminometer. Readout 
was normalized to total protein. 
Electron microscopy was performed on a Tecnai G Spirit BioTWIN instrument. At least 
10 randomly selected fields containing cardiomyocytes were imaged per sample. 
Quantitation of sarcomere assembly for iPSC-CMs plated on anisotropic gelatin substrate 
was performed on randomly acquired confocal images. Images were overlaid with a point-
counting grid, which was used to measure overall cell area and cell area containing linearly 
organized ACTN2 staining. 
 
Gene expression analysis 
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 Samples were fixed in 4% paraformaldehyde and permeabilized with 0.05% Triton X-
100. Imaging was performed on an Olympus FV1000 or Zeiss LSM 5 LIVE confocal 
microscope. qRTPCR was performed from total RNA using primers listed in Table 5_2. Sybr 
green chemistry was used for real time PCR detection on an ABI 7500 instrument.  
 
Modified RNA synthesis and delivery 
The OCT4, SOX2, KLF4, cMYC, and LIN28 cDNA templates were obtained from 
Addgene (plasmids 26815-9). The TAZ modRNA cDNA template was expressed from 
pcDNA3.3-TOPO-T7-5’UTR-cMyc-3’UTR, which contains the T7 promoter and optimized 5’ 
and 3’ untranslated regions (Addene plasmid 26818). The vector was modified to place unique 
AscI and NheI restriction sites between the 5’ and 3’ untranslated regions. Full length human 
TAZ cDNA corresponding to Refseq NM_000116 with a 5’ FLAG tag was cloned into modified 
vector. 
To synthesize the modRNA, the UTRs and ORF were PCR amplified using a polyA-
tailed primer. 1.6 µg of purified PCR productwas transcribed in a 40 µl reaction system using the 
MEGAscript T7 kit (Ambion, Austin, TX) and a custom ribonucleoside cocktail from Allele 
Biotechnology (No. ABP-PP-NTPMIX), containing pseudouridine-5´-triphosphate, 
Methylcytidine-5´-triphosphate, GTP, ATP, and ARCA (Cap Analog). Reactions were incubated  
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Table 5.2. Oligonucleotide Primers used in this study. 
Name Sequence 
OCT-4F AGTTTGTGCCAGGGTTTTTG 
OCT-4R ACTTCACCTTCCCTCCAACC 
NANOGF TTTGGAAGCTGCTGGGGAAG 
NANOGR GATGGGAGGAGGGGAGAGGA 
NKX2.5F CATTTACCCGGGAGCCTACG 
NKX2.5R GCTTTCCGTCGCCGCCGTGCGCGTG 
MYL7F GAGGAGAATGGCCAGCAGGAA 
MYL7R GCGAACATCTGCTCCACCTCA 
BrachyuryF CGGAACAATTCTCCAACCTATT 
BrachyuryR GTACTGGCTGTCCACGATGTCT 
Vcam1F CCGGATTGCTGCTCAGATTGGA 
Vcam1R AGCGTGGAATTGGTCCCCTCA 
Human GAPDHF GTGGACCTGACCTGCCGTCT 
Human GAPDHR GGAGGAGTGGGTGTCGCTGT 
Rat TAZF TGAAACTCCGCCACATCTG 
Rat TAZR CCCTTTCTGATAGACACCATGTC 
Rodent GAPDH control Applied Biosystems  Cat No.4308313 
   
 
 
 
6 hr at 37°C. After DNase treatment RNA was purified with Ambion MEGAclear spin columns, 
then treated with Antarctic Phosphatase (New England Biolabs) for 30 min at 37°C .Treated 
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RNA was repurified and adjusted to 100 ng/mL working concentration with Tris-EDTA (pH 
7.0). 
 
Modified mRNA transfection were performed with RNAiMAX (Invitrogen). 
Transfection media was supplemented with 200 ng/ml B18R interferon inhibitor (eBioscience). 
After 4 hours, the transfection medium was replaced with fresh culture medium containing 200 
ng/ml B18R. 
 
Microcontact Printing 
Standard soft lithography techniques were used to fabricate polydimethylsiloxane 
(PDMS) stamps for microcontact printing (Sylgard 184, Dow Corning Midland, MI), as 
previously described. Briefly, a silicon wafer was spun coat with SU-8 3005 (MicroChem Corp., 
Newton, MA) and selectively exposed to UV light using a photomask. After being developed, 
the wafer was used as a template for PDMS stamps. For the single cell studies, we used stamps 
with 95 µm x 13 µm rectangles. For the muscular thin film studies, we used stamps with 15 µm 
wide lines separated by 2 µm.  
To measure sarcomere organization in single cell studies, glass coverslips (diameter 18 
mm) were spun coat with PDMS and cured. PDMS stamps were coated with 50 µg/mL 
fibronectin (BD Biosciences, San Jose, CA) for one hour, dried, and inverted onto the coverslips 
after treatment in a UVO cleaner (Jelight Company Inc., Irvine, CA). Stamps were removed and 
the coverslips were incubated in 1% F127 Pluronic Acid (BASF, Mount Olive, NJ) for at least 
five minutes before rinsing with PBS and storage at 4°C. MACS-purified iPSC-CMs were plated 
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on microfabricated fibronectin islands for five days and transfected daily with the indicated 
modRNA. 
 
Muscular Thin Film Fabrication and Experiments 
Muscular thin film (MTF) chips were fabricated on 22 mm X 22 mm X 0.13-0.16 mm 
thick glass coverslips (Ted Pella Inc., Redding, CA). Coverslips were covered with low adhesion 
Scotch tape (3M, St. Paul, MN) and two rectangles of dimensions 18 mm X 5.8 mm spaced 8.6 
mm apart (center to center distance) were cut into the tape with a 10.6 micron wavelength CO2 
laser prototyping system (VersaLaser 2.0, 10W, Universal Laser systems, Scottsdale, AZ). Cut 
rectangles were peeled using a sharp tweezer and then 10%  (w/v) solution of poly(N-
isopropylacrylamide), PIPAAm, (Polysciences, Inc., Warrington, PA) in 99% butanol was spun 
coat at 6000 rpm for 1 minute. This allowed the PIPAAm deposition within bare glass regions. 
The rest of the tape was then peeled off and PDMS mixed at 10:1 base to curing agent ratio was 
spun coat at 4000 rpm for 1 minute. PDMS-coated chips were placed in a 65°C for at least 8 
hours to allow complete curing of the elastomer. Young's modulus in compression of the cured 
Sylgard 184 mixed in the ratio of 10:1 base to curing agent ratio was determined to be 1.52 ± 
0.05 MPa (N = 18 samples, Mean ± Standard deviation) using an Instron 3342 mechanical 
apparatus (Instron, Norwick, MA). In the final step, two rows of cantilever outlines were cut into 
the elastomer within the PIPAAm rectangular regions such that the final cantilevers were 5 mm 
X 2 mm spaced 2.5 mm apart (center to center distance). For each batch of films, the thickness of 
the elastomer was measured using a proﬁlometer (Dektak 6M, Veeco Instruments Inc., 
Plainview, NY) and found to be in the range of 11.4-13.4 µm.  
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MACS-purified iPSC-CMs were seeded on MTF constructs at a density of 10
5
/cm
2
 and 
allowed to develop for five days, with daily transfection with modRNA as indicated. For 
contraction assays, MTF constructs were transferred to 37°C Tyorde’s buffer solution (1.8 mM 
CaCl2, 5 mM HEPES, 1 mM MgCl2, 5.4 mM KCl, 135 mM NaCl, 0.33 mM NaH2PO4, and 
either 5 mM glucose or galactose depending on the experimental conditions, pH 7.4) and placed 
on the stage of a Zeiss Discovery V8 Stereo Microscope at room temperature. Tweezers were 
used to manually peel each thin film away from the glass coverslip as the PIPAAm layer 
dissolved due to the slight drop in temperature. When all films were peeled, the constructs were 
re-warmed to 37°C and paced with platinum field stimulation electrodes. Films were paced at 1, 
2, 3, 4, and 5 Hz and their movement was recorded from above at 100 frames per second. 
 
MTF Stress Calculation 
The longitudinal planar projections of contracting MTFs were automatically detected 
using custom ImageJ (NIH, Bethesda, MD) software and used to calculate the radius of curvature 
of each film using custom MATLAB (Mathworks, Natick, MA) software, as previously 
described. The stress of the cell layer was determined from the radius of curvature using a 
modified form of Stoney’s equation:  
   scc
s
cell
ttRtv
Et
/116 2
2


  (1) 
where σcell is the stress of the cell layer, E, v and ts are the Young’s modulus, Poisson’s 
ratio, and thickness of the PDMS film, respectively, R is MTF radius of curvature, and tc is cell 
layer thickness. Equation (1) can be readily derived based on the theory of the cylindrical 
bending of thin plates and the static equilibrium of the force and torque of plate bending. Note 
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s
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that the plate modulus E/(1 - v
2
) instead of the biaxial modulus E/(1 - v), appears in equation (1) 
because the anisotropic contraction of the cell layer bends the PDMS film into a cylindrical 
shape instead of a bowl-like shape. The factor (1 + tc/ts)
-1
 is a correction to the standard Stoney’s 
equationwhen the thickness of the cell layer approaches that of the PDMS layer. We previously 
used a more comprehensive model to calculate not only the stress in the film but also the 
shortening of the muscle layer. For the MTFs used in this paper, the stresses calculated by these 
two methods are almost identical, so we chose to adopt the simpler analytical form of the 
modified Stoney’s equation. 
Stress values for the six conditions failed the Shapiro-Wilkinson test for normality and 
were thus statistically compared using Kruskal-Wallis One-Way ANOVA on Ranks and Dunn’s 
method for pairwise comparisons. Tests with a p-value less than 0.05 were considered 
statistically significant. 
 
Single Cell Structural Analysis 
Images of single myocytes stained for sarcomeric α-actinin were analyzed using custom-
designed software in ImageJ (NIH, Bethesda, MD) and MATLAB (Mathworks, Natick, MA). 
Images were pre-processed to highlight the filamentous structure of the cytoskeleton using a 
tubeness operator, which replaces each pixel in the image with the largest non-positive 
eigenvalue of the image Hessian matrix. To calculate the ability of single cells to spread across 
the microcontact printed islands, the convex hulls of sarcomeric α-actinin and fibronectin 
binarized immunostains were obtained and utilized to calculate cell projected surface area. 
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The regularity of spacing between the cytoskeletal elements that stained positive for 
sarcomeric α-actinin was assessed by first considering the magnitude of the oscillatory portion of 
the 2D Fourier transform of pre-processed and binarized immunostains: 
 
 (2) 
To fully automate the analysis and remove any user-bias (10), 512 radial profiles of the 
2D Fourier transform were summed to obtain a 1D representation – Γ(ωn) – of the 2D spectrum 
(blue-dots in Fig. S10 Aiii and Biii) that was further normalized so that the total area under the 
curve would be 1. A least square minimization was performed to find the vector of parameters γ 
for which the function  best fit the N experimental data points: 
 
   (3) 
 
    (4) 
The functional form of  was composed by an aperiodic component, representing 
the effect of poorly developed cytoskeletal structures (black curve, Equation (5)) and a periodic 
component (red curves, Equation (6)) relating to periodically spaced Z-disks: 
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In agreement with Fourier analysis, the periodic component was approximated with a 
series of Gaussian peaks localized at integer multiples of the spatial frequency (ω0 =1/r0) 
associated with the sarcomere length (r0 ~ 2 μm). 
The area under the peaks of the periodic component was taken as a metric of structural 
organization and named sarcomere organization: that is, the organization increases as more 
sarcomeric α-actinin positive elements become localized in the Z-disks, at a distance ~r0. We 
normalized all sarcomere organization values to the maximum value observed across all single 
cells before plotting. 
 
Statistics 
Unless otherwise noted, results are expressed as mean ± SEM. Group means for 
metabolic assays were compared using Welch’s t-test. For the sarcomere assembly and MTF 
assays, values were first tested for normality (Shapiro-Wilkinson) and only then represented as 
mean ± standard error of the mean. Statistical comparison between the four groups was 
conducted through 1-way ANOVA test followed by post-hoc Student-Newman-Keuls pairwise 
comparison. Differences were deemed statistically significant when statistical tests returned a p-
value lower than 0.05. 
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Chapter 6 
Conclusion and future prospects 
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Conclusion 
Here, I summarize the work described in this thesis and provide avenues for future 
investigation. In Chapter 2, I described re-TALENs as an improved tool for genome editing and 
created an optimized pipeline for generating scarlessly edited hiPSCs within 3 weeks. This 
pipeline includes:  1) a simplified re-coded TALE generation protocol that that facilitates 
genome editing tool synthesis and enables the production of functional lentivirus particles; 2) a 
bioinformatics package and platform, GEAS, to assess the frequency of genome editing events 
that is 400 times more sensitive compared with currently existing methods; and 3) an efficient 
genotype screening method of monoclonal hiPSCs. In Chapter 3, I described reprogramming the 
CRISPR system into a facile and effective tool for human cell engineering. The design and 
construction simplicity of this tool empowers researchers with unprecedented flexibility to 
conduct human genome engineering. To compare the performance of the new CRISPR system 
with existing genome editing tools, we compared the efficiency and specificity of CRISPRs 
relative to reTALENs. To enhance the performance of CRISPR, we devised a double-nickase 
system to improve specificity and mitigate off-target effects. To investigate safer genome 
editing, we created targeted deaminases as described in Chapter 4. This novel class of genome-
editing tools introduces mutations in the human genome without incurring DSBs or nicks, and 
therefore can be applied in the practice of multiplexed-genome targeting where other nucleases-
based tools may be toxic. To demonstrate the utility of our genome editing tools, in Chapter 5, 
we demonstrated the use of our genome editing tools in combination with the “heart-on-a-chip” 
technology to model cardiovascular disease and study the pathogenesis.   
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Resolving Specificity Issues 
To fully realize the potential of genome editing tool in basic research and clinic medicine, 
a task of utmost importance is to improve specificity and mitigate deleterious off-target effects. 
The generation of off-target DSBs can generate undesirable mutations, thus confounding 
biological studies and impeding the use of gene-editing tools in clinical practice.  
There are two aspects of specificity issues that require resolution: first, genomic DSBs 
introduced by a customized nuclease needs to be sequence-specific; second, the genomic 
changes following occurrence of a DSB should be dictated by the donor DNA -- not the non-
specific NHEJ products.  
To improve the DSB sequence specificity, we propose three broad strategies: 1) to 
determine the target bias of different type of nucleases and judiciously choose the target site; 2) 
to evolve genome-editing nucleases to have higher specificity; 3) to further engineer obligate 
cooperativity.  
Targeted nucleases, including ZF, TALE, and CRISPR, can tolerant one to multiple 
mismatches in their binding sites. However, we and others have observed dramatic content 
difference so that the mismatches are tolerant to varied degrees depending on the position (1, 2). 
Additional experiments are needed to elucidate the rules governing the position-dependent 
specificity, which would provide us with guidelines to computationally predict the optimal 
targeting sites with minimal off-target potential at gene of interest.  
Second, directed evolution might be utilized to improve Cas9 specificity to a level 
sufficient to completely preclude off-target activity.  Such a project is likely to require extensive 
modifications to the Cas9 protein.  As such, novel methods permitting many rounds of evolution 
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in a short timeframe (3) may be warranted. For more detailed reviews of CRISPR systems, see 
references (4, 5). 
Third, efforts have been made to engineer obligated dimers to increase the specificity of 
customized nucleases, such as ZFN/TALEN in which the FokI nuclease domain only functions 
as a dimer. Our group recently reported off-set Cas9-nickases as a new strategy to mitigate the 
off-target issue of CRISPR system (1). Moving forward, more engineering is needed to decrease 
the affinity of nuclease monomers and enhancer cooperative effects between the monomers.  
To ensure specific genomic changes at DSBs, coupling of genomic cutting and HR is 
critical to promote HR and disfavor undesirable non-specific NHEJ events. There may exist 
multiple ways in which DSB and HR can be coupled to mitigate non-specific NHEJ events. An 
example of spatial coupling would be conjugating the DNA donor with the gRNA of CRISPR to 
ensure the availability of DNA donor near the CRISPR cutting site. An example of temporal 
coupling may involve fusing customized nucleases with a proper cyclin domain to synchronize 
the expression of nucleases in G1/S of the cell cycle, during which HR is most active, thus 
maximizing the likelihood of an HR event relative to the likelihood of an NHEJ event (6). Third, 
DSB generation and HR can be enzymatically coupled as illustrated by the mechanism of natural 
recombinases (7). The theoretically appealing, engineered recombinases with fully 
programmable specificity may serve as a better alternative to nucleases for introducing specific 
changes in the genome.  
  
Genome editing beyond cellular level: Patients-on-a-ChiP and in vivo editing 
In chapter 5, we described our effort of combining engineered hiPSC with “heart on-a-
ChiP” to study the pathogenesis of a certain cardiovascular disease. Currently, several organ-on-
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chips are being designed in an effort to reproduce key structural, functional and mechanical 
properties of human organs (8, 9), including lung-on-a-ChiP, heart-on-a-Chip, kidney-on-a-Chip, 
artery-on-a-Chip. Such technology can be extended to reconstruct liver, neuronal tissue, and 
gastrointestinal organs. In addition, researchers are working towards building a multi-channel 3D 
microfluidic system that mimics multiple organs in the whole body (10). We envision that the 
human genome editing technology, generating stem cells with designated genome type, 
combined with organ-on-Chips technology, will expand the capacity of cell culture models and 
provide low-cost alternatives to animal and clinical studies for drug screening and toxicology 
applications for particular diseases.  
Furthermore, genome editing can be applied in higher levels of life-forms, from single 
cell to organic and to organismic levels. Combining efficient genetic editing technologies with 
specific gene delivery methods will enable the application of these tools as direct therapeutic 
approaches in vivo.  
 
Beyond genome editing: multiple levels of cellular manipulation  
Over the course of last decade, the rapid innovations of genome editing tools have 
dramatically enhanced our ability to manipulate the primary genomic DNA sequence. With 
powerful tools to recognize sequence of interest, we suggest that other levels of cellular 
manipulation can be also achieved, including 1) chromosomal 3D structure modulation, 2) 
epigenetic information recoding, and 3) transcriptional regulation.  
Recent genomic studies have shown that the unique, higher-order genome structure 
profoundly influences transcriptional regulation (11). Theoretically, we can design DNA-binding 
proteins with multiple independent domains fused by linkers with each one recognizing distinct 
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region in the genome. This hypothetical chimeric protein would serve as a scaffold to bring 
designated region into vicinity. Such a tool can be used to investigate the still elusive 
functionalities of chromosomal spatial arrangement as well as to manipulate long-range gene 
regulation.  
Second, in principle, recruitment by DNA binding protein of any of the major chromatin 
remodeling complexes, including SWI/SNF, histone acetylases and deacetylases, methylases and 
demethylases, kinases and phosphatases, DNA methylases and demethylases could potentially 
facilitate targeted reprogramming of chromatin modification endogenous loci. If successful, 
these capabilities will transform our ability to investigate the nature of epigenetic control and to 
engineer long-lasting gene expression changes.  
Finally, targeted recruitment of transcriptional activators, such as VP64, or suppressors, 
such as SID and KRAB domain, by DNA-binding proteins could be deployed to directly 
modulate the transcription of endogenous genes to a desired level of activity. For example, we 
can deliver the transcriptional suppressor of HMG-CoA into liver to achieve a desired decrease 
in the synthesis of cholesterol, thus theoretically treating hypercholesterolemia in a 
transcriptional manner, akin to the use of small-molecule drugs used to modulate cholesterol 
synthesis. Due to the design simplicity of customized transcription regulators, we can apply the 
same principle to address unmet needs of medicine. For example, there is no effective drug to 
target mutated κ-ras, which accounts for most of the untreatable non-small-cell-lung cancers. In 
principle, potent κ -ras expression suppressor can be administrated into lung tissue through 
inhalation, thus delaying the progression of symptoms.  
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This thesis describes the creation of a repertoire of human genome editing tools that will 
significantly enhance disease modeling, functional genomics and gene therapy.  The 
convergence of both effective genome “reading” capabilities with genome “editing” technologies 
will be transformative for biologists dissecting the genetic determinants of disease and for 
clinicians who aim to deliver customized cell therapies for their patients.   These advances will 
be complemented by strengthening genome “writing” capability to insert new genetic programs 
into the cell by assembling new sequences de novo. For example, we will be able to engineer 
muscle cells to secrete insulin in a highly regulated fashion, behaving as functional pancreatic 
beta cells. The potential to insert new genetic programs into any therapeutically desirable target 
will likely provide us new venues to combat diseases, enhance function and longevity.  
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Appendix B 
RNA-Guided Human Genome Engineering via Cas9 
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Appendix C 
Patent Application of Targeted deaminases 
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